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ABSTRACT 
Pitha Paandu (Iron Deficiency Anemia) is the most prevalent type of anaemia 
which attribute to 50% of total population suffering from anaemia. It becomes a major 
problem in the developing countries like India due to majority of people living below 
poverty line, unhygienic food habits and nutritional deficiency. Since the diagnosis and 
management of Pitha paandu (Iron deficiency anaemia) remains a great challenge, I have 
chosen this disease and made an attempt to search for a perfect remedy for the same.  
20 patients of the either sex as OP & 20 patients in IP were selected and they were 
administered with the trial medicine “THIRIPALAI MATHIRAI” (INTERNAL) 1 
tablet bd and the adjuvant Karisalai kudineer 100 ml bd during the whole study period. 
 Thiripalai mathirai was chosen for this study with reference from “KADUKKAI 
VALLARAIYIN THANI MAANBU”-Third Edition: 1992, Page No: 81.Author: 
Hakkim. P. Mohammed Abdullah Sahib. 
 The trial drug was subjected to Phytochemical analysis, Bio chemical analysis, 
Antimicrobial, Pharmacological and Toxicological (Acute and Sub-acute) studies.  
  At the end of the study period, the majority of the cases showed significant results. 
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CHAPTER - 1 
INTRODUCTION 
Siddha medicine is a form of traditional medicine, the oldest prevailing system 
of medicine in India. It is unique in many aspects like its antiquity rationale of 
diagnosis, treatment modalities based on individual constitution of the body emphasis 
on special diet and aiming at not only curing the disease but also strengthening the 
body. Siddha medicine employs a variety of herbs and minerals which were 
developed now under advanced scientific technique.  
The divine power guards the soul and the body. The support for the body 
namely Pancha bootha combination and permutation is the support for the soul are 
the three thathus. They become as the three gunas and guard the soul and the body, 
say the Siddhars, the ancestors of the land. 
“cUnghUs; jhq;F KlY KapUk; 
clw;fhjhu nkhd;gQ; rg+jg; 
gQ;rP fuzg; ghd;ikah nkdTk; 
capHf;fh jhu KapHj;jh njdTk; 
Kg;gphp thfp Kf;Fz kZfp 
cliy AKapiuA Nkhk;gpf;fhj;J 
tUnkd KJkiw tFf;Fe; JzpNg” 
- Neha; ehly; Neha; Kjy; ehly; 
Many chronic diseases considered incurable in other system of medicine can 
be treated successfully with siddha medicine; one among such diseases is Paandu noi 
(Iron deficiency anaemia). It is a condition that denotes the pallor of the body. This 
clinical condition in which pallor of the body occurs is also known as “Veluppu noi”, 
“Ratha sogai”. It is described as a diseased condition in which the natural colour of 
the body including skin and the mucous membrane becomes pale. 
In Siddha medicine, Yugi muni classified Paandu Noi into five types namely, 
1.Vatha paandu 2.Pitha paandu 3.Kapha paandu 4.Mukkutra paandu and 5.Visha 
paandu. The symptoms of “Pitha Paandu Noi” is almost correlated with the clinical 
conditions of “Iron deficiency Anaemia” as described in modern science. 
Paandu Noi compared to Anaemia, is a condition in which the number of red 
blood cells or their oxygen-carrying capacity is insufficient to meet physiologic needs, 
which vary by age, sex, altitude, smoking, and pregnancy status. Anemia is usually 
associated with decreased levels of hemoglobin and/or a decreased packed cell 
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volume (hematocrit), and/or a decreased RBC count. Iron deficiency anaemia is the 
anaemia caused by a lack of Iron. Iron deficiency is thought to be the most common 
cause of anaemia globally, although other conditions, such as folate, vitamin B12 and 
vitamin A deficiencies, chronic inflammation, parasitic infections, and inherited 
disorders can cause anaemia. 
Iron deficiency anaemia is the most common and widespread nutritional 
disorder in the world. As well as affecting a large number of children and women in 
developing countries, it is the only nutrient deficiency which is also significantly 
prevalent in Industralized Countries. Over 2 billion people – over 30% of the world’s 
population – are anaemic, many due to iron deficiency, and in resource-poor areas, 
this is frequently by infectious diseases. Malaria, HIV/AIDS, hookworm infestation, 
schistosomiasis, and other infections such as tuberculosis are particularly important 
factors contributing to the high prevalence of anaemia in some areas. 
Iron deficiency Anaemia can be classified based on the size of red blood 
cells and amount of hemoglobin in each cell. If the cells are small, it is microcytic 
anemia, if they are large, it is macrocytic anemia and if they are normal sized, it 
is normocytic anemia. Diagnosis in men is based on hemoglobin less than 130 to 
140 g/L (13 to 14 g/dL) while in women it must be less than 120 to 130 g/L (12 to 
13 g/dL). Further testing is then required to determine the cause. 
A moderate degree of iron-deficiency anemia affects approximately 
610 million people worldwide or 8.8% of the   population. It is slightly more common 
in females (9.9%) than males (7.8%). Mild iron deficiency anemia affects another 
375 million. 
Yugi munivar classified Paandu roga nithanam into five types in Yugi 
Vaithiya Cinthamani 800. Pitha Paandu is one among them. The symptoms of pitha 
paandu are yellowish discolouration of the body, pallor, visual disturbances, 
excessive thirst and salivation, shortness of breath, dyspnoea, and giddiness.  
 Siddha medicine is the promising alternative medicine in treating various 
kinds of diseases with fewer side effects. So, I have chosen my clinical drug as 
„„THIRIPALAI MATHIRAI” with its reference in “KADUKKAI VALLARAIYIN 
THANI MAANBU”, a Siddha formulary text by the author Hakkim. P. Mohammed 
Abdullah Sahib, which is indicated for „„Paandu Noi”. It has been correlated in 
modern science as Iron deficiency anaemia (IDA). 
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CHAPTER - 2 
AIM AND OBJECTIVES 
2.1 AIM 
 A Prospective open labelled non-randomized phase-II clinical trial to evaluate 
the therapeutic efficacy of the Siddha medicine “THIRIPALAI MATHIRAI” 
(Internal) for the treatment of “PITHA PAANDU (Iron deficiency Anaemia)”. 
 
2.2 OBJECTIVES 
2.2.1 PRIMARY OBJECTIVE 
To evaluate clinical and therapeutic efficacy of the trial medicine 
“THIRIPALAI MATHIRAI” (INTERNAL) in treatment of “PITHA PAANDU 
(IRON DEFICIENCY ANAEMIA)” 
2.2.2 SECONDARY OBJECTIVES  
 To collect the literature of both Siddha and Modern aspect of the disease, 
Pitha Paandu and establish a correlation between them.  
 To evaluate Phytochemical analysis, Bio chemical analysis, Antimicrobial 
studies, Toxicological (Acute and Sub-acute) of the trial medicine and Bio-
statistical analysis of the clinical study.  
 To evaluate the Haematinic activity of the trial drug “THIRIPALAI 
MATHIRAI” and the adjuvant “KARISALAI KUDINEER”. 
 To evaluate the safety profile of the trial medicine and the adjuvant. 
 To study the Clinical course of the disease with observation on Etiology, 
Classification, Pathology, Prognosis, Complications and Treatment by 
Siddha aspect.  
 To have an idea about the incidence of the disease with Age, Occupation, 
Socio- economic status, Habits and Climate conditions.  
 To evaluate the Pathology of Pitha paandu noi by concentrating Mukkutram, 
Udalthathukal, Udalkattugal and Envagaithervu. 
 To evaluate the additional effects and changes of siddha parameters in Pitha 
paandu. 
 To have the Modern Parameters to confirm the Diagnosis and Prognosis of 
the disease. 
 To evaluate the Biostatistical analysis of the clinical study. 
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CHAPTER - 3 
REVIEW OF LITERATURE 
3.1 REVIEW OF DISEASE 
3.1.1 SIDDHA ASPECT 
Siddha literature deals with classification of diseases mainly by Tridosha theory 
that is Vatham, Pitham and Kabam. 
Pithapaandu noi is caused by derangement of Pitham. Hence the basic details 
regarding Pitham are briefly explained before going into the study about Pitha pandu 
noi. 
MUKKUTRA THEORY OF PITHAM 
Pitham is one of the three vital humours (Vatham, Pitham, and Kabam). 
Among the Panchaboodhas, it is formed by the Theyu bootham. In healthy 
individuals, the existences of the three humours are found in the following ratio of 1: 
½: ¼ respectively. This is told as, 
 
―nka;asT thjnkhd;W Nky; gpj;jNkhuiuahk; 
Iaq; fhnyhd;Nw mwp‖ 
- fz;Zrhkpak; 
When this ratio is altered in our body, there is disturbance to Pitha dhosham 
caused by dietary habits, environmental factors etc, which leads to alteration of 
Pitham leading to Pitha diseases. 
SITES OF PITHAM 
As per kannusaamiyam thought, 
 Between the heart and the naval, 
 Pingalai, Piranavayu, Neerpai, Moolaakkini, Irudhayam, 
Thalai, Koppul, Undhi, Iraippai, Viyarvai, Naavil 
Oorukintraneer, Senneer, Saaram, Kan, Thol. 
As per Yugimuni’s thought, 
―Nghnkd;w gpj;jjJf;fpUg;gplNk Nfsha; 
Nguhd fz;lj;jpd; fPojhFk;‖      
- A+fp Kdp 
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GENERAL CHARACTERISTICS OF PITHAM 
 Veppam (Heat) 
 Koormai (Sharpness)  
 Neippu (Lubricative) 
 Nekizhchi (Elastic) 
Pitham conceives the properties of the substance to which it combines. 
CHANGES IN PITHAM BY FOOD 
Some of characters of food we consume which leads to aggravation of Pitha 
humour or neutralizing the aggravated Pitha humour, which is given as follows; 
Six qualities of food which aggrevate Pitham: 
1. Hot 
2. Acidic 
3. Mobility 
4. Liquid 
5. Aggressive 
6. Pungent 
 
Six neutralizing qualities of food for aggrevated Pitham: 
1. Cold 
2. Sweet 
3. Immobility 
4. Solid 
5. Calmness 
6. Bitter 
   
Qualities of aggrevated Pitham: 
 Yellowish tinge of eyes, skin, urine and stool. 
 Excessive thirst and appetite. 
 Burning sensation all over the body. 
 Decrease in sleep. 
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Qualities of reduced Pitha: 
 Decrease in normal colour of the skin 
 Loss of appetite 
 Chillness 
 Affecting the normal growth of Kabha humour. 
 
Natural Properties of Pitham: 
―grpjhfk; Xf;nfhspfz; ghu;itgz; lj;J 
Urpnjup rj;jpntk;ik tPuk; - crpj 
Kjp$u;j;j Gj;jptdg; gspj;Jf; fhf;Fk; 
Mjpfhup ahq;fh doy;‖     
- cly; jj;Jtk; 
 Seripithal (Digestion), Vanmai (Strong), Vemmai (Hot), Menmai (Softness), 
Paarvai (Sight), Pasi (Hunger), Neervetkai (Thirst), Suvai (Taste), Oli (Brightness), 
Ninaippu (Thought) and Arivu (Knowledge) are the properties of pitham. 
 
Physiological Functions of Pitham: 
1. Increasing the body temperature. 
2. Giving red or yellow tinge to the body, skin, eye, motion and urine. 
3. Raising the body temperature during digestion and assimilation. 
4. Produces perspiration and giddiness. 
5. Raising the volume of blood and its expulsion. 
6. All tastes are found to be sour, bitter. 
7. Anger, irresponsible, immobile, thoughtfulness, emaciation, feeling of 
irritation and excitement. 
 
Relationship of Pitham with taste: 
Salt - Water + Fire 
Sour - Earth + Fire 
Pungent - Air + Fire 
Salt, sour and pungent tastes increase Pitham, because they are formed by fire 
(heat). So they possess Veppa Veeriyam. 
Astringent, sweet and bitter tastes neutralize Pitham, because they do not 
contain Agni (heat). Hence they Possess Seedha Veeriyam. 
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Astringent - Earth + Air 
Sweet - Earth + Water 
Bitter - Space + Air 
―gpj;jkjp fhpg;gpd; NgRk; ghpfhuk;  
 Rj;jj; JtNuhL nrhy;ypdpg;Gr; rj;jhFk;  
 ifg;Gr; RitNa fUjtjd; tPW  
 va;g;gilA nkd;Wiuj;jh hpq;F‖.       
- fz;Zrhkpak; 
Aggravation of Pitham in daily routine: 
Pitham is raised at the time of 10 a.m to 2 p.m and 10 p.m to 2 a.m 
Aggravation of pitham in week days: 
If pitha gets aggravated at morning hours of Sunday, Tuesday, Saturday and 
Krishnapatcham Thursday, the vigour and vitality of body is maintained. 
PHYSIOLOGICAL ASPECTS OF SENNEER THATHU [BLOOD] 
Our body is made up of seven udal thathus namely saaram, senner, oon, 
kozhuppu, enbu, moolai, sukkilam / suronitham. These seven thathus constitute the 
body in normal condition. Senneer has the characters of pitha and it gives life to each 
cell and tissue of the body. Blood is the only vehicle, which is concerned with 
anabolic and catabolic functions of the body. 
Among the seven thathus, senneer is considered as pitham, which has the 
character of Thee (Theyu). Circulation and digestion represent thee in the body. Blood 
is the connective tissue of the body. It reflects the changes that occur in the body. The 
blood is the combination of various elements like Venthavalam, Senthavalam, 
Prakruthi mayai, Pranavayu and Neer. Senthavalam moves like a worm in blood. It is 
mentioned in the following verses; 
―CWk; GOtpd; xOq;Nfh> ePupil 
itj;j kyj;jpd; Fg;igNah> itj;Jf; 
fl;ba euk;gpd; fapNwh> clk;gpw;Fs; 
gpupah njhWf;Fk; gpzpNah> njupahJ 
,d;dJ ahd; vd;W mwpNad; vd;id‖ 
- gl;bdj;jhu; (jpUtpilkUJ}u; Kk;kzpf;Nfhit-13) 
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Nourishment of Senneer: 
Among seven body constituents, Senneer is placed in second order next to 
saram. This is stated by Thirumoolar as follows, 
―,uj Kjyhd Vo;jhJ %d;wpd; 
cupa jpdj;jpd; xUGw; gdpNghy; 
mupaJsp tpe;J thFNko; %d;wpd; 
kUtpa tpe;J tsUq;fh aj;jpNy‖    
- jpUke;jpuk; - 1897 
According to Siddhars, as the digestion takes place in the body ―Saram‖ 
or―Rasa thathu‖ is formed on the very first day. The second day ―Raktha thathu‖ is 
formed from the Rasa thathu, ―Mamisam‖ is formed from this Raktha thathu on third 
day. ―Kozhuppu‖ is formed from Mamisa thathu on the fourth day. ―Enbu‖ is formed 
from kozhuppu on the fifth day, ―Moolai‖ is formed from enbu on the sixth day and 
finally ―Sukkilam‖ is formed from moolai on the seventh day. The nutrients absorbed 
after digestion are responsible for the metabolism and formation of blood. They are 
also responsible for the formation of muscular, adipose and nervous tissues and 
calcification of bones. As saaram and senneer are the primary important thathus of the 
body, they get deranged themselves and followed by derangement of other thathus. In 
Paandu noi, saaram and senneer thathu are mainly affected. 
ghz;L Neha; 
NtWngah;: 
ntz;ik Neha;> ntSg;G Neha;> ntz;ghz;lk; 
,ay;G: 
,aw;if epwk; khwp> cly; ntSj;J> fz;> eff;fz; ,itfis ePf;fpg; 
ghh;f;fpy; FUjpapd;wp ntSj;jpUf;Fk; Nehahk;.    
T.V. rhk;grptk;;; gps;is mfuhjp, 
ghz;L which  means only  ntz;ik refers  merely  to  anaemia where  
patient  turns  pale or white. 
In Agathiyar Gunavagadam, 
  ―Njulh Njfj;jpy; ,uj;jk; tw;wpj;  
      jPq;fhd tpe;jNeha; fhZ kg;gh‖ 
- mfj;jpau; Fzthflk; 
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In Agathiyar Vaithiya Kaviyam 
 ―RopothFe;j Njfkg;gh fhzj;jJ te;jha;  
 tw;wptpL kd;dthry; Nfl;fpy;  
 gopfhuh; Kfj;jpdpy; Kopahh; NghNy ghz;lnky;yhk;  
 ntDf; fbj;jJ uj;jk;‖  
According to Pattinathar there are crores of uyir anukkal in blood.   
 Nktpa Gd;kaph;j; njhifNa mk;kaph; 
 ghtpa Njhypd; gug;Ngh Njhdpilg;  
 Gfypl;Lg; nghjpe;j Gz;Nzh Gz;zpil  
 CWk; cjpug; GdNyh $Wnra;J  
 ,ilapil epw;Fk; vYk;Ngh vYk;gpil 
 KilnfO %is tpONjh tOtOj;J 
 cs;spil nahOFk; tOk;Ngh nky;y epd;W  
 CWk; GOtpd; xOq;Nfh ePhpil... 
- gl;bdj;jhh;  
(jpUtpilkUJ}h; Kk;kzpf;Nfhit) 
In Uyir Kaakum Siddha Maruthuvam, 
The Characters of Pandu noi are natural colour of the body will be pale 
and glowing, Oedema in face, Eyes in blue and dark yellow colour urination. 
In Agathiyar vaithiya pillai tamil,  
In Pandu, Red blood cells are reduced in blood and the skin is pale in 
colour. 
 
Neha; tUk; top: (Aetiology)  
 According to “Yugimuni” in yugivaithiya chinthamani-800, 
―mwpe;JNk cw;gj;jp nrhy;yf; Nfsha; 
    mjprhu kykpsfp  nae;Ne ue;jhd; 
gwpe;JNk GspAg;G ngUj;j jhYk; 
    ngj;jkh kf;fpdpap ypUj;j yhYk; 
gpwpe;Jjhk; G+ykpf mUe;j yhYk; 
    kPwpNa kJf;fisj; jhd;Grpj;j yhYk;; 
gwpe;J gfy; epj;jpiuNa nra;jyhYk; 
    ghz;Lte;J ghhpYs;Nshh; gLk; ghlhNk 
ghlhd gQ;Rjidj; jpUb Ndhh;f;Fk; 
    ghq;fhd rptJapiyg; gUfp Ndhh;f;Fk; 
khlhd gRtijg; gl;bdpahf  
    itf;fpd;Nwhh; kiwtopia ele;jp lhjhh; 
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fhlhd thuzpae; jdpw;g wpj;Jf; 
    fLtijfs;! nra;fpd;Nwhh; fz;fh zhj 
Nfhlhd gopnrhy;ypf; Fbnf Lf;Fk; 
    nfhLk;ghtp ghz;Ltpdhw; Fjpnfhs; thNu‖ 
       - A+fpitj;jpa rpe;jhkzp -800 
   The etiopathogenises of paandu noi is said to be excessive intake of 
salt and sour taste foods, staying in hot climate, excessive intake of alcohol, excessive 
chewing of pan and nuts, day time sleep. These are some of the factors causing 
Paandu noi. 
 
In Thanvanthiri Vaithiyam,  
―jpUe;jpLk; ghz;L NuhfQ; Nrh;e;jpLk; Fzj;ijf; Nfsha; 
,Ue;jpLk; thjgpj;jr; rpNyw;gd kpitjhd; khwpg; 
Ghpe;Jjh ndhd;Nlhd;W nghUe;JtjhY kz;Nzh 
gUe;JtjhYk; ghz;L tize;jpL nkd;dyhNk‖         
―Mfpa %ye;jd;dp yize;jTl; lzj;jpdhYs; 
Njhifau; Nkhfj;jhYe; Jau;kpF Nrhfj;jhYe; 
NjfNgh~ izAs;shh;f;Fj; jupj;jpuQ; Nrh;jyhYk; 
Ntfkhe; jpupNjhlq;fs; kpQ;rpNa ghz;LthNk‖  
According to the above mentioned lines, imbalance between the three humors 
[Vatham, Pitham, and Kabam], appetite of eating mud, excessive heat accumulation, 
excessive Sorrow and psychosocial factors are some of the causes of Paandu noi.         
 
In Agathiyar kanmakandam kouvmathi,  
―ehnkhd;W nrhy;YfpNwhk; ghz;L te;j  
    eykhd fUkkJ nrhy;yf;NfS 
jhnkd;w jha;je;ij kdk;Nehfr; nra;jy; 
    juzpjdp Ys;sth;f;Fk; tk;Ng nrhy;y  
nynkd;w TWg;gopj;jy; nrtpR thr  
    kw;Wg; ngha; nrhy;yhq;fhuQ; nra;jy; 
Ntnkd;w fUkkJ gpj;j Nkwp 
   ntSj;Jjlh ntg;GkpQ;rpf; iffhNyha;Nt‖ 
Agathiyar mentioned that Irresponsiblity and regret to parents, speaking lie, 
getting anxious and furious on others stimulates pitha dhosha which leads to paandu 
Noi. 
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In Agathiyar Paripooranam 400, 
―ey;Nyhh;fs; nghpNahh;fs;e lj;JQ; nra;if 
     ehl;bYs;s Jr;rhjdh;fs;e ifj;jhNy 
nghy;yhj tp~f;fbePh; gw;wp te;J 
     nghd;dhd jpNufnky;yhq; Flk; NghNy 
nrhy;yhjfb tplq;fs; Fd;kk; ghz;L 
     Jah;jPuhf; fd;ktpid nra;j ghtk; 
vy;yhU eiff;fTlk;ng Lj;j ghtp 
     ,d;dKz;L tpgukjhap sfpf; NfNs‖ 
Hemolysis due to toxin, Acid peptic disease, Abnormal morphological 
changes in RBC (Genetic Disorder) and kanma vinai are the causes of this disease 
 
In Agathiyar Gunavagadam, 
―nfhs;slh mgf;Ft Nghrdj;jhYk; 
     Fb nfLj;J ngUk;ghL fpuhzpahYk; 
fs;slh fUg;gj;jpd; fpue;jpahYk; 
    fdkhd ,uj;jj;jpd; Nghf;fpdhYk; 
ms;slh mjpahk ftdj;jhYk; 
     mstw;w tprhue;jh dilAk; NghJk; 
njs;sNt Njfj;jpy; ,uj;jk; nfl;L 
njspthd ghz;lJT Kz;lhk; ghNu‖  
According to agathiyar Improper cooked foods, Altered food habits, 
Imbalanced diet, menorrhagia in females, chronic Diarrhoea, karupa kirani, blood loss 
due to various  aetiology, stress and strains are the causes for pandu noi. 
 
In Agathiyar Vaidhyam- 80  
  ―Fapy;tha; F~;lk; raq;Fd;k ePhpopT Ruq;fpuhzp  
   ePuilg;G ghz;L %ytha;T fd;kthA  
tUq;fz;zpy; Fe;jha; fbde; jrtha;T  
   fhzthf Kd;nra;j caph;fSk; tpidjhNd‖ 
According to this, Paandu noi is refered as one among the Kanma disease. 
According to Theraiyar Vagadam, 
  “fUjpa kPdpd; Ks;Sk; fyj;Jkp nea;apd;  
  kUtpa vYk;Gq; fy;Yk; kq;ifah; kUe;jpLNk  
 gUfpa goQ;Nrhw;whYk; goky epwifahYk;  
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  kUfpa kaph;fshYk; te;jpLk NehapjhNk  
 Gwtiu Az;if ahYk; Nghf ePUz;ifahYk;  
  RUsNt Klf;fpf; nfhz;L Kwf;fplf; ifahYk;  
 kUsNt NkLjd;dpy; kdKwf; fplf;ifahYk; 
  ngUf ntz;ghbapdhYk; gpwf;f Nehnad;WfhNz‖ 
In the above versus, Intake of fish bones, paddy brane, small and store old 
rice, hairs which can produce paandu secondly severe constipation, polluted water, 
sleeping in abnormal posture were also believed to cause veluppu Noi. 
Also in the following versus, it is said that negligence of food and water causes 
paandu noi, 
―jhf KWk; grpahy; jhKz;zh uhkhfpy; 
NfhjUePu; jhfj;jhw; nfhs;shuha; - Nghj 
kpuj;je; jidf;Fbf;Fk; kpd;gtplha; Nghf;Fk; 
gUj;j tpopFUlhk; ghu;‖  
– Njiuau; thflk; 
 
According to Noinadal Noimudhal nadal, 
―fpUkpahy; te;jNjhlk; ngUfTz;L 
Nfl;fyjpd; gpuptjidf; fpukkhf 
nghUkp tUk; thA ty;yhq; fpUkpahNy 
GOf;fb Nghy; fhZkJ fpUkpahNy 
Njfkjpy; Nrhiff; Fl;lk; fpUkpahNy 
#l;rKld; fpupkpaifj; njhopy; nra;tPNu‖  
– Neha;ehly; Neha;Kjy; ehly; jpul;L 
 Worm infestations are the root cause of several diseases including paandu noi. 
 
ruNge;jpuh; ghz;L fhkhiy Nuhf rpfpr;ir vd;Dk; E}ypy;, 
 Gspg;G> cg;Gg; gjhh;j;jq;fisAk;>fhu gjhh;j;jq;fisAk; mjpfkhfg; 
Grpj;jy; 
 rhuhak; Nghd;w Nghij jUk; t];Jf;fis cgNahfpj;jy; 
 kz; rhg;gpLjy;> rhg;gpl;lTld; gfypy; mjpfkhf cwq;fy;> Njfg;gapw;rp 
 ];jphP rq;fkk; ,itfspdhy; rhPuj;jpYs;s gpj;jk; Kjypa Njhlq;fs; 
gpuNfhgk; mile;J ,uj;jj;ijf; nfLj;Jr; rhPuj;ij ntSg;ghf 
nra;fpd;wd vd $wg;gl;Ls;sJ. 
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T.V.rhk;grptk;gps;is mfuhjpapy; $wg;gl;Ls;s Neha;tUk; top,  
 rpy;nyd;W tPRk; FspUk; fhw;wpy; jphptjhYk;> cl;fhh;e;J my;yJ 
gLj;J ,Ue;jhYk; 
 Fz;bf;fha; Neha;> EiuaPuy;> kz;zPuy; Kjypa cWg;Gfisj; jhf;Fk; 
Neha;f; NfhshWfshYk; 
 ngz;fSf;F khjtplha; NfhshwpdhYk; Vw;gLk; 
 md;wpAk; ,e;Neha; gpwtp NehahAk; ,Uf;fyhk; 
 Nkfrk;ge;jkhd fpue;jp Kjypa Neha;fs;> Nrhif Neha; ,tw;whYk; 
cz;lhfyhk; $wg;gl;Ls;sJ. 
gpj;jghz;L cz;lhff; fhuzq;fs;: 
―Va;e;jTl; bdf;fhyj;jpy; vOk;gpLk; gpj;je; jd;dpy;  
tha;e;jpLk; cg;Gg; Gspg;G khpre;jh ndDk; gjhh;j;jk;  
Nrh;e;Jgpj; je;jhd nfl;L rpNyw;gdk; nghUe;jpj; Njf;fpw;  
gha;e;J tz;ze; jidf; nfLf;Fk; gapj;jpag; ghz;LthNk‖  
- jd;te;jphp itj;jpak; ,uz;lhk; ghfk;  
 
 cl;bz fhyj;jpy; rhjhuzkhfg; gpj;jk; mjpfhpj;jpUf;Fk; NghJ cg;G> 
Gspg;G> kpsF Kjyhditfis mjpfk; rhg;gpl;lhy; gpj;jk; nfl;Lg; 
Nghk;. 
 fgKk; Nflile;J Njf fhe;jpia mopf;Fk;. gpj;j ghz;L NuhfKk; 
cz;lhFk;. 
NILAM 
―FwpQ;rp tUepyj;jpw; nfhw;wKz;b uj;jk; 
cwpQ;rp tURu Kz;lhk; mwpQiuf; 
ifaNk jq;Fjuj; jhik ty;iyAq; fjpf;Fk; 
IaNk jq;Fk; mwp‖    
- rpj;j kUj;Jthq;f RUf;fk; 
People living in mountain regions have more chances for the occurrence of paandu 
noi. 
Neha; vz;: (Classification) 
According to ―Yugimuni” Paandu Noi is classified into 5 types as,  
    ―$wNt ghz;Ltplg; ngaiuf; Nfsha; 
        Fwpg;ghf ite;Jtpj khFk; ghNu 
    thuNt thjkhk; ghz;L NthL 
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        khh;f;fkh gpj;jj;jpd; ghz;L thFk; 
    NjwNt rpNyl;Lkhk; ghz;L jhDk; 
        jphpNjhlg; ghz;NlhL tplg;ghz; lhFk; 
    MwNt ghz;Ltpl thz;ik nay;yhk; 
        Muha;e;J nrhy;yNt mwpe;J nfhs;Ns‖ 
     - A+fp itj;jpa rpe;jhkzp;  
[e;J gphpTfshf $wg;gl;Ls;sJ. mit 
1. thj ghz;L 
2. gpj;j ghz;L 
3. rpNyj;Jk ghz;L 
4. jphpNjhl ghz;L 
5. tpl ghz;L 
 
jd;te;jhp itj;jpak; 
    ―gapj;jpa ghz;L thj ghz;LNt rpNyj;kghz;L 
    tpaj;jphp Njhlg; ghz;L ntSk; gpj;jr; rpNyj;k ghz;L 
    gapj;jpa thjghz;L gfh; re;epthjghz;L  
    eag;GWk; ghz;L Ntopd; Fzj;ij ehd; etpyYw;Nwd;‖  
VO gphpTfshf $wg;gl;Ls;sJ. mit 
1. gpj;j ghz;L 
2. thj ghz;L 
3. rpNyj;k ghz;L 
4. re;epghj ghz;L 
5. gpj;jrpNyj;k ghz;L 
6. gpj;j thj ghz;L 
7. jphpNjhl  ghz;L 
 
mfj;jpah; Fzthflk;  
    ―ghulh ghz;L tif nrhy;yf; Nfsha; 
    ghpthd ghz;lJ jhdQ; NrahFk; 
    thulh tpthj gpj;jk; rPPj ghz;L 
    tifahd tplghz;L kpUj;jpfh ghz;L‖ 
[e;J gphpTfshf $wg;gl;Ls;sJ. mit 
1. thj ghz;L 
2. gpj;j ghz;L 
3. rPj ghz;L 
4. tplghz;L 
5. kpUj;jpfh ghz;L 
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T.V.rhk;grptk; gps;is mfuhjp  
vl;L gphpTfshf $wg;gl;Ls;sJ. mit 
1. gpj;j ghz;L 
2. thj ghz;L 
3. rpNyl;Lk ghz;L 
4. tp~g; ghz;L 
5. jphpNjh~g; ghz;L 
6. CJ ghz;L 
7. ePh;g; ghz;L 
8. vhpg; ghz;L 
ruNge;jpuh; ghz;L fhkhiy Nuhf rpfpr;ir  
   [e;J gphpTfshf $wg;gl;Ls;sJ. mit 
1. thj ghz;L 
2. gpj;j ghz;L 
3. fg ghz;L 
4. re;epghj ghz;L 
5. kz; jpd;wjhNyw;gl;l ghz;L 
mDgt itj;jpa Njtufrpak;  
[e;J gphpTfshf $wg;gl;Ls;sJ. 
1. thj ghz;L  
2. gpj;j ghz;L 
3. rpNyj;k ghz;L 
4.  jphpNjhl ghz;L 
5.  kz; ghz;L 
rpfpr;rh uj;d jPgk; - ,uz;lhk; ghfk;  
[e;J gphpTfshf $wg;gl;Ls;sJ. mit 
1. thj ghz;L 
2. gpj;j ghz;L 
3. rpNyj;Jk ghz;L 
4. jphpNjhl ghz;L 
5. tp~ghz;L 
Nuhf eph;za rhuk;  
[e;J gphpTfshf $wg;gl;Ls;sJ. mit 
1. thj ghz;L 
2. gpj;j ghz;L 
3. rpNyj;Jk ghz;L 
4. jphpNjhl ghz;L 
5. tp~ ghz;L 
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MURKURIKUNANGAL (Premonitory symptoms): 
In Siddha Maruthuvam Pothu, Kuppusamy Mudaliar states that,  
Paandu patients exhibit the following symptoms from their initial stage of 
development itself. The patient experiences insidious onset of fatiguability, dyspnoea 
on exertion, diminished vision, fainting, palpitation and pallor of the skin. 
According to Theraiyar Neerkuri, 
―,aw;if ePu; RUq;fpDk; ,JTk; ryg; nghUs; 
nraw;if ahaUe;jpDk; rpWj;j ePupJk; 
ghz;L Neha;r; rk;gtj;jij; jUkpjpy;‖   
-  Njiuau; ePu;f;Fwp 
Oliguria occurring suddenly and oliguria occurring even after excessive 
intake of water are explained as premonitory symptoms of Paandu noi. 
 
ghz;L FwpFzq;fs; (Clinical features) 
In Siddha Maruthuvam Pothu, Kuppusamy Mudaliar states; 
Inability to walk, headache, palpitation, blurring of vision, giddiness, syncope, 
dyspnoea, anorexia, vomiting, paleness of the skin, nail beds become swollen and 
pallor, fissured tongue, glossitis, hoarseness of voice are general signs and symptoms 
of Pandu noi. In females scanty menstruation, sometimes menorrhagia may occur. If it 
occurs in children and elderly, it may manifest because of worm infestation and blood 
disorders. If it occurs in pitha thegi, anorexia, indigestion, burning sensation, pallor of 
skin, glossitis, and dysphagia, Vomiting with bile, bitter taste and diarrhoea occurs. If 
the symptoms persist for longer duration it results in jaundice. 
 
mfj;jpah; Fzthflk; vd;Dk; E}ypy;, 
―cz;lhFk; Ntisjd;dpy; Njf Neh;ik 
cWjpaha;r; nrhy;YfpNwd; ed;wha;ghU 
Fz;lhd Kfk;fz;fs; cjL ehf;F 
Fwpg;ghd tha;NtWk; Njf Kw;Wk; 
Ntz;lhf NtAyh;e;J ntz;ikahfp 
tpuy; efq;fs; KOtjpYk; uj;jk; tw;wp 
fz;lhd fhy;fs;jhd; jzpe;J epw;Fk; 
fUthd ehbaJ nkJtha;g; NghNk 
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NghNkjhd; jPgdq;fs; kl;Lg;gl;L 
nghypthd fz;tpopfs; ngUj;Jj; Njhd;Wk; 
MNkjhd; mrf;jpA khahrq; fz;L 
mth; eilAk; jsh;e;J ngU%r;Rf; fz;L 
Nkjhd; %h;r;irAld; khh; Jbj;J 
Kbthd fZf;fhypy; tPf;f Kz;lha; 
Nkjh dpUjaj;jpd; tjde; jd;dpe; 
JUj;jpepfh; rj;jkJ Nfl;Fk; ghNu‖ 
Stomatitis, dryness of the skin, pallor of the face, eyes, lips, tongue and nails, 
lassitude, tiredness, low volume pulse, anorexia, swelling of the eyelids, dyspnoea on 
exertion, palpitation, oedema of the ankle joint, added heart sounds in the precordium 
are mentioned as the signs and symptoms of Paandu noi. 
a+fpKdp itj;jpa fhtpak; vd;Dk; E}ypy;  
―apUkYk; apisg;Gk; neQ;rpy; apbg;Gld; Jbg;Gk; cz;lhFk;  
 ngUfNt elf;Fk; NghJ mjpfk; MFk;  
ntUTwf; fpWfpWj;J NkdpAk; ntSj;Jjf;fp  
cUfpby; gpj;jghz;L Nuhfk;nad;Wiuf;fyhNk‖ 
Dyspnoea on exertion, Chest pain, Giddiness, Pallor present all over the body 
are mentioned as symptoms of Paandu noi. 
mf];jpau; itj;jpa uj;d RUf;fk;; vd;Dk; E}ypy;, 
―cw;wNjhu; md;dNgjk; mNuhrfk; cjuke;jk; 
Kw;wpa khu;GNeha; %j;jpuk; nghd;dpd; td;ik 
ntw;wp Nru;Gwq;fhy;if fz;tPq;Fly; ntSj;jy; Ntu;j;jy; 
gw;wp njhf;fpw;fha; gapj;jpa ghz;LthNk‖  
 
Indigestion, Change of taste, Flatulence, Chest tightness, yellowish 
discolouration of urine, Oedema of limbs, Palor of skin, Sweating  are  the  symptoms 
of  Pitha paandu.  
―Mdfz; kyrq;fs; mzpefq; fWg;gjhq; 
jhfkh kq;fnkq;Fk; jbab gLifNghy 
fdkha; eLf;fKz;lh tpire;J Ju;gyKz;lhk;‖ 
Discolouration of conjunctiva, urine, faeces and nails, Excessive thirst, Pain in 
whole body, lassitude and Fatigue are also the features. 
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gjpndz; rpj;jh;fs; ehb rh];jpuk; vd;Dk; E}ypy;, 
―,Uk;gY kpisg;Gk; neQ;rpy; ypbaJ kpfTz;lhFk; 
ntUfpa fpWfpWg;Gk; NkdpAk; ntspwpg; NghFk; 
ngUfpa gpj;jghz;L nad;dNt NgryhNk 
fUfpa gy;Yk;ehTq; fha;r;rYkpsg;G Kz;lhk;‖ 
Cough,  Dyspnoea on exertion, Chest pain, Giddiness, Pallor present all over 
the body are mentioned as symptoms of Paandu noi. 
guuhr Nrfuk; vd;Dk; E}ypy;, 
―gpj;jj;jp nyLj;j ghz;L NgReh twl;rp Az;lhk;  
kw;Wly; gRik ahfp kQ;rsp dpwKz;lhk; 
Cw;wpL %h;r;ir jhf nkhsp nfLq; fz;zkhKk; 
J}w;wpL kow;rp thapw; Wh;ehw;wk; Gspj;Njf;Fz;lhk; 
,UkNy apisg;G neQ;rpypbg;Gld; Yug;G khfpg;  
ngUfNt elf;Fk;NghJ NgR Kl;lJNk ahFk; 
ntWTwf; fpUkp Wf;F NkdpAk; ntSj;jijf;Fk; 
ngUfpNa gpj;j ghz;L thkd NgrpdhNu 
Cjanka; aijj;Jf; iffh Nyha;e;Jld; Rue;J Nehtha;g; 
GijaNt tPq;Fk; fz;Zk; NghjNt ntSf;FQ; Nrhh;thg; 
ghjfu kfpY kpQ;rpQ; nrhwptjh arYgw;Wk; 
tpjKW Fzq;fs; gpj;j ghz;nld tpsk;gpdhNu‖ 
Dryness of mouth, Greenish and yellowish discolouration of  body colour, 
Lassitude, Excessive thirst, Bad odour in mouth, Indigestion, Cough, dyspnoea on 
exertion, Paleness, Cardiac murmurs, Oedema of body and limbs and Tiredness are 
the features  of  Pitha paandu.  
 
 jPUk; jPuhjit: 
A+fp itj;jpa rpe;jhkzp  
tplghz;L jPuhJ vd $wg;gl;Ls;sJ     
jd;te;jhp itj;jpak; ghfk; 2 
jphpNjhl ghz;L 
re;epghj ghz;L jPuhJ 
rhj;jpah rhj;jpak; :  
mDgt itj;jpa Njtufrpak;  
tPf;fk;> Nrhk;gy;> jhfk;> mNuhrfk;>the;jp> tpf;fy;>,Uky; Ngjpnad;Dk; 
Fzq;fSz;lhfp ve;j t];Jit ghh;j;jhYk; kQ;rs; epwkhf Njhd;Wjy;> 
fz;fspYk;> efq;fspYk;> kQ;rs; epwKk; cz;lhfpy; mrhj;jpak;. 
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mfj;jpah; Fzthflk; 
jhdhd mrhj;jpaj;jpd; ghz;b Ndh;ik 
jhdwpar; nrhy;YfpNwd; juzp Nahh;f;F 
Cdhd Njfj;jpy; ,Uky; Ngjp 
cWjpaha; the;jpAld; tpf;fy; fhZk; 
Njdhd Njhw;wklh kQ;rs; fhl;Lk; 
njspthd eff;fz;fS kQ;r shfp 
tPzhfg; NghFklh kUe;J nra;jhy;  
tpz;Zyfpw; nry;thd;ghh; tpjpjPh;e; jhNd 
,Uky;> Ngjp> the;jp> tpf;fy;> Njfk; kQ;rshjy;> efq;fspYk; 
fz;fspYk; kQ;rs; epwk; Njhd;wy; mrhj;jpak; vd $wg;gl;Ls;sJ. 
fz;Zrhkpak; vd;Dk; itj;jpa Nrfuk; vd;Dk; E}ypy;,  
―ghz;L gpuNkfk; gd;thj R+iyFd;kk; 
Ntz;lh raQ;rd;dp ntz;Nrhig – ePz;l 
mjpePNu fhkhiy ahdgpzp jk;K 
sjp rhukh fhjwp‖ 
ghz;L Nehapy; mjprhuk; cz;lhdhy; mrhj;jpak; vd $wg;gl;Ls;sJ. 
―ntg;Gg; gpzpajdpy; ntk;Nkfj;jhy; tUe;jpd; 
jg;Gkpif ePNujh dpwq;fpd; nrg;Gk; 
fpuhzpapw; ghz;by; fpsh;ePh; RUq;fpw; 
gpuhzd; gphpAnkdg; NgR‖ 
Nehahspf;F RuNehapYk;> NkfNehapYk; rpWePh; mjpfhpj;J ,wq;fpdhYk;, 
fpuhzp> ghz;L Kjypa Nehapy; rpWePh; Fiwe;J ,opapDk; caph;f;F jPJ. 
 
Kf;Fw;w NtWghLfs;: 
cly; td;ik Fiwe;J grpj;jP Nflile;J cz;l czT rhpahfr; 
nrhpahj fhuzj;jhy; ,urf; FUjpfs; Cl;lk; ngwh> mitfSld; mdy; 
gpj;jKk; nfl;L> NjhYf;F epwj;ijf; nfhLf;Fk; moy; (,uQ;rpj gpj;jKk;) 
nkype;J epwj;jpYk; vilapYk; Fiwe;J jPf;Fw;wj;ijg; ngUf;Fk;. mjd; 
fhuzkhf kw;w ,U Fw;wq;fSk; jd;dpiy kpFe;J guTfhypd; (tpahdd;) 
td;ikiaf; nfLj;J ntSg;G Nehia cz;lhf;Fk;. 
Nehapd; td;ik ngUfg; ngUf IaKk; ngUfp tPf;fk; Kjypatw;iw 
Jiz Nehahf;fpf; nfhs;Sk;. 
ehb eil:  
 gpj;j thjk;  
 thj fgk;  
 fg thjk;  
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“rpwg;ghd gpj;jj;jpy; thj ehb 
               NrhpYU jhJel;l Kjpu gPil  
        ciwg;ghfr; nrhpahik Fd;kQ; R+iy 
               cw;wRuq; fpuhzptapw; wpiur;ry; ke;jk; 
        miwg;ghd Xq;fhu GwePh;f; Nfhit  
               Mahrq; ,uf;fnkhL kaf;f %h;r;ir  
        Kiwf;fha;T tpltPf;fk; %y tha;T 
               Kulhd Neha;gyTk; KLFk; gz;Ng”. 
      - Neha;ehly; Neha;Kjy; ehly; 
 
ghq;fhd thjj;jpy; Nrj;Jk ehbg;  
   ghprpj;jhy; jpkph;NkT Kisr;r yhFk;. 
  jPq;fhd ,UkYld; re;ep Njhlk;  
   Nrh;e;jtplk; ntb#iy ,Uj; Nuhfk;  
  thq;fhj <iske; jhu fhrk;  
   typAlNd GwtPr;R cs;tPr;R tPf;fk;  
  Xq;fhZQ; RuKlNd Rthrfhrk;  
   cz;lhFk; ntFNeha;f;F KWjp jhNd 
     - Neha;ehly; Neha;Kjy; ehly; 
 
fz;lhNah rpNyw;gdj;jpy; thjehb  
   fye;jpLfpy; taWnghUky; fdj;j tPf;fk;  
  cz;lhNyh Xq;fhuQ; rf;jp tpf;fy;  
   cWjpul;ir tha;Ttyp re;ep Njhlk;  
  tpz;lhNyh ,isg;gpUky; Nrhig ghz;L  
   tplghfk; tpa#iy gf;fthjk;  
  jpz;lhL ehrpfh gPlq; ff;fy;  
   rpuNeha;fs; gyTk;te;J rpf;Fe; jhNd  
          - rjf ehb 
caph;jhJf;fs; : 
 thjkha; gilj;J> gpj;j mdyha; fhj;J  
 Nrj;Jk rPjkha; Jilj;J 
        - Njiuah; kUj;Jt ghujk;                                                                
VATHAM 
Sites of Vatham: 
 Below Naval, Urinary bladder, intestines, Pelvis, umbilical cord, thigh, bone, 
skin, nerve endings, joints, Musculature, hair root. 
           Properties: Dryness, lightness, clearness, coolness, mobile formless. 
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Function  
1. Pranan (uyirkaal) :  
This controls knowledge, mind and five sense organs, which are useful for 
breathing and digestion. 
2. Abanan (Keezh nokku kaal) :  
This is responsible for all down ward movements such as passing urine, stools, 
semen, menstrual flow etc. 
3. Samanan (Nadukkaal) :  
This aids in proper digestion. 
4. Viyanan (paravukaal) : 
This is responsible for all movements of all parts of the body. 
5. Uthanan (Mel Nokkukaal) : 
Responsible of all upward visceral movements, such as vomiting, erection and 
nausea. 
6. Nagan :  
Responsible for opening and closing the eyes. 
7. Koorman :  
Responsible for vision and yawning. 
8. Kirugaran : 
Responsible for salivation, nasal secretion and appetite. 
9. Devathathan :  
Resposible for Laziness, sleeping and anger. 
10. Thananjeyan :  
Produces bloating of the body after death. It escapes on the third day after 
death bursting out of the cranium. 
 
In Pitha Paandu 
Piranan  : Affected (dyspnoea on exertion) 
Abanan  : Affected (in case of menorrhagia and Constipation) 
Viyanan               : Affected (Joint pain) 
Samanan  : Affected (loss of appetite) 
Kirukaran  : Affected (loss of appetite) 
Devathathan : Affected (fatigue) 
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PITHAM 
Sites of Pitham: 
 Between the heart and naval, sweat, lymph, blood, stomach, urinary bladder, 
heart, saliva, eye and skin. 
Properties: 
 Dry, cold, hot, light, subtle, keen, soft, liquid, bitter. 
Function 
1. Anal Pitham  : It promotes appetite and helps in digestion. 
2. Ranjagam      : It gives colour to the blood. 
3. Prasagam       : It gives complexion to the skin. 
4. Alosagam      : It brightens the eyes. 
5. Sathagam    : It controls the whole body. It has the property to fulfill all the 
activities which the mind desires. 
In Pitha Paandu 
 Anal Pitham    -   Affected (loss of appetite) 
 Ranjaga pitham - Affected (Pallor of skin, mucous membrane and                       
conjuctiva) 
 Saathaga pitham -   Affected (Difficulty in working) 
 Pirasaga pitham -   Affected (Pallor of skin)           
 
KABAM 
Sites of Kabam: Above the heart, stomach, fat, sperm, tongue, uvula, bone marrow, 
blood, nose, nerves, bones, large intestine, eyes, joints. 
Properties: Heavy, cold, mild, watery, sweet stable and slimy 
Function  
1. Avalambagam: Lies in the lungs, controls the heart and other kabhams. 
2. Kilethagam   : Lies in the stomach, makes the food moist, soft and helps in        
.                          digestion 
3. Pothagam       : Responsible for recognizing taste. 
4. Tharpagam     : Present in the head and responsible for cooling sensation of     
                          Eyes and the body 
5. Santhigam      : Responsible for lubrication and free movements of joints.   
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In Pitha Paandu  
 Avalambagam      -Affected (dyspnoea on exertion) 
 Kilethagam        -Affected (loss of appetite) 
         
Ezhu Udal Thathukkal (Physical constituents)  
Normal functions: 
Saram: 
 It is responsible for the growth and development.  It keeps the individual in 
good spirit. It gets separated from food and nourishes the body 
Senneer: 
 Blood imparts colour to the body and nourishes the muscle responsible for the 
ability, intellect of the individual. It is responsible for existence of knowledge, 
strength, and blood component 
Oon: 
 It gives shape to the body according to the requirements for the physical 
activity, nourishes fat. 
Kozhuppu: 
 It helps in lubricating different organs, functioning of organs and provides a 
cover for the body 
Enbu: 
 Structural unit of the body, responsible for posture and movements of the 
body. 
Moolai: 
 It fills the bony cavity, nourishes semen, simparts strength endurance and 
shining appearance. It represents the bone marrow and strengthens the bone.  
Sukkilam / Suronitham: 
 It is responsible for reproduction.   
In Pitha Paandu: 
 Saaram : Affected (fatigue) 
 Senneer : Affected (pallor of skin, mucous membrane and conjunctiva) 
 Sukkilam / Suronitham:  Affected (in case of menorrhagia/ amenorrhoea) 
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PINIARI MURAIMAI- (DIAGNOSIS): 
 Diagnostic methods in Siddha system are very unique and solely based on 
clinical acumen of the physician. 
1. Poriyal Arithal (or) understanding by the fire organs of perception (Mei, Vai, 
Kann, Mooku, Sevi) 
2. Pulanal Arithal (or) understanding by the sense objects (Uraithal, Suvaithal, 
Parthal, Mugarthal, and Kettal) 
3. Vinaidal (or) Interrogation 
 Tools used by Siddha Physicians: 
(1) Kanndal (Perception) 
(2) Karuthal (Inference) 
(3) Oorai (The instruction of the inspired) (Njh.fp.M) 
 The application of these three is very extensive in diagnosis and treatment. 
 
ENNVAGAI THERVU (Eight tools of Diagnosis) 
 Ennvagai thervukal is a unique method of diagnosing the disease, which was 
developed by siddhars.  
―ehbg;ghprk; ehepwk; nkhoptpop  
kyk; %j;jpukpit kUj;JtuhAjk;‖.      
     - Neha; ehly; Neha; Kjy; ehly; 
Naa: 
 Colour of the tongue, size, shape, anomalies, surface, mobility and local lesion 
should be noted. Coating deposition of the tongue, increased salivation and dryness of 
the tongue. 
 In Pitha Paandu, pallor of the tongue is present. 
Niram: 
 Colour of the skin all over the body, a local region of affection, conjunctiva, 
tongue, nail bud, hair etc. 
 Vatha Udal  - Black and whitish colour 
 Pitha Udal  - Yellowish (or) Reddish colour 
 Kapha udal  - White or golden colour 
 Thontha udal    - Mix of two udal colours 
 In Pitha Paandu, the colour of skin is pale. 
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Mozhi: 
 Speech and voice should be observed. 
Vizhi: 
 Observation of colour, character, vision. 
 In Pitha Paandu - pallor of conjunctiva is present 
Sparisam: 
 Colour of the skin, Eruption, Hemorrhages, Ulcers, Boils, trophic changes, in 
the skin can be identified. 
 Any changes in the internal organs can be noted by palpation (or) percussion. 
 In Pitha Paandu - normal temperature, sometimes hypothermia, dry skin 
is present 
Malam: 
 Quantity, colour, smell, froth should be observed. 
            In Pitha Paandu - constipation present.  
Moothiram:        
           Quantity, colour, froth, smell and specific gravity of urine should be noted. 
 
ghz;L Neha; cw;gj;jpiaf; fhl;Lk; ePupd; vQ;ry; ,yf;fzk;: 
     ―,aw;if ePu; RUq;fpDk; ,JTk; ryg;nghUs; 
     nraw;if ahapUe;jpDk; rpWj;j ePupJTk; 
     ghz;L Neha;r; rk;gtj;ijj; jUkpjpy; 
     Jz;Lwhg; NgjpAk; Nrhu;Tk; gpwf;FNk‖ 
                          - Neha; ehly; Kjy; ghfk; 
 xU fhuzKkpd;wp ,aw;if msTf;Ff; Fiwe;J ,opAk; ePUk; 
ePu;g;nghUl;fis kpFjpahAz;zpDk; Fiwe;jpopAk; ePUk; ghz;L Neha; 
cw;gj;jpf;F topahFk;. 
 
epwf;Fwp  
     ―mUe;JkhwpujKk; mtpNuhjkjha; 
     m/fy; myu;jy; mfhyt+d; jtpu;e;jow; 
     Fw;wstUe;jp cwq;fp itfiw 
     Mbf;fyrj; jhtpNa fhJ nga; 
     njhUK$u;j;jf; fiyf;Fl;gLePupd; 
     epwf;Fwp nea;f;Fwp epUkpj;jy; flNd‖ 
                     - Neha; ehly; Kjy; ghfk;  
26 
 
Collection of Sample Urine: 
 The patient must take well cooked food in the previous day.  The intake must 
be proportionate to the degree of his appetite.  Food intake should be taken, at 
appropriate time.  We must have sound sleep on the previous night.  The urine is 
collected on the down of the next day in a glass container and closed immediately to 
prevent contamination.  This specimen must be examination with in one and half 
hours.  This procedure should be followed strictly to get accurate observation of 
Neerkuri and Neikuri. 
 
nea;Fwp: 
    ―epwf;Fwpf; Fiuj;j  epUkhz ePupw; 
     rpwf;f ntz;nza;Nahu;  rpWJsp eLtpLj; 
     njd;Wwj; jpwe;njhyp Vfhjikj;jjp 
     dpd;wjptiy Nghk; newptpopawpTk; 
     nrd;wJ  GfYQ;  nra;jpia  AzN‖u 
      - Neha; ehly; Kjy; ghfk; 
NEIKURI: 
 The diagnosis and prognosis of deranged Mukkutrams are studied on the basis 
of the behaviour of a drop of gingelly oil gently dropped on the surface of the urine 
kept in a wide vessel in the sunlight. 
      ―Mop Nghw;gutpd; m/Nj gpj;jk;‖ 
                     - Neha; ehly; Kjy; ghfk;  
In Pitha Paandu, the oil dropped in urine, showed a ring shaped structure.  
Neikuri in pandu noi:  
―tpiuTld; fjpHNghy; ePz;L Ntw;Wikf; Fzq;fs; fz;lhy;  
 FUjpjhd; nfl;L ehrk; Fd;wpa Fzknjd;Nd‖.          
         - NjiuaH  
 If the oil spreads like a kathir (ray), it indicates Pandu noi. 
 
Naadi: 
 Pulse diagnosis is the confirmatory diagnosis.  
  In Pitha Paandu - Pitha Vatham, Vatha Kabam, Kaba Vatham 
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PROGNOSIS OF PAANDU:  
Curable and Incurable Types:  
 It is said that Vida Pandu had poor prognosis. Even though other types are 
curable, symptoms like vomiting, diarrhoea, oedema of body, excessive thirst, 
hiccough, diabetes mellitus, tuberculosis occurs it leads to complications.  
According to Sarabendrar Vaidhya Muraigal:  
 mjpf ehshd ghz;L Nuhfk; rpfpr;irf;F trg;glhJ. GjpjhdhYk; cly; 
tPf;fj;jpy; kQ;rs; epwk; fhzg;gl;lhy; Fzk; Vw;glhJ. kyr;rpf;fNyh my;yJ 
gr;ir epwkhd mjprhuNkh Vw;gl;lhy; mrhj;jpak;> gytPdk;> the;jp> %h;r;ir 
ehtwl;rp> ,uj;j Fiwtpdhy; cly; ntSg;G KjypaitfSld; $ba 
NuhfpAk; FzkiltJ rpukk;. gw;fs;> efk;> fz; ,itfs; mjpfk; 
ntSjj;hYk; vy;yhtwi;wAk; ntz;zpwkhf ghh;j;jhYk; me;j Nuhfk; 
mrhj;jpakhFk;. mrhj;jpa Nuhfj;ij Kw;wpYk; Fzg; gLj;j Kbahtpl;lhYk; 
rpwpJ FwpFzq;fis Fiwj;J MAisAk; rpyfhyk; ePbf;f nra;ayhk;.  
  iffs;> fhy;fs;> jiy Kjyhd ,lq;fspy; tPf;fk; Vw;gl;L ,isj;J 
iffhy;fSk; ,isj;J tapW ngUj;Jk; cs;s ghz;L NuhfpiaAk;> Mz;Fwp> 
njhilapLf;F Mfpa ,lq;;fspy; tPf;fk;> mbf;fb kaf;fk;> mjprhuk;> Ruk; 
fz;lhy; jPuhJ.  
 ghz;L Nuhfpf;F tPf;fk;> Nrhk;gy;> jhfk;> mNuhrfk;> the;jp> tpf;fy;> 
,Uky;> Ngjp vd;Dk; ,f;Fzq;fs; cz;lhfp ve;j t];Jit ghh;j;jhYk; 
kQ;rs; epwKz;lhfpy; mrhj;jpak;. - mfj;jpah; itj;jpag; gps;isj; jkpo;.  
 
FATE OF THE DISEASE:  
Kannusamiyam States that,  
    ―ntg;Gg; gpzpajdpy; ntk; Nkj;jhy; tUe;jpd;  
   jg;G kpif ePNu jhdpwq;fpd; - nrg;Gk;    
 fpuhzpapw; ghz;by; fpsH ePH;RUq;fpw;    
 gpuhzd; gphpAnkdg; NgR.‖         
         - fz;Zrhkpak;  
 ―ghz;L gpuNkfk; gd;thj #iy Fd;kk;   
 Ntz;lh raQ;rd;dp ntz;Nrhig - ePz;l   
 mjpePNu fhkhiy ahdgpzp jk;K  
 sjp rhukh fhjwp‖         
         - fz;Zrhkpak;  
28 
 
NOI NEEKKAM (TREATMENT):   
 The speciality of siddha treatment emphasis not only for complete healing but 
also for the prevention and rejuvenation. This is said as follows,    
 Kappu (Prevention)    
 Neekkam (Treatment)   
 Niraivu (Restoration)  
 Siddha system stated that even during the time of conception, some defects 
creep into the fertilized embryo. These defects form the basis of the manifestation of 
certain constitutional disease later on during the existence of the individual.  Diseases 
are produced by the unequilibrium of three thathus, which may be due to various 
causes like diet, life style pattern, mental and physical activities.  When treating the 
diseases the following principles must be noted.  
 
―Neha;ehb Neha;Kjy; ehbaJ jzpf;Fk;  
  tha;ehb tha;g;gr; nray;.‖  
   
―cw;whdsTk; gpzpasTk; fhyKk;  
  fw;whd; fUjpr; nray;.‖      
        - jpUf;Fws;   
 So it is essential to know the disease and the cause for the onset of disease, the 
nature of the patient, the severity of the illness, the season and the time of occurrence 
of the disease must be observed.  
 
LINE OF TREATMENT OF PANDU:   
In Veluppu noi, the appetite is lost. The food taken will not be digested well 
which results in anaemia and body weakness. Besides these, ‗Anal Pitham‘ and the 
Ranja kapitham which gives the natural colour to our skin are affected by this disease. 
The body will be pale and loses its weight. It will increase ‗Azal‘ humour. The 
increased Azhal humour also increases the other two humours‘ and Vyanan which 
results in Anaemia. So the purgatives are given to correct the deranged humours. 
Later, the appetizer, digestive tonics, and hematinic will be given. The medicines 
given to induce purgation may be chosen as laxatives. Especially in Pitha Paandu noi, 
29 
 
Rasam and Ratha thathus are mostly affected. So Iron rich components are used in the 
trial drug. 
The trial drug THIRIPALAI MATHIRAI is given 1 tablet with Karisalai 
kudineer 100 ml BD dose to increase the Hb level. Iron rich foods are also 
recommended. 
PAANDU ROGA HARAM (drugs for Anaemia): 
 Trikadugu (dried ginger, pepper and long pepper), Buffalo buttermilk, goat 
buttermilk, Mandooram (Ferric oxide), Ayam (Iron), Ceylon lead wort (Plumbago 
zeylanica) root bark, cow‘s urine, embelia ribes, castor seeds (Ricinus communis), 
Honey, Irumanjal (Curcuma longa, Curcuma zedoaria), Chebulic myrobalan 
(Terminalia chebula), Beleric myrobalan (Terminalia bellerica) and Embelica 
officinalis (Indian goose berry) are drugs given for Anaemia. 
czT Kiwfs;: 
 Neha; njhlf;fj;jpy;> grpiaj; J}z;lf;$baJk;> clypd; FUjpiag;      
ngUf;ff;$baJkhd czTg; nghUl;fis toq;f Ntz;Lk;. 
 tapw;Wg; GOf;fs; ntspahapd;> mfj;jpfPiuia mbf;fb Nru;j;J tUtJ 
ed;W. 
 czTk; vspjpy; nrupf;f$bajhfNt ,Uj;jy; Ntz;Lk;. 
 cztpypUe;J fpilf;Fk;; ,Uk;Gr;rj;J clypy; cl;fpufpf;fg;gl 
itl;lkpd; rp Njit. itl;lkpd; rp rj;J epiwe;j czTfis Nru;j;J 
nfhs;s Ntz;Lk;. - ney;ypf;fha;> vYkpr;ir rhW  
 fPiu tiffspy;> fuprhiy> nghd;dhq;fhzp> mWfPiu> rpWfPiu> 
kzj;jf;fhsp ,itfs; FUjpiag; ngUf;ff; $bait. 
 fha;fwpfspy;>fj;jupg;gpQ;R> KUq;ifg;gpQ;R> thiof;fr;ry;> mtiug;gpQ;R 
vspjpy; nrupf;ff;$bait. 
 nts;shl;Lf;fwp> mjd; <uy;> vYk;G KjypadTk;> fhil> nfsjhup 
Kjypad clw;F Cl;lj;ij je;J FUjpapd; ngUf;if cz;lhf;Fk;. 
 Neha; td;ik kpFe;jpUg;gpd;> grpj;jP Fiwe;J> cztpy; ntWg;G the;jp 
,itfs; cz;lhFkhifahy;> vspjpy; nrupf;ff;$ba czTfshfpa 
fQ;rp tiffisAk;> Czpd ,urj;ijAk; toq;f Ntz;Lk;. 
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,Uk;Gr;rj;J epiwe;j czTfs;: 
 vy;yhtpjkhd fPiufs;: KUq;iff;fPiu> Kisf;fPiu> mfj;jpf;fPiu> 
Gspr;rfPiu kw;Wk; miuf;fPiu. 
 ntq;fhaj;jhs;> Ks;sq;fPiu kw;Wk; fhypgpstu; fPiu. 
 ghfw;fha;> Rz;ilf;fha;> nfhj;jtiu Nghd;w fha;fwpfs;. 
 khJsk;gok;> rg;Nghl;lh> Mg;gps;> ju;g+rzp> md;dhrp> mj;jp> ehty; 
Nghd;w fdpfs;        
 cyu;e;j NguPr;rk;gok;> jpuhl;ir Nghd;w cyu;e;j goq;fs;. 
 Nfo;tuF> fk;G> nfhs;S> vs;S> rhik> NrhahgPd;];> cyu;e;jgl;lhzp> 
fhuhkzp 
 nkhr;ir Nghd;w jhdpaq;fSk; gapW tiffSk; 
 jhtu tiffis tpl <uy;> kz;zPuy;> Ml;L ,iwr;rp> Nfhop <uy;> kPd;> 
,uj;jk;>fUthL Nghd;w czTg; nghUl;fspy; cl;fpufpf;ff; $ba 
,Uk;Gr; rj;J (Haem iron) mjpfkhf cs;sJ. 
 nty;yj;jpy; ,Uk;Gr;rj;J mjpfkhf cs;sJ. ,dpg;G gyfhuk; nra;a 
ru;f;fiuiaj; jtpu;j;J nty;yj;ij Nru;j;Jf; nfhs;syhk;. 
 
,Uk;Gr;rj;J epiwe;j czTg; gz;lq;fs;: 
 Nfo;tuF kw;Wk; nty;yk; Nru;j;J jahupj;j mjpurk;. 
 Ntu;f;fliy my;yJ nghl;Lf;fliyAld; vs;S kw;Wk; nty;yk; 
Nru;j;J jahupj;j cUz;il 
 Nfo;tuF> KUq;iff;fPiu kw;Wk; nty;yk; Nru;j;J jahupj;j mil. 
 iff;Fj;jy; mtypy; jahupj;j czTg; gz;lq;fs;. 
 Gjpdh kw;Wk; fUNtg;gpiyj; Jitay;. 
 gPl;&l; rhW 
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3.1.2 MODERN ASPECT 
DISORDERS OF THE BLOOD 
Disorders of the blood cover a wide spectrum of illnesses, ranging from some 
of the most common disorders affecting mankind (anaemias), to relatively rare 
conditions such as leukaemias and congenital coagulation disorders. Although the 
latter are uncommon, advances in cellular and molecular biology have had major 
impacts on their diagnosis, treatment and prognosis. Haematological changes occur as 
a consequence of diseases affecting any system and give important information in the 
diagnosis and monitoring of many conditions. 
FUNCTIONAL ANATOMY AND PHYSIOLOGYNCTIONAL ANATOM IO
 Blood flows throughout the body in the vascular system, and consists of 
plasma and three cellular components: 
      • red cells, which transport oxygen from the lungs to the tissues 
      • white cells, which protect against infection 
      • platelets, which interact with blood vessels and clotting factors to maintain 
vascular integrity and prevent bleeding. 
HAEMATOPOIESIS 
Figure – 3.1.2 a 
 
Haematopoiesis describes the formation of blood cells, an active process that 
must maintain normal numbers of circulating cells and be able to respond rapidly to 
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increased demands such as bleeding or infection. During development, 
haematopoiesis occurs in the liverand spleen and subsequently in red bone marrow in 
the medullary cavity of all bones. In childhood, red marrow is progressively replaced 
by fat (yellow marrow), so that in adults normal haematopoiesis is restricted to the 
vertebrae, pelvis, sternum, ribs, clavicles, skull, upper humeri and proximal femora. 
However, red marrow can expand in response to increased demands for blood cells. 
Bone marrow contains a range of immature haematopoietic precursor cells and a 
storage pool of mature cells for release at times of increased demand. Haematopoietic 
cells interact closely with surrounding connective tissue stroma, made of reticular 
cells, macrophages, fat cells, blood vessels and nerve fibres. In normal marrow, nests 
of red cell precursors cluster around a central macrophage, which provides iron and 
phagocytoses extruded nuclei. Megakaryocytes are large cells which produce and 
release platelets into vascular sinuses. White cell precursors are clustered next to the 
bone trabeculae; maturing cells migrate into the marrow spaces towards the vascular 
sinuses. Plasma cells are antibody-secreting mature B cells which normally represent 
< 5% of the marrow population and are scattered throughout the intertrabecular 
spaces. 
STEM CELLS 
All blood cells are derived from pluripotent stem cells. These comprise only 
0.01% of the total marrow cells, but they can self-renew (i.e. make more stem cells) 
or differentiate to produce a hierarchy of lineage-committed stem cells. The resulting 
primitive progenitor cells cannot be identified morphologically, so they are named 
according to the types of cell (or colony) they form during cell culture experiments. 
CFU–GM (colony-forming unit–granulocyte, monocyte) is a stem cell that produces 
granulocytic and monocytic lines, CFU–E produces erythroid cells, and CFU–Meg 
produces megakaryocytes and ultimately platelets. A range of growth factors, 
produced in bone marrow stromal cells and elsewhere, controls the survival, 
proliferation, differentiation and function of stem cells and their progeny. Some, such 
as granulocyte macrophage–colony stimulating factor (GM–CSF), interleukin-3 (IL- 
3) and stem cell factor (SCF), act on a wide number of cell types at various stages of 
differentiation. Others, such as erythropoietin (Epo), granulocyte–colony stimulating 
factor (G–CSF) and thrombopoietin (Tpo), are lineage-specific.  
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HAEMOGLOBIN 
Haemoglobin is a protein specially adapted for oxygen transport. It is 
composed of four globin chains, each surrounding an iron-containing porphyrin 
pigment molecule termed haem. Globin chains are a combination of two alpha and 
two non-alpha chains; haemoglobin A (αα/ββ) represents over 90% of adult 
haemoglobin, whereas haemoglobin F (αα/γ γ) is the predominant type in the fetus. 
Each haem molecule contains a ferrous ion (Fe2+) to which oxygen reversibly binds; 
the affinity for oxygen increases as successive oxygen molecules bind. When oxygen 
is bound, the beta chains ‗swing‘ closer together; they move apart as oxygen is lost. In 
the ‗open‘ deoxygenated state, 2, 3 diphosphoglycerate (DPG), a product of red cell 
metabolism, binds to the haemoglobin molecule and lowers its oxygen affinity. These 
complex interactions produce the sigmoid shape of the oxygen dissociation curve. The 
position of this curve depends upon the concentrations of 2, 3 DPG, H+ ions and 
CO2; increased levels shift the curve to the right and cause oxygen to be released 
more readily, e.g. when red cells reach hypoxic tissues. Haemoglobin F is unable to 
bind 2, 3 DPG and has a left-shifted oxygen dissociation curve which, together with 
the low pH of fetal blood, ensures fetal oxygenation. Genetic mutations affecting the 
haem-binding pockets of globin chains or the ‗hinge‘ interactions between globin 
chains result in haemoglobinopathies or unstable haemoglobins. Alpha globin chains 
are produced by two genes on chromosome 16 and beta globin chains by a single gene 
on chromosome 11; imbalance in the production of globin chains produces the 
thalassaemias. Defects in haem synthesis cause the porphyrias. 
 
FACTORS NECESSARY FOR HAEMOGLOBIN FORMATION: 
1. First class proteins and amino acids:  
 Proteins of high biological value are essential for the formation of 
haemoglobin. Amino  acids  derived  from  these  proteins  are  required  for  the  
synthesis  of  protein  part  of  haemoglobin,  the  globin. 
2. Iron: It is necessary for the formation of heme part of the haemoglobin. 
3. Copper: It is necessary for the absorption of iron from the gastrointestinal tract. 
4. Cobalt  and  nickel:  Cobalt  and  nickel  are  essential  for  the  utilization  of  iron  
during  haemoglobin  formation. 
5. Vitamins: Vitamin C, riboflavin, nicotinic acid and pyridoxine are also essential 
for the formation of haemoglobin. 
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DESTRUCTION 
Red cells at the end of their lifespan of approximately 120 days are 
phagocytosed by the reticulo-endothelial system. Amino acids from globin chains are 
recycled and iron is removed from haem for reuse in haemoglobin synthesis. The 
remnant haem structure is degraded to bilirubin and conjugated with glucuronic acid 
before being excreted in bile. In the small bowel, bilirubin is converted to stercobilin; 
most of this is excreted, but a small amount is reabsorbed and excreted by the kidney 
as urobilinogen. Increased red cell destruction due to haemolysis or ineffective 
haematopoiesis results in jaundice and increased urinary urobilinogen. Free 
intravascular haemoglobin is toxic and is normally bound by haptoglobins, which are 
plasma proteins produced by the liver. 
 
IRON 
It is present in ferrous (fe++) form. It is in unstable or loose form. Under  
certain conditions, the  iron  may  be  present  in  ferric  (fe++) state, which is a  stable  
form. 
IRON METABOLISM 
Iron is a critical element in the function of all cells, although the amount of 
iron required by individual tissues varies during development. At the same time, the 
body must protect itself from free iron, which is highly toxic in that it participates in 
chemical reactions that generate free radicals such as singlet O2 or OH-. 
Consequently, elaborate mechanisms have evolved that allow iron to be made 
available for physiologic functions while at the same time conserving this element and 
handling it in such a way that toxicity is avoided. The major role of iron in mammals 
is to carry O2 as part of hemoglobin. O2 is also bound by myoglobin in muscle. Iron 
is a critical element in iron-containing enzymes, including the cytochrome system in 
mitochondria.  Without iron, cells lose their capacity for electron transport and energy 
metabolism. In erythroid cells, hemoglobin synthesis is impaired, resulting in anemia 
and reduced O2 delivery to tissue.  
Iron taken in diet is absorbed at all parts of GI tract especially duodenal 
mucosa. Acid medium favours iron absorption. Acid medium favours formation of 
soluble macromolecular complexes of iron with vitamin C, sugar, amino acid or bile 
in the duodenum. Only 10% of the ingested iron is absorbed. Normal serum iron level 
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is 50 to 150 mg/dl. Frank iron deficiency increases absorption by 30- 40% and in iron 
overload, absorption decreases. Iron absorption is increased in (1) ferrous state, (2) 
increased erythropoiesis (3) iron deficiency. Iron absorption is decreased in (1) ferric 
state, (2) in the presence of phosphates and phytates, (3) bone marrow hypoplasia. 
The absorbed iron is stored in the form of ferritin (water soluble form) and 
haemosiderin (water insoluble form). In men, storage compartment contains about 
1000 mg of iron and in women, it ranges from 0-500 mg; In one-third of healthy 
women, there is no significant iron in storage compartment. The storage organs are 
liver, spleen, lymph nodes and bone marrow. Iron is transported after binding with 
transferrin, a cytoplasmic protein. Transport iron compartment contains 3 mg of iron. 
Transferrin concentration in plasma is measured by estimating total iron binding 
capacity or immunologically. Normally l mg of elemental iron is lost from shedding 
of senescent cells of gastrointestinal tract and genitourinary tract, and from 
desquamation of skin. 
 
Figure 3.1.2 b) Iron Metabolism  
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ANAEMIA 
Anaemia refers to a state in which the level of haemoglobin in the blood is 
below the normal range appropriate for age and sex. Other factors, including 
pregnancy and altitude, also affect haemoglobin levels and must be taken into account 
when considering whether an individual is anaemic. The clinical features of anaemia 
reflect diminished oxygen supply to the tissues. A rapid onset of anaemia (e.g. due to 
blood loss) causes more profound symptoms than a gradually developing anaemia. 
Individuals with cardiorespiratory disease are more susceptible to symptoms of 
anaemia. The clinical assessment and investigation of anaemia must not only assess 
its severity but also define the underlying cause. 
Figure 3.1.2 c) Anaemia 
 
 
CAUSES OF ANAEMIA 
 Decreased or ineffective marrow production 
• Lack of iron, vitamin B12 or folate 
• Hypoplasia 
• Invasion by malignant cells 
• Renal failure 
• Anaemia of chronic disease 
 Peripheral causes 
• Blood loss 
• Haemolysis 
• Hypersplenism 
Around 30% of the total world population is anaemic and half of these, some 
600 million people, have iron deficiency.  
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CLASSIFICATION OF ANEMIA 
 Anemia is classified by two methods 
 A. Morphological classification 
 B. Etiological classification  
Morphological Classification: 
 Morphological classification depends upon the size and colour of RBC. 
Colour is determined by quantity of hemoglobin, according to this anemia is classified 
into four types. 
1. Normocytic Normochromic Anemia 
 The size and heamoglobin content of RBC are normal but the number of RBC 
is less. 
2. Macrocytic Normochromic Anemia 
 The RBC is larger in size with normal hemoglobin content, the RBC count 
decreases. 
3. Macrocytic Hypochromic Anemia 
 The RBCs are larger in size. The hemoglobin content in the cell (MCH) is less 
so the cells are pale in colour. 
4. Microcytic Hypochromic Anemia 
 The RBCs are smaller in size and the hemoglobin content (MCH) is less. 
 
Etiological Classification 
On the basis of etiology anemia is classified into five types:  
1. Hemorrhagic anemia. 
2. Hemolytic anemia. 
3. Nutritional deficiency anemia. 
4. Aplastic anemia. 
5. Anemia of chronic disease. 
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IRON DEFICIENCY ANAEMIA 
Iron deficiency is one of the most prevalent forms of malnutrition. Globally, 
50% of anemia is attributable to iron deficiency and accounts for approximately 
841,000 deaths annually worldwide. Africa and parts of Asia bear 71% of the global 
mortality burden; North America represents only 1.4% of the total morbidity and 
mortality associated with iron deficiency.  
 
STAGES OF IRON DEFICIENCY 
The progression to iron deficiency can be divided into three stages. The first 
stage is negative iron balance, in which the demands for (or losses of) iron exceed the 
body‘s ability to absorb iron from the diet. This stage results from a number of 
physiologic mechanisms, including blood loss, pregnancy (in which the demands for 
red cell production by the fetus outstrip the mother‘s ability to provide iron), rapid 
growth spurts in the adolescent, or inadequate dietary iron intake. Blood loss in excess 
of 10–20 mL of red cells per day is greater than the amount of iron that the gut can 
absorb from a normal diet. Under these circumstances, the iron deficit must be made 
up by mobilization of iron from RE storage sites. During this period, iron stores 
reflected by the serum ferritin level or the appearance of stainable iron on bone 
marrow aspirations decrease. As long as iron stores are present and can be mobilized, 
the serum iron, total iron-binding capacity (TIBC), and red cell protoporphyrin levels 
remain within normal limits. At this stage, red cell morphology and indices are 
normal. When iron stores become depleted, the serum iron begins to fall. Gradually, 
the TIBC increases, as do red cell protoporphyrin levels. By definition, marrow iron 
stores are absent when the serum ferritin level is <15 μg/L. As long as the serum iron 
remains within the normal range, hemoglobin synthesis is unaffected despite the 
dwindling iron stores. Once the transferrin saturation falls to 15–20%, hemoglobin 
synthesis becomes impaired. This is a period of iron-deficient erythropoiesis. Careful 
evaluation of the peripheral blood smear reveals the first appearance of microcytic 
cells, and if the laboratory technology is available, one finds hypochromic 
reticulocytes in circulation. Gradually, the hemoglobin and hematocrit begin to fall, 
reflecting iron deficiency anemia. The transferrin saturation at this point is 10–15%. 
When moderate anemia is present (hemoglobin 10–13 g/dL), the bone marrow 
remains hypoproliferative. With more severe anemia (hemoglobin 7–8 g/dL), 
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hypochromia and microcytosis become more prominent, target cells and misshapen 
red cells (poikilocytes) appear on the blood smear as cigar- or pencil-shaped forms, 
and the erythroid marrow becomes increasingly ineffective. Consequently, with 
severe prolonged iron-deficiency anemia, erythroid hyperplasia of the marrow 
develops, rather than hypoproliferation. 
 
CAUSES OF IRON DEFICIENCY 
Conditions that increase demand for iron, increase iron loss, or decrease iron 
intake or absorption can produce iron deficiency. 
 Increased Demand for Iron 
 Rapid growth in infancy or adolescence 
 Pregnancy 
 Erythropoietin therapy 
 Increased Iron Loss 
 Chronic blood loss 
 Menses 
 Acute blood loss 
 Blood donation 
 Phlebotomy as treatment for polycythemia vera 
 Decreased Iron Intake or Absorption 
 Inadequate diet 
 Malabsorption from disease (sprue, Crohn‘s disease) 
 Malabsorption from surgery (gastrectomy and some forms of bariatric 
surgery) 
 Acute or chronic inflammation 
 
STAGES IN IRON DEFICIENCY ANAEMIA  
There are three stages in the development of iron deficiency anaemia.  
a. Negative iron balance  
b. Iron deficient erythropoiesis 
 c. Iron deficiency anaemia 
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CLINICAL PRESENTATION OF IRON DEFICIENCY 
Certain clinical conditions carry an increased likelihood of iron deficiency. 
Pregnancy, adolescence, periods of rapid growth, and an intermittent history of blood 
loss of any kind should alert the clinician to possible iron deficiency. A cardinal rule 
is that the appearance of iron deficiency in an adult male means gastrointestinal blood 
loss until proven otherwise. Signs related to iron deficiency depend on the severity 
and chronicity of the anemia in addition to the usual signs of anemia—fatigue, pallor, 
and reduced exercise capacity. Cheilosis (fissures at the corners of the mouth) and 
koilonychia (spooning of the fingernails) are signs of advanced tissue iron deficiency. 
The diagnosis of iron deficiency is typically based on laboratory results.  
 
INVESTIGATIONS  
I) Blood Investigation 
1. Total red blood cell count 
2. Differential count 
3. Erythrocyte sedimentation rate 
4. Mean corpuscular hemoglobin 
5. Mean corpuscular volume 
6. Mean corpuscular hemoglobin concentration 
7. Packed cell volume 
8. Red cell survival 
9. Serum iron 
10. Serum ferritin concentration 
11. Serum protein 
12. Serum creatinine 
 
II) Urine investigation 
1. Urine sugar 
2. Urine albumin 
3. Deposits 
4. Red blood cells 
5. Pus cells 
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 From the above investigations the following are predominant in iron 
deficiency anemia  
 Haemoglobin level: When Hb is greater than 10 gm/ dl, symptoms of anaemia 
develop only on exertion or on exposure to hypoxia or high altitude. If Hb 
level is less than 7 gm/dl, patient is symptomatic even at rest. 
 Microcytic, hypochromic (MCHC < 32%) RBCs in the peripheral smear.  
 The hemoglobin may fall to as low as 3gm/100ml but the red cell count is 
rarely below 2.5 million/cubic millimeter. 
 Reticulocyte and platlets are normal or increased. 
 The white cell count in normal serum iron is usually below 30 mug/100 ml 
(normal is 90-150 mug/100 ml)  
 Bone marrow hemosiderin is absent 
 The MCHC is below 27gm/dl.  
 
DIFFERENTIAL DIAGNOSIS 
1. Anaemia of chronic disease  
2. Thalassaemias  
3. Haemoglobinopathies (Hb E)  
4. Chronic liver disease  
5. Chronic renal disease  
6. Myelodysplastic disorders (refractory anaemia with ringed sideroblasts)  
7. Myeloproliferative disorders  
8. Hereditary sideroblastic anaemia  
9. Myxoedema  
10. Congenital atransferrinaemia. 
 
DIET: 
 Stomachic and haematinic food items are advised.  
 Apart from these, Agati grandiflora green leaves, and bitter gourd (Momordica 
charantia) like anthelmintic foods may also be advised.  
 Easily digestable food items generally advised. 
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3.2. REVIEW OF DRUGS 
KADUKKAI - TERMINALIA CHEBULA RETZ. 
Family: Combretaceae.  
Habitat: Kadukkai is the pericarp of mature fruit devoid of seeds, of Terminalia 
chebula Retz. (Fam. Combretaceae), a moderate sized or large tree found throughout 
India, chiefly in deciduous forests and areas of light rainfall upto about 1500 m. 
elevation, throughout India, It is abundant in Northern India.  
English: Chebulic Myrobalan, Black Myrobalan.  
Siddha/Tamil: Kadukkai.  
Phytochemical constituents: Shikimic, gallic, triacontanoic and palmitic acids, beta-
sitosterol, daucosterol, triethylester of chebulicacid and ethyl ester of gallic acid; a 
new ellagitannin, terchebulin, along with punicalagin and tea ﬂavin A have been 
isolated from the fruits. A new triterpene, chebupentol, and arjungenin, terminoic acid 
and arjunolic acid were also isolated from the fruit. Antioxidant constituents of the 
plant, phloroglucinol and pyrogallol have been isolated along with ferulic, vanillic, p-
coumaric and caffeic acids.  
Actions: Gentle purgative (The main purgative ingredient of Triphala is T. chebula 
(the purgative principle is in the pericarp of the fruit), astringent (unripe fruits are 
more purgative, ripe ones are more astringent; sennoside A and anthraquinone 
glycoside is laxative, tannins are astringent), stomachic, antibilious, alterative. Bark - 
diuretic.    
Uses: Along with other therapeutic applications, indicated the use of powder of 
mature fruits in intermittent fevers, chronic fevers, anaemia and polyuria. The fruits of 
T. chebula are used in combination with Emblica officinalis and T. bellirica (under 
the name Triphala) in the treatment of liver and kidney dysfunctions. Used in 
prescriptions for treating ﬂatulence, constipation, diarrhoea, dysentery, cyst, digestive 
disorders, vomiting, enlarged liver and spleen, cough and bronchial asthma, and for 
metabolic harmony.  
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Pharmacological activities: Ether extract showed higher antioxidant activity than 
BHA and BHT, Acid esters present in phenolic fraction of extract, were found most 
effective (C P Khare (Ed.) Indian Medicinal Plants, 2007). 
The modern pharmacological studies show that myrobalan has multiple 
biological activities, including antimicrobial, anti-inflammatory, antioxidation as well 
as anti-tumor (Zhang XJ et al., Zhongguo Zhong Yao Za Zhi, 2016). 
GUNAPADAM ASPECT 
fLf;fha; 
NtW ngau;fs;: mk;ik> mKjk;> mupjfp> gj;jpak;> tupfha; 
Rit: Kf;fpa Rit - Jth;g;G;  rpwpJ - ,dpg;G> Gspg;G> fhh;g;G> ifg;G 
jd;ik - ntg;gk; 
gpupT - ,dpg;G 
nghJf;Fzk;: 
jhil fOj;jf;fp jhY Fwpaptplg; 
gPil rpypgjKw; NgjpLKlk; - Milnal;lhj; 
J}ykpb Gz;thj Nrhzpfh khiytapuz; 
lhykpb Nghk;tupf;fh aha;. 
fLf;fhapd; rpwg;G: 
fLf;fhAe; jhAq; fUjpnyhd;nwd; whYk; 
fLf;fha;j; jha;f;fjpfq; fhz;eP – fLf;fha;Neha; 
Xl;b Alw;Nww;Wk; cw;wtd;id NahRitfs; 
Cl;bAlw; Nww;W Kte;J. 
- mfj;jpau; Fzthflk; 
 
THANRIKKAI - TERMINALIA BELLIRICA ROXB. 
Family: Combretaceae.  
Habitat: Throughout deciduous forests of India.  
English: Belleric Myrobalan, Bastard Myrobalan.  
Siddha/Tamil: Thaanrikkaai, Thandri.  
Actions: Fruit—purgative when half ripe, astringent when ripe; antipyretic; used in 
prescriptions for diarrhoea, dyspepsia, biliousness, cough, bronchitis and upper 
respiratory tract infections, tropical pulmonary eosinophilia and allergic eruptions. 
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Phytochemical constituents: The fruits contain beta-sitosterol, gallic and ellagic 
acids, ethyl gallate, galloyl glucose, chebulagic acid and acardiac glycoside, 
bellaricanin. The fruit contains all components of Chebulic myrobalan (T.chebula) 
except corilagin and chebulic acid. The ﬂeshy fruit pulp contains 21.4% tannin, both 
condensed and hydrolysable types. 
Pharmacological activities: The fruits produce hepato-protective effect in CCl4-
induced liver injury in mice. Alcoholic extract of the fruit exerted a negative chrono-
andinotropic and hypotensive effect of varying magnitude in a dose dependent fashion 
on isolated rat and frog atria and rabbit heart. The ﬂower showed spermicidal activity. 
(C P Khare (Ed.) Indian Medicinal Plants, 2007) 
GUNAPADAM ASPECT 
jhd;wpf;fha; 
NtW ngau;fs;: mf;fe;jk;> mKjk;> mk;gyj;jp> vupfl;gyk;> fe;Jfd;> rfjk;> 
jhgkhup> tpgPjfk;> jpwpypq;fk;> G+jthrfk; 
Rit: Jtu;g;G 
jd;ik - ntg;gk; 
gpupT - ,dpg;G  
nra;if:  
Jtu;g;gp (Astringent) 
cukhf;fp (Tonic) 
Nfhioafw;wp (Expectorant) 
kykpsf;fp (Laxative) 
 
nghJf;Fzk;: 
―rpye;jptplk; fhkpag;Gz; rPohd Nkfq; 
fye;JtUk; thjgpj;jq; fhNyh – lyu;e;Jlypy; 
Cd;wpf;fha; ntg;g Kjpugpj; Jq;fuf;Fe; 
jhd;wpf;fha; ifapnyLj; jhy;‖ 
―Mzpg;nghd; Nkdpf; foFk; xspAkpFk; 
Nfhzpf;nfhs; thjgpj;jf;nfhs;ifNghk; - jhdpf;fha; 
nfhz;ltu;f;F NkfkWk; $wh mdw;wzpAk; 
fz;ltu;f;F thjk;Nghk; fhz;‖ 
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NELLI - EMBLICA OFFICINALIS GAERTN. 
Synonym: Phyllanthus emblica Linn.  
Family: Euphorbiaceae  
Habitat: Native of tropical Southeast Asia; distributed throughout India; also planted 
in public parks.  
English: Emblic, Indian gooseberry.  
Siddha/Tamil: Nellikkaai, Nelli.  
Actions: Fruit- haematinic, anabolic, antiemetic, bechic, astringent, antihaemorrhagic, 
antidiarrhoeal, diuretic, antidiabetic, carminative, antioxidant.  
Uses: It is used in jaundice, dyspepsia, bacillary dysentery, eye trouble and as a 
gastrointestinal tonic. Juice with turmeric powder andhoneyis prescribed in diabetes 
insipidus. Seed - antibilious, antiasthmatic, used in bronchitis. Leaf - juice is given in 
vomiting. A decoction of powdered pericarp is prescribed for peptic ulcer. Key 
application - as an antacid. (Indian Herbal Pharmacopoeia) 
Phytochemical constituents: The fruit is an important source of vitamin C, minerals 
and amino acids. The edible fruit tissue contains protein concentration three fold and 
vitaminC (ascorbic acid) concentration 160-fold than those of apple. The fruit also 
contains considerably higher concentration of most minerals and amino acids than 
apple. The fruit gave cytokinine like substances identiﬁed as zeatin, zeatin riboside 
and zeatin nucleotide; suspension culture gave phyllembin. The leaves contain gallic 
acid (10.8 mg/g dry basis), besides ascorbic and music acid.  
Pharmacological activities:  
The fruit contains superoxide dismutase 482.14units/g fresh weight and 
exhibits antisenescent (anti-aging) activity. Fruit, juice, its sediment and residue are 
antioxidant due to gallic acid. EtOH (50%) extract -antiviral. Aqueous extract of the 
fruit increases cardiac glycogen level and decreases serum GOT, GPT and LDH in 
rats having induced myocardial necrosis. (C P Khare (Ed.) Indian Medicinal Plants, 
2007) 
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Phyllembin exhibits CNS depressant and spasmolytic activity, potentiates 
action of adrenaline and hypnotic action of Nembutal.  
Preliminary evidence suggests that the fruit and its juice may lower serum 
cholesterol, LDL, triglycerides and phospholipids without affecting HDL levels and 
may have positive effect on atherosclerosis. (Jacob A et al., Eur J clin Nutr, 1988; 
Anila L et al., Phytother Res, 2000) 
An aqueous extract of the fruit has been reported to provide protection against 
radiation-induced chromosomal damage in both pre-and post irradiation treatment. 
The fruit is reported to enhance natural killer cell activity and antibody dependent 
cellular cytotoxicity in mice bearing Dalton‘s lymphoma ascites tumour. The extract 
of the fruit and ascorbic acid prevents hepatotoxic and nephrotoxic effects induced by 
lead and aluminium. The toxicity could be counteracted to a great extent by the fruit 
extract than by an amount of ascorbic acid alone equivalent to that contained in fruits 
(The fruit can be used as a dietary supplement to counteract prolonged exposure to 
metals in population in industrial areas). The fruits are reported to activate trypsin 
(proteolytic enzyme) activity. (C P Khare (Ed.) Indian Medicinal Plants, 2007) 
GUNAPADAM ASPECT 
ney;yp 
NtW ngau;fs;: Mkyfk;> Mk;gy;> jhj;jhup> Nfhuq;fk;> kpWJgyh 
,jd; gok; cyu;e;j gpd; fWg;G epwkhf ,Uf;Fk;. ,jw;F ney;ypKs;sp vd;W 
ngau;.  
Rit: Gspg;G> Jtu;g;G> ,dpg;G 
jd;ik - jl;gk; 
gpupT - ,dp;g;G 
gok; 
nra;if:  
Fspu;r;rpAz;lhf;fp (Refrigerant) 
rpWePu;g;ngUf;fp (Diuretic) 
kykpsf;fp (Laxative) 
nghJf;Fzk;: 
―ney;ypf;fha;f; Fg;gpj;jk; ePq;Fk ;jd;Gspg;ghy; 
nry;YNk thjkjpw; Nru;Jtuhy; - nrhy;Yikak; 
XLkpijr; rpj;jj;jpy; cd;d mdYlNd 
$Lgpw NkfKk; Nghq; $W‖ 
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ney;ypKs;spapd; Fzk; 
Mftd yQ;rrpm rpu;f;nfd;G Uf;fpfz;Nzha; 
jhf Kjputpj;je; jhJ e\;lk; - Nkfdj;jpd; 
,y;ypKs;sp NghyUfy; vz;fh kpatpaq;fk; 
ney;ypKs;sp ahw;Ngh ep;id 
 
ey;yney;yp Ks;spaJ ehf;Ff; FUrpjUk; 
my;yy;tpup gpj;jk; mfw;Wkij – nky;yj; 
jiy KOff; fz;FspUe; jhTgpj;j the;jp 
,iyapopNk fq;fSk; Nghk; vz;.  
- Njiuau; Fzthflk; 
 
VALLARAI - CENTELLA ASIATICA LINN. 
Synonym: Hydrocotyle asiatica Linn.  
Family: Umbelliferae; Apiaceae.  
Habitat: In marshy places throughout India up to 200m.  
English: Asiatic Pennywort, Indian Pennywort 
Siddha/Tamil: Vallaarai 
Actions: Adaptogen, central nervous system relaxant, peripheral vasodilator, sedative, 
antibiotic, detoxiﬁer, blood-puriﬁer, laxative, diuretic, emmenagogue.  
Uses: Used in Indian medicine as a brain tonic and sedative. (IndianHerbal 
Pharmacopoeia). Used as a brain tonic for improving memory and for overcoming 
mental confusion, stress, fatigue, also used for obstinate skin diseases and leprosy.  
Phytochemical constituents & Pharmacological activity: Triterpenoid saponins—
brahmoside, asiaticoside, thankuniside; alkaloids (hydrocotyline); bitter principles 
(vellarin).  
Brahmoside, present in the plant, is reported to exhibit tranquilizing and 
anabolic activity. Raw leaves are eaten or plant decoction is drunk to treat 
hypertension. Asiaticoside, extracted from leaves, gave encouraging results in 
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leprosy. It dissolves the waxy covering of Bacillus leprae. (C P Khare (Ed.) Indian 
Medicinal Plants, 2007) 
Asiaticoside reduced the number tubercular lesions in the liver, lungs, nerve 
ganglia and spleen in experimental animals. Another derivative of asiaticoside, 
oxyasiaticoside, inhibits growth of Tubercle bacillus at a concentration of 0.15ml/ml 
Asiaticosides are also hyperglycaemic. The Asiatic acid acts against resistantbacteria, 
particularly Mycobacterium tuberculosis and M.leprae as well as Gram-positive cocci. 
Asiaticosides elevate blood glucose, triglycerides and cholesterol levels. They seem to 
decrease blood urea nitrogen and acid phosphatase levels. (Pharmacological ﬁndings, 
Natural Medicines Comprehensive Database, 2007) 
In research, using rats, the herb exhibited protective effect against alcohol-
induced and aspirin-induced ulcers. (Sairam K et al., J Exp Biol, 2001) 
GUNAPADAM ASPECT 
ty;yhiu 
NtW ngau;fs;: rz;lfp> gpz;Bup> Nahrdty;yp  
Rit: Jtu;g;G> ifg;G, ,dpg;G 
jd;ik - jl;gk; 
gpupT - ,dp;g;G 
nra;if:  
cukhf;fp (Tonic) 
clw;Nww;wp (Alterative) 
ntg;gKz;lhf;fp ( Stimulant) 
UJTz;lhf;fp (Emmenagogue) 
rpWePu;g;ngUf;fp (Diuretic) 
nghJf;Fzk;: 
mf;fu Neha; khWk; mfYk; tapw;wpopT 
jf;ftpuj; jf;fLg;Gj; jhNdFk; - gf;fj;jpy; 
vy;yhiu AkUe;njd; NwAiuj;J ed;kidAs; 
ty;yhiu iatsu;j;J it. 
- Njiuau; Fzthflk; 
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KARISALAI - ECLIPTA ALBA (LINN.) 
Synonym: E.prostrata Roxb.  
Family: Compositae; Asteraceae.  
Habitat: Throughout India, up to 2000m on the hills.  
English: Trailing Eclipta Plant.  
Siddha/Tamil: Karisalaankanni.  
Actions: Deobstruent, antihepatotoxic, anticatarrhal, febrifuge.  
Uses: The plant is also reported to be effective in the treatment of peptic ulcer, 
inﬂammatory diseases, including rheumatoid arthritis, diseases of the gallbladder and 
skin infections. Also used in hepatitis, spleen enlargements, chronic skin diseases. 
Leaf—promotes hair growth. Its extract in oil is applied to scalp before bed time in 
insomnia. The herb is also used as an ingredient in shampoos.  
Key application: As hepatoprotective. (Indian Herbal Pharmacopoeia)  
Phytochemical constituents: The herb should be dried at room temperature under 
shade. Its active principles are lost due to aerial oxidation during sundrying or drying 
under reduced pressure below 40°C. The herb contains wedelolactone and demethyl 
wedelolactone, 
Pharmacological activities: The active principle showed a dose dependent effect 
against CCl4, d-galactosamine or phalloidin induced cytotoxicity in primary cultured 
rat hepatocytes, and exhibited potent antihepatotoxic property. The whole plant shows 
effect on liver cell regeneration (Rownak Jahan et al., Int Sch Res Notices. 2014).   
Immunoactive property has been observed against surface antigen of 
hepatitisB-virus. Aqueous extract of leaves exhibits myocardial depressant and 
hypotensive activity. (C P Khare (Ed.) Indian Medicinal Plants, 2007) 
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GUNAPADAM ASPECT 
fupryhq;fz;zp 
NtW ngau;fs;: fuprhiy> ifNfrp> ifahe;jfiu> gpUq;fuh[k;> ifahd; 
Rit: ifg;G>  
jd;ik - ntg;gk; 
gpupT - fhh;g;G 
nra;if:  
gpj;jePu;g;ngUf;fp (Cholagogue) 
cukhf;fp (Tonic) 
clw;Nww;wp (Alterative) 
the;jpAz;lhf;fp (Emetic) 
gpj;jePu;g;ngUf;fp (Chologogue) 
ePu;kyk;Nghf;fp (Purgative) 
tPf;fKUf;fp (Deobstruent) 
<uy;Njw;wp (Hepatotonic) 
nghJf;Fzk;: 
―Fuw;fk;kw; fhkhiy Fl;lnkhL nrhig 
Aww;ghz;L gd;Ndh nahopa – epuw;nrhd;d 
nka;ahe; jfiunahj;j kPsp z;Z ew;Gyj;Jf; 
ifahe; jfiunahj;jf; fhy;‖ 
- mfj;jpau; Fzthflk; 
 
 
KEEZHANELLI -PHYLLANTHUS AMARUS SCHUM. & THONN. 
Family: Euphorbiaceae.  
Habitat: Throughout the hotter parts of India, particularly on cultivated land, up 
to1,000m. 
Phytochemical constituents: The leaves yielded lignans—phyllanthin(bitter), 
hypophyllanthin (nonbitter); niranthin, nirtetralin and phyltetralin. The whole plant 
gave a number of ﬂavonoids, including quercetin, quercitrin, astragalin, rutin, 
kaempferol. Isolation of ahydrolysable tannins, amarulone, is reported from the plant. 
Actions: Plant—diuretic, deobstruent, astringent, anti-inﬂammatory, styptic. Used as 
a single drug in the treatment of jaundice.  
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Uses: Used in prescriptions for dyspepsia, indigestion, chronic dysentery, urinary 
tract diseases, diabetes, skin eruptions.  
Pharmacological activities: The plant is reported to show antiviral activity against 
hepatitis virus and related hepadnavirus. It was also found to effectively repair CCl4-
induced liver damage in rats. (C P Khare (Ed.) Indian Medicinal Plants, 2007) 
The herb exhibited hypotensive and hypoglycaemic activity. (Srividhya N et 
al., Indian J Exp Biol, 1995) 
GUNAPADAM ASPECT 
fPo;f;fha;ney;yp 
NtW ngau;fs;: fPohney;yp> fPo;tha;ney;yp  
Rit: Jtu;g;G> ifg;G, Gspg;G> ,dpg;G 
jd;ik - jl;gk; 
gpupT - ,dp;g;G 
nra;if:  
Fspu;r;rpAz;lhf;fp (Refrigerant) 
rpWePu;g;ngUf;fp (Diuretic) 
tPf;fKUf;fp (Deobstruent) 
Jtu;g;gp (Astringent) 
nghJf;Fzk;: 
rPjkjp gpj;jtplk; nrt;tpopapd; Ndha;f; $l;lk; 
G+jnkhL Ngapuj;jg; Nghf;FfSk; - G+jyj;Js; 
jho;tha;g; gzpe;NjFe; jg;ghJ ngha;ayNt 
fPo;th naDney;ypf; Nf. 
- mfj;jpau; Fzthflk; 
 
NEERMULLI - HYGROPHILA AURICULATA (K.SCHUM.)HEINE. 
Synonym: H.schulli(Ham.) MR & SM Almeida. H.spinosa T.anders. Asteracantha 
longifolia(L.)Nees.  
Family: Acanthaceae.  
Habitat: Throughout India along the banks of fresh or stagnant water ditches and 
swampy grounds, mixed with marshy grasses and sedges.  
Siddha/Tamil: Neermulli.  
52 
 
Action: Leaves, roots and seeds— diuretic; used for diseases of the urinogenital tract, 
spermatorrhoea. Seeds promote sexual vigour, arrest abortion and cure diseases due to 
vitiated blood.  Also used for arthritis and oedema.  
 
Phytochemical constituents: The seeds contain linoleic acid (71%), besides diastase, 
lipase and protease. The seeds contain large amounts of tenacious mucilage and 
potassium salts, which may be responsible for the diuretic property of seeds. The 
plant contains lupeol, stigmasterol and hydrocarbons. 
 
Pharmacological activity: EtOH (50%) extract of the plant is spasmolytic and 
hypotensive. The chloroform soluble fraction of ethanolic extract of aerial parts 
exhibited promising hepatoprotective activity in albino rats (Kshirsagar AD et al., 
Pharmacogn Rev. 2010). 
 
GUNAPADAM ASPECT 
ePu;Ks;sp 
 
NtW ngau;fs;: epjfk;> ,f;Fuk;> fhfz;lk;> Jufj%yk;> Kz;lfk;. 
Rit: ,dpg;G> rpWifg;G 
jd;ik - jl;gk; 
gpupT - ,dpg;G 
Ntu; 
nra;if:  
Fspu;r;rpAz;lhf;fp (Refrigerant) 
rpWePu;g;ngUf;fp (Diuretic) 
cs;soyhw;wp (Demulcent) 
cukhf;fp (Tonic) 
 
nghJf;Fzk;: 
ghz;L FSg;igaWk; ghupYW ePNuw;wk; 
khz;LtpLk; ePu;f;fl;L khWq;fhz; - G+z;lnjhU  
tPf;fnkyhk; ePuha; tpLNkePu; Ks;spf;Fj; 
jhf;F kapy;tpopahy;! rhw;W 
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ANNABEDHI – FERRI SULPHAS 
Eng: Green vitriol, Green copperas, copperas of commerse, sulphates of iron (FeSo), 
Crude ferrous sulphate, Iron sulphate, Salt of steel. 
Tam: Annabedhi 
Source: It is a salt usually obtained by the decomposition of iron-pyrites by the action 
of atmospheric moisture. It can be obtained also by dissolving iron wires in sulphuric 
acid by the aid of heat 
Structure and colour: Pale bluish green oblique rhombic prisms, crude greenish blue 
crystals of iron sulphate available in all bazaars of India. 
Taste: Astringent without any odour, acid reaction, soluble in water, insoluble in 
alcohol. 
Action: Haematinic, Tonic, Astringent. 
 
GUNAPADAM ASPECT 
md;dNgjp 
Rit: Jtu;g;G 
tPupak;: ntg;gk; 
nra;if: 
cukhf;fp (Tonic) 
ntg;gKz;lhf;fp ( Stimulant) 
UJTz;lhf;fp (Emmenagogue) 
GOf;nfhy;yp (Vermifuge) 
Jtu;g;gp (Astringent) 
Kiwntg;gfw;wp (Febrifuge) 
nghJf;Fzk;: 
―KistpuzQ; #iyke;j Kl;lhikf; fl;b 
tpisawd;k NfhjuNeha; tPl;Lk; - tiskiyNghw; 
fhl;Lkd;de; jd;idf; fzj;jpw; rykhf;fpf; 
fhl;Lkd;d NgjpaJ fhz;‖. 
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Fig 3.2.1  KADUKKAI 
 
Fig 3.2.2  THANRIKKAI 
 
Fig 3.2.3  NELLI 
 
Fig 3.2.3a  NELLIMULLI 
 
Fig 3.2.4  VALLARAI 
 
Fig 3.2.5 ANNABEDHI 
CHENDURAM 
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Fig 3.2.6  KARISALAI 
 
Fig 3.2.7  KEEZHANELLI 
 
Fig 3.2.8  NEERMULLI 
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CHAPTER - 4 
MATERIALS AND METHODS 
 
4.1 STUDY AREA AND SETTING   
The study period is covered from June 2017 to July 2019 at the Govt. Siddha 
Medical College and Hospital, Palayamkottai- 627 002, Tirunelveli, Tamil Nadu. All 
procedures were carried out after getting the permission from Institutional Ethical 
Committee.  
 
4.2 STUDY DESIGN 
 The study design is a prospective open labeled non-randomized Phase-II 
clinical trial of 40 Pitha paandu (Iron deficiency anaemia) subjects. The included 
selection were newly diagnosed and already diagnosed as anaemic patients with or 
without taking treatment.  A written informed consent form was recruited in the study. 
The purpose of the study was explained to the patients before administration of the 
trial drug. The patient’s basic information, life style and siddha parameters were 
recorded before starting the treatment. The total number of 40 patients, equally in 
both sex and patient age between 18 and 60 were taken for this study. The selected 
patients were treated with the trial drug during the study period (30 days).  
 
4.3 SELECTION OF PATIENTS 
The criteria for selection of patients are given below (4.3.1). After inclusion of 
cases, screening is done before starting the treatment.  
Detailed personal history, family history, occupation, habits, clinical 
symptoms, medical history, and the duration of illness were recorded in all patients. 
 
4.3.1 Inclusion Criteria 
The parameters for the selection were,  
1. Hb level between 7.1-10 gms% 
2. Fatigue 
3. Weakness  
4. Headache 
5. Bodyache 
57 
 
6. Dyspnoea on exertion 
7. Palpitation 
8. Giddiness 
9. Pallor of Skin, Conjunctiva, Nailbeds, Mucous membrane of lips and pale 
tongue 
10. Koilonychia 
11. Constipation 
12. Worm infestations 
 
4.3.2 Exclusion Criteria 
Patients are excluded in the following conditions  
1. Age below 18 and above 60  
2. Hb less than 7 and above 10 
3. Congenital heart disease 
4. Chronic renal diseases 
5. Liver diseases  
6. Inherited hemolytic defects 
7. Haemorrhagic disorders 
8. Thalassemia 
9. Thyroid disorder 
10. Diabetes mellitus 
 
4.3.3 Diagnosis 
The Siddha diagnostic procedures were included this study, which is,                  
 Poriyal Arithal 
 Pulanal Arithal 
 Vinathal 
 Mukkutra nilaigal 
 Envagai thervugal 
 Nilam 
 Kaalam & Udal kattugal 
 
 
 
58 
 
4.3.4 Investigations 
Blood - Complete blood analysis TC, DC, Hb, TRBC, ESR, PCV, MCV, 
MCH, MCHC, Sugar, Urea, and Serum Creatinine were carried out. 
Specific investigations (For people who are willing) 
- Peripheral blood smear, Serum Ferritin, Serum Iron, TIBC 
 Routine Urine Analysis- Albumin, Sugar, Deposits are noted. 
The Lab investigations were carried out before and after administration of trial drug.  
 
4.4 TREATMENT 
4.4.1 Preparation of the Trial Medicine (Annexure - I) 
  The herbomineral preparation of THIRIPALAI MATHIRAI with the adjuvant 
KARISALAI KUDINEER was selected from the Classical Siddha literature,  
Reference: “KADUKKAI VALLARAIYIN THANI MAANBU”-Third Edition:1992, 
Page No:81, Author: Hakkim. P. Mohammed Abdullah Sahib 
 
4.4.2 Collection and authentication of Trial Medicine  
The required raw drugs for preparations of THIRIPALAI MATHIRAI are 
purchased form a well reputed country shop in Nagarkoil, Tamilnadu and raw drugs 
are identified and authenticated by the Medicinal Botanist and Gunapadam experts of 
Govt. Siddha Medical College& Hospital, Palayamkottai, then they are purified and 
the medicine is prepared in the P.G.Gunapadam Practical hall of Govt. Siddha 
Medical College & Hospital, Palayamkottai.  
 
4.5 PRECLINICAL ANALYSIS OF TRIAL MEDICINE 
All the preclinical studies of the study drug which includes Bio chemical and 
pharmacological studies are cross checked before starting the treatment. 
A. Biochemical Analysis - It was done in Dept.of Biochemistry, GSMCH, 
Palayamkottai. The analysis was carried out to find the presence of sulphate, 
chloride, starch, ferrous iron, unsaturated compound, reducing sugar, amino acid, 
calcium, carbonate, ferric iron, phosphate, albumin, tannic acid and zinc. 
B. Phytochemical Analysis - Phytochemical analysis were done in Biogenix lab, 
Trivandrum. The qualitative phytochemical analysis was carried out for major 
compound of interest such as Alkaloids, Flavanoids, Saponins, Phenol, Steroids, 
Glycosides, Tannins and Terpenoids. The analysis of phytochemicals has 
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followed by Harborne and Onwukaemeand coworkers, 1999. The Quantitative 
estimation was done through spectrophotometric method for alkaloids estimation 
and FolinCio-calteau method for phenols.  
C. Antimicrobial assay -       
 Antimicrobial activity was carried out in Biogenix lab, Trivandrum. 
It was done by using Agar well diffusion method.  
 Materials required for this study were, 
 Antibacterial activity - Muller Hinton agar medium(1L), Nutrient 
broth(1L), Streptomycin(10mg/ml), Culture of test organisms - E.coli, 
Pseudomonas aeroginosa, Klebsiella pneumonia, Streptococcus mutans 
and Staphylococcus aureus (growth of culture adjusted according to 
McFarland Standard, 0.5%) 
 Antifungal activity - Potato Dextrose Agar Medium (1 L), Clotrimazole 
(standard antifungal agent, concentration: 10mg / ml), Culture of test 
organisms - Aspergillus niger, Candida albicans (growth of culture 
adjusted according to McFarland Standard, 0.5%) 
D. Pharmacological studies - The Haematinic activity of the trial drug in 
phenylhydrazine induced anaemic rats was done in K.M.College of Pharmacy, 
Madurai, Tamil nadu.  
E. Toxicity study - Acute toxicity and subchronic toxicity of the trial drug is carried 
out as per OECD-423 guidelines after the animal ethical clearance from 
Institutional Animal Ethics Committee. Toxicity studies were done in K.M 
College of Pharmacy, Madurai, Tamilnadu.  
 
4.6 ETHICAL REVIEW 
  The study was conducted in accordance with the ethical principles that are 
consistent with Good Clinical Practice guidelines and obtained prior approvals before 
start of the trial from the Institutional Ethical Committee of GSMCH, Palayamkottai 
(GSMC-IV-IEC/2017/Br-I/03/29.05.2017) and Institutional animal ethical committee 
(IAEC) of K.M. College of Pharmacy, Madurai (IAEC/B.MAHESHWARI/ 
TNMGRMU/MD(S)/321611003/KMCP/25/2018). The trial was applied and approved in 
Clinical Trial Registry of India (CTRI/2018/04/013122). 
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4.7 STUDY ENROLMENT   
An open labeled non-randomized phase II clinical trial on “Pitha Paandu” 
was conducted in Government Siddha Medical College and Hospital, Palayamkottai, 
Tirunelveli. Totally forty cases were selected 20 patients treated as OP remaining 20 
patients were treated as IP. The clinical signs and symptoms of “Pitha Paandu” of 
both sexes of different ages were selected and studied under the guidance of the 
professor, reader and lecturer of P.G. Pothu Maruthuvam Department. 
Participants were informed regarding the trial, the expected benefits and their 
right to opt-out of trial at any time without prejudice.  Informed written consent was 
obtained from each participant, prior to his/her inclusion into the trial. During the 
visit, body weight, blood pressure, cardiovascular and respiratory system were 
clinically recorded. At the end of the study period, all the patients were instructed to 
follow diet. They were also advised to pursue the further treatment in the PG, Pothu 
Maruthuvam OP for the follow up study. 
 
4.8. WITHDRAWAL CRITERIA 
Patients are advised to withdraw in following conditions - Intolerance to the 
drug and development of any serious adverse effects during the trial. Patients turned 
unwilling to continue in the course of clinical trial, poor compliance, any other acute 
illness which needs rescue medication and to follow regular diet schedule. The 
subjects with history of treatment with other drugs and serious medical or 
psychological condition are excluded from the study.  Any adverse reaction or side 
effect occurs during the treatment, immediately inform the patient and 
pharmacovigilence committee.  
 
4.9 STATISTICAL ANALYSIS  
All data were analysed using the SPSS 20.0 (IBM). Data were expressed as 
means and standard deviation. The significance of the difference between the means 
of the baseline and the final examinations was tested using the paired “t” test. A 
probability value of <0.05 was considered to be statistically significant. 
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CHAPTER - 5 
RESULTS AND OBSERVATIONS 
5.1. PRECLINICAL STUDY  
5.1.1. Biochemical analysis   
Preparation of the extract:  
 5gms of the drug was weighed accurately and placed in a 250ml clean beaker 
then 50ml of distilled water is added and dissolved well. Then it is boiled well for 
about 10 minutes. It is cooled and filtered in a 100ml volumetric flask and then it is 
made   to 100ml with distilled water.  This fluid is taken for analysis. 
 
Table 5.1.1 a) Qualitative Analysis of “THIRIPALAI MATHIRAI” 
S.No EXPERIMENT OBSERVATION INFERENCE 
01 Test for Calcium 
 
No white precipitate 
was formed 
Absence of Calcium 
02 Test for Sulphate 
 
A white precipitate 
was formed 
Presence of Sulphate 
03 Test for Chloride 
 
A white precipitate 
was formed 
Presence of Chloride 
04 Test for Carbonate 
 
No brisk effervescence 
was formed 
Absence of 
Carbonate 
05 Test for Starch Blue colour was  
formed 
Presence of Starch 
06 Test for Ferric Iron 
 
Blue colour was  
formed 
Presence of 
Ferric iron 
07 Test for Ferrous Iron  
 
Blood red colour was 
formed 
Presence of 
Ferrous iron 
08 Test for Phosphate 
 
No yellow precipitate 
was formed 
Absence of 
Phosphate 
09 Test for Albumin 
 
No yellow precipitate 
was formed 
Absence of 
Albumin 
10 Test for Tannic Acid 
 
Blue black precipitate 
was formed 
Presence of 
Tannic acid 
11 Test for Unsaturation 
 
It does not 
get decolourised 
Absence of 
Unsaturated 
compound 
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12 Test for the Reducing 
suga 
Colour change occurs Presence of 
Reducing sugar 
13 Test for Amino Acid 
 
No Violet colour was 
formed 
Absence of Amino 
acid 
14 Test for Zinc 
 
No white precipitate was 
formed 
Absence of Zinc 
 
Inference: 
The above table indicates the presence of sulphate, chloride, starch, ferrous 
iron, ferric iron, tannic acid and reducing sugar; Absence of calcium, carbonate, 
phosphate, albumin, amino acid, unsaturated compound and zinc. 
 
Table 5.1.1 b) Qualitative Analysis of “KARISALAI KUDINEER” 
S.No EXPERIMENT OBSERVATION INFERENCE 
01 Test for Calcium 
 
No white precipitate 
was formed 
Absence of Calcium 
02 Test for Sulphate 
 
A white precipitate 
was formed 
Presence of 
Sulphate 
03 Test for Chloride 
 
A white precipitate 
was formed 
Presence of Chloride 
04 Test for Carbonate 
 
No brisk effervescence 
was formed 
Absence of 
Carbonate 
05 Test for Starch Blue colour was  
formed 
Presence of Starch 
06 Test for Ferric Iron 
 
No blue colour was 
formed 
Absence of Ferric 
iron 
07 Test for Ferrous Iron  
 
Blood red colour was 
formed 
Presence of Ferrous 
iron 
08 Test for Phosphate 
 
No yellow precipitate 
was formed 
Absence of 
Phosphate 
09 Test for Albumin 
 
No yellow precipitate 
was formed 
Absence of 
Albumin 
10 Test for Tannic Acid 
 
No blue black 
precipitate was formed 
Absence of Tannic 
acid 
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11 Test for Unsaturation 
 
It gets  
decolourised 
Presence of 
Unsaturated 
compound 
12 Test for the Reducing 
Sugar 
Colour change 
occurs 
Presence of 
Reducing sugar 
13 Test for Amino Acid 
 
Violet colour was 
formed 
Presence of Amino 
acid 
14 Test for Zinc 
 
No white precipitate 
was formed 
Absence of Zinc 
 
Inference: 
The above table indicates the presence of sulphate, chloride, starch, ferrous 
iron, unsaturated compound, reducing sugar and amino acid; Absence of calcium, 
carbonate, ferric iron, phosphate, albumin, tannic acid and  zinc. 
 
5.1.2. Phytochemical analysis of Thiripalai mathirai 
The Qualitative phytochemical screening of the aqueous extract of TPT was 
resulted in the presence of glycosides, alkaloids, flavonoids, saponins, phenols, 
steroids, terpenoids and tannins 
 
Table 5.1.2 Phytochemical Analysis of THIRIPALAI MATHIRAI 
Test Observation Inference 
Alkaloids 
No characteristic change was 
observed 
Presence of alkaloids(+) 
Flavanoids 
A reddish pink or reddish 
brown colour was produced 
Presence of flavanoids (+) 
Saponins 
A honey comb like froth was 
formed 
Presence of Saponins(+) 
Phenols 
A blue or green colour was 
formed 
Presence of phenols(+ +) 
Steroids 
A red color was produced in 
the chloroform layer. 
Presence of steroids(+) 
Glycosides 
No characteristic change was 
observed 
Presence of glycosides(+) 
Terpenoids 
No red colour was produced in 
the chloroform layer 
Presence of terpenoids(+) 
Tannins 
No yellowish brown 
precipitate was formed 
Presence of tannins(+) 
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5.1.3. Antimicrobial Analysis  
The trial drug Thiripalai mathirai has potential antimicrobial activity against 
both bacteria and fungi.  
BACTERIA 
GRAM NEGATIVE 
Table 5.1.3 a: Organism - E.coli 
Sample Concentration (μg/mL) Zone of inhibition (mm) 
Thiripalai mathirai Streptomycin (100µg) 24 
250 Nil 
500 10 
1000 14 
 
Table 5.1.3 b: Organism - Pseudomonas aeroginosa 
Sample Concentration (μg/mL) Zone of inhibition (mm) 
Thripalai mathirai Streptomycin (100µg) 28 
250 Nil 
500 11 
1000 16 
 
Table 5.1.3 c: Organism - Klebsiella pneumoniae 
Sample Concentration (μg/mL) Zone of inhibition (mm) 
Thiripalai mathirai  Streptomycin (100µg) 25 
250 Nil 
500 Nil 
1000 12 
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GRAM POSITIVE 
Table 5.1.3 d: Organism - Staphylococcus aureus 
Sample Concentration (μg/mL) Zone of inhibition (mm) 
Thiripalai mathirai Streptomycin (100µg) 15 
250 Nil 
500 Nil 
1000 10 
 
Table 5.1.3 e: Organism - Streptococcus mutans 
Sample Concentration (μg/mL) Zone of inhibition (mm) 
Thiripalai mathirai Streptomycin (100µg) 24 
250 Nil 
500 Nil 
1000 Nil 
 
FUNGI 
Table 5.1.3 f: Organism - Aspergillus niger 
 
 
 
 
Sample Concentration (μg/mL) Zone of inhibition (mm) 
Thiripalai mathirai Clotrimazole 25 
250 Nil 
500 10 
1000 15 
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Table 5.1.3 g: Organism - Candida albicans 
Sample Concentration (μg/mL) Zone of inhibition(mm) 
Thiripalai mathirai Clotrimazole 20 
250 Nil 
500 10 
1000 15 
 
It was observed that Thiripalai mathirai possess maximum activity against the 
bacteria E.coli (Table 5.1.3a), P.aeroginosa (Table 5.1.3b), K.pneumoniae (Table 
5.1.3c), S.aureus (Table 5.1.3d) and the fungi A.niger (Table 5.1.3f), C.albicans 
(Table 5.1.3g) compared to positive control and the zone of inhibition was 14mm, 
16mm, 12mm, 10mm and 15mm respectively. It shows no effect on S.mutans (Table 
5.1.3e). The trial drug Thiripalai mathirai was highly sensitive to 1000µl/ml; Zone of 
inhibition (ZIC) of anti bacterial, anti fungal was 14, 16 and 15 mm respectively. The 
results reveal that the activity was higher against Gram -ve strains than Gram +ve 
pathogens. The antimicrobial activity against pathogens showed results with effective 
and significant inhibitory action. 
 
5.1.4. Pharmacological activity 
5.1.4.1 Haematinic activity of the trial drug Thiripalai mathirai and the adjuvant 
Karisalai kudineer in phenylhydrazine induced anaemic rats    
Phenylhydrazine is used for the induction of haemolytic anaemia and the study 
of its mechanism in many species including rats. Phenyl free radical produced via the 
2- electron oxidation of phenylhydrazine by oxyhemoglobin. This free radical binds 
with red cell and hemolyzes it rapidly and converts oxyhemoglobin into 
methemoglobin.  Thus, PHZ-induced haemolytic injury seems to be derived from 
oxidative alterations to red blood cell proteins rather than to membrane lipids. The 
RBC, Hb, and PCV of rats administered Phenylhydrazine decreased significantly (P < 
0.01) while the MCV and MCH increased giving rise to macrocytic anaemia (P < 
0.05). Thiripalai Mathirai and Karisalai kudineer at oral doses of 100 mg and 200 mg 
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each, showed good percentage of improving in haemoglobin level, which was almost 
equivalent to standard treated group indicating   correction   of   anaemia   induced   by   
Phenyl hydrazine after 14 days treatment. Treatment with Thiripalai Mathirai and 
Karisalai kudineer each at single oral doses of 100 mg and 200 mg for 14 day is 
represented in Table 5.1.4.1a and Table 5.1.4.1b respectively. Significant increase in 
Hb (p < 0.01) was observed when compared to positive control and it was comparable 
to standard drug used in this study. Phenylhydrazine altered the haematological 
parameters by haemolysis characterized by decrease in haemoglobin concentration, 
total RBC counts and PCV on day 7. However, the haematological parameters were 
restored to normal range after treatment with Thiripalai Mathirai and Karisalai 
kudineer at single oral doses of 100 mg and 200 mg for 14 days. Effective changes 
were observed after one week of treatment of anaemic rats with Thiripalai Mathirai 
and Karisalai kudineer reversed the influence of Phenylhydrazine resulting to a 
significant (P < 0.05) increase in RBC, Hb, and PCV. The Hb, RBC and PCV reached 
near normal at the second week of the treatment. Rats treated with Phenylhydrazine 
(10mg/kg/day for 7 days) resulted in a marked haemolytic anaemia characterised by 
decreased RBC, Hb and PCV. The main function of the RBC is the transportation of 
oxygen in to the tissues of the body. At such, any pathological or physiological 
condition that affects the RBC alters its function and this may be detrimental to the 
body. In this study Phenylhydrazine altered the function of RBC by haemolysis 
characterised by decreased levels of RBC, Hb and PCV. However, this effect was 
restored after one week of Thiripalai Mathirai and Karisalai kudineer treatment. Also 
the recovery was progressive such that after 1 week of continuous treatment, the Hb 
concentration and PCV were higher in the treated groups than in the normal control 
group. 
Table 5.1.4.1a) Results in Hematological Parameters of Rats after treatment with 
TPM 
Parameters G1 G2 G3 G4 G5 
HB g/dl 13.60±1.22 8.34±0.90** 12.18±1.08** 12.49±1.20** 14.15±1.28** 
PCV (%) 48.20±2.05 41.60±1.98 44.38±2.15** 45.22±2.28** 48.40±2.35** 
RBC 4.28±0.26 4.12±0.22 4.44±0.56 4.50±0.60 4.68±0.75 
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MCV 76.15±2.20 92.45±2.98 86.12±2.50** 82.26±2.40** 79.42±2.34 
MCH 25.85±2.48 33.90±2.92 31.60±2.82 29.30±2.70 27.44±2.55 
MCHC g/dl 33.22±1.20 32.50±1.05 33.40±1.28 34.15±1.41 34.60±1.50 
 
Values are mean ± S.E.M.  **P<0.01Vs Control (N = 6) 
Table 5.1.4.1b) Results in Hematological Parameters of Rats after treatment with KK 
Parameters G1 G2 G3 G4 G5 
HB g/dl 13.94±1.34 8.22±0.85** 12.36±1.16** 12.58±1.26** 14.22±1.34** 
PCV (%) 47.60±2.15 41.55±1.94 44.45±2.28** 45.30±2.34** 48.45±2.85** 
RBC 4.34±0.28 4.18±0.20 4.42±0.59 4.54±0.62 4.72±0.78 
MCV 77.24±2.24 93.48±3.18 86.24±2.56** 83.08±2.42** 79.36±2.30 
MCH 26.25±2.58 34.88±2.86 31.45±2.74 29.25±2.72 27.35±2.50 
MCHC g/dl 33.20±1.18 32.45±1.08 33.42±1.30 34.24±1.40 34.62±1.52 
 
Values are mean ± S.E.M.  **P<0.01Vs Control (N = 6) 
 
5.1.5. TOXICITY STUDY  
5.1.5.1 Acute toxicity study with Thiripalai Mathirai 
  The acute toxicity of Thiripalai Mathirai was evaluated using OECD- 423 
guidelines. There was no mortality or morbidity observed in animals through the 15-
days period following single oral administration at all selected dose levels of the 
Thiripalai Mathirai (Table 5.1.5.1a). The animals did not show any changes in the 
general appearance during the observation period. Morphological characteristics such 
as fur, skin, eyes and nose appeared normal. No tremors, convulsion, salivation, 
diarrhea, lethargy or unusual behaviors such as self mutilation, walking backward and 
so forth were observed. Gait and posture, reactivity to handling or sensory stimuli, 
grip strength was also normal.  
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Table 5.1.5.1a) Acute toxicity study of TPM on experimental mice.  
 Dose (mg.kg
-1
) Sign of Toxicity (ST.NB
-1
) Mortality (D.S
-1
) 
Group I              0                      0/3            0/3 
Group II            300                      0/3            0/3 
Group III           2000                      0/3            3/3 
 
The acute toxicity of Thiripalai Mathiraion experimental mice was tested 
using OECD-423 guidelines, where ST- sign of toxicity; NB- normal behaviour; D- 
died; S- survive.  Values are expressed as number of animals (n=3). 
 
Effect of Thiripalai Mathirai in Subacute Toxicity  
Thiripalai Mathirai was evaluated for subacute toxicity. 
 
Effect of Thiripalai Mathirai on body weight changes in rats 
The effect of Thiripalai Mathirai was observed for their effect on the body 
weight changes from the study it was observed that, there was significant increase 
(p<0.05) in body weight in all the animals observed.   The results are shown in Table 
5.1.5.1b.  
Table 5.1.5.1b) Effect of TPM on body weight changes in rats.    
Treatment Day 1 Day 5 Day 10 Day 20 
Control 187.15±6.8 187.47  ±6.25 196.15 ±6.37 196.7±6.58 
Thiripalai Mathirai 
 50 mg.kg
-1 
 
194.30 ±6.4 193.30  ±6.35 198.25 ±6.72 198.30±6.72
*
 
Thiripalai Mathirai 
100 mg.kg
-1
 
186.35 ±5.7 189.30  ±6.45 196.55  ±7.12 197.36±6.30
*
 
Thiripalai Mathirai 
200 mg.kg
-1
 
195.30  ±7.2 198.15±6.55 198.90  ±7.22
**
 206.45±7.26
**
 
Thiripalai Mathirai 
400 mg.kg
-1
 
190.65  ±6.05 195.15 ±5.65 195.60  ±6.37
**
 207.66±7.38
**
 
 
A study on the effects of Thiripalai Mathiraion body weight changes in rats 
was carried out. where, group I animals (GPI) were treated with normal saline                  
(5 ml.kg
-1
), group II animals (GPII) with 50 mg.kg
-1
 of Thiripalai Mathirai,  group III 
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animals (GPIII)  with 100 mg.kg
-1
 of Thiripalai Mathirai, group IV animals (GPIV)  
with 200 mg.kg
-1 
of Thiripalai Mathirai, group V animals (GPV)  with 400 mg.kg
-1
 
Thiripalai Mathirai. The values are expressed as mean ± S.E.M. n=6. The results of 
group I were compared with other groups such as II, III, IV, and V.   The statistical 
analysis was carried out using one way ANOVA method, where **P<0.01 *P<0.05. 
Effect of Thiripalai Mathirai on kidney, heart, liver and brain in rats  
The effects of Thiripalai Mathirai on kidney, heart, liver and brain of the rats 
were observed. From the study it was clear that, significant (p<0.01) changes in the 
weights of various organs of the animals occurred with higher doses of the extract 
(400 mg.kg
-1
 bwt), but macroscopic examinations did not show any changes in colour 
of the organs of the treated animals compared with the control.   The results are 
shown in Table 5.1.5.1c. 
Table 5.1.5.1c) Effect of TPM on kidney, heart, liver and brain of the rats. 
                    Treatment Heart (gms) Kidney (gms) Liver (gms) Brain (gms)   
Control 0.36± 0.07 0.66± 0.05 3.32± 0.07 0.67± 0.10 
Thiripalai Mathirai @  
50 mg.kg
-1
 
0.37± 0.04 0.82± 0.05 3.44± 0.05 0.70± 0.8 
Thiripalai Mathirai @ 
100 mg.kg
-1
 
0.38± 0.08 0.80± 0.06 3.36±0.04 0.68± 0.7 
Thiripalai Mathirai @  
200 mg.kg
-1
 
0.37± 0.06 0.75± 0.04 3.34± 0.04 0.75± 0.10 
Thiripalai Mathirai @ 
400 mg.kg
-1
 
0.36± 0.05 0.76± 0.05 3.37± 0.05 0.77± 0.10 
A study on the effects of Thiripalai Mathirai on kidney, heart, liver and brain 
of the rats was tested. where, group I animals (GPI) treated with normal saline (5 
ml.kg
-1
), group II animals (GPII)  with 50 mg.kg
-1
 of Thiripalai Mathirai,  group III 
animals (GPIII)   with 100 mg.kg
-1
 of Thiripalai Mathirai, group IV animals (GPIV)   
with 200 mg.kg
-1 
of Thiripalai Mathirai, group V animals (GPV)  with 400 mg.kg
-1
 
Thiripalai Mathirai. The values are expressed as mean ± S.E.M. n=6.   The results of 
group I were compared with other groups such as II, III, IV, and V.  The statistical 
analysis was carried out using one way ANOVA method, where **P<0.01. 
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Effect of Thiripalai Mathirai on biochemical profiles of rats   
The effect of Thiripalai Mathirai on various biochemical parameters of the 
experimental animal ‘rats’ were tested.  From the study it was evident that, there was 
significant decrease (p<0.05) in the plasma glucose level in treated rats especially at 
higher dose (400 mg.kg
-1
) compared with control rats. The control rats were 
administered only with 5 ml of normal saline. Significant decrease (p<0.05) in the 
plasma total cholesterol (TC), triglyceride (TG) and LDL-cholesterol levels were 
observed. But a significant increase (p<0.05) in HDL-cholesterol levels were 
observed in all the treated animals compared with the control animals. AST, ALT and 
ALP levels were also normal in the Thiripalai Mathirai treated animals. From the 
results of biochemical study there was no evidence of severe toxicity associated with 
the administration of higher concentration of Thiripalai Mathirai. The results are 
shown in Table 5.1.5.1d and 5.1.5.1e. 
 
Table 5.1.5.1d) Effect of TPM on biochemical parameters such as glucose, 
cholesterol, triglyceride, HDL and LDL. 
Treatment Glucose 
(mg.dl
-1
) 
Cholesterol 
(mg.dl
-1
) 
Triglyceride 
(mg.dl
-1
) 
HDL 
(mg.dl
-1
) 
LDL 
(mg.dl
-1
) 
Control 94.70± 
0.65 
39.62± 0.56 28.25± 0.45 135.25± 0.55 84.15±1.72 
Thiripalai 
Mathirai @  
50 mg.kg
-1
 
9.55± 
0.61 
25.85±0.25
*
 13.22± 0.23
*
 175.28±0.65
*
 71.59±1.28 
Thiripalai 
Mathirai @ 
100 mg.kg
-1
 
97.50± 
0.52 
26.74±0.26
*
 15.42± 0.28
*
 165.18±0.78
*
 69.84±1.10 
Thiripalai 
Mathirai @  
200 mg.kg
-1
 
908.30±
0.58
**
 
33.18± 0.30 17.84± 0.38
*
 184.30±0.84
*
 48.60±1.30 
Thiripalai 
Mathirai @  
400 mg.kg
-1
 
86.30± 
0.48
**
 
32.78± 0.28 19.28± 0.34
*
 182.2± 0.85
*
 
 
46.50±0.84 
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A study on the  effect of Thiripalai Mathirai on biochemical parameters such 
as glucose, cholesterol, triglyceride, HDL and LDL in rats was tested.where, group I 
animals (GPI) treated with normal saline (5 ml.kg
-1
), group II animals (GPII)  with 50 
mg.kg
-1
 of Thiripalai Mathirai,  group III animals (GPIII)  with 100 mg.kg
-1
 of 
Thiripalai Mathirai, group IV animals (GPIV)  with 200 mg.kg
-1 
of, group V animals 
(GPV)   with 400 mg.kg
-1
 Thiripalai Mathirai. The values are expressed as mean ± 
S.E.M. n=6.   The results of group I were compared with other groups such as II, III, 
IV, and V.  The statistical analysis was carried out using one way ANOVA method, 
where **P<0.01 *P<0.05 
Table 5.1.5.1e) Effect of TPM on biochemical parameters such as AST, ALT, 
ALP, TP and Albumin in rats.  
Treatment AST 
(IU.l
-1
) 
ALT 
(IU.l
-1
) 
ALP 
(IU.l
-1
) 
TP 
(g.l
-1
) 
ALBUMIN 
(g.l
-1
) 
Control 328.5±12.40 71.5±3.18 253.58±8.80 69.85±3.32 39.15±2.35 
Thiripalai  
Mathirai @  
50 mg.kg
-1
 
317.0±9.50
**
 69.5±2.20
**
 266.10±2.75
**
 70.30±2.32 36.30±2.65 
Thiripalai  
Mathirai @  
100 mg.kg
-1
 
318.3±7.20
**
 67.1±3.15
**
 260.18±6.70
**
 80.15±2.82 38.30±3.05 
Thiripalai  
Mathirai @  
200 mg.kg
-1
 
313.4±7.95 62.4±2.90 265.00±5.20 69.25±3.32 40.20±2.75 
Thiripalai 
Mathirai @  
400 mg.kg
-1
 
323.2± 8.20 64.3±3.52 269.40± 4.40 74.05±2.58 39.48±2.70 
A study on the effects of Thiripalai Mathirai on biochemical parameters such 
as AST, ALT, ALP, TP and Albumin rats was tested. where, group I animals (GPI)  
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were treated with normal saline (5ml.kg
-1
),  group II animals (GPII) with 50 mg.kg
-1
 
of HAEBD group III animals (GPIII)  with 100 mg.kg
-1
 of Thiripalai Mathirai, group 
IV animals (GPIV)  with 200 mg.kg
-1 
of Thiripalai Mathirai,  and group V animals 
(GPV)  with 400 mg.kg
-1
 Thiripalai MathiraiThe values are expressed as mean ± 
S.E.M. n=6.   The results of group I were compared with other groups such as II, III, 
IV, and V.   The statistical analysis was carried out using one way ANOVA method, 
where **P<0.01 *P<0.05. 
Effect of Thiripalai Mathirai on haematological parameters in rats   
The effects of Thiripalai Mathirai were observed for its effect on 
haematological parameters on the experimental rats. From the study it was evident 
that, a significant increase (p<0.01) were observed in the haemoglobin contents and  
RBC count  in the group treated with 200 mg.kg
-1
 body weight of Thiripalai 
Mathiraiand a significant decrease of the parameters occurred in the group treated 
with 400 mg.kg
-1
 b.w.t compared with the control. There was no significant change in 
the calcium level in all the treated animals compared to the control. 
 
Table 5.1.5.1f) Effect of TPM on haematological parameters such as HB, 
Calcium, RBC and WBC in rats.  
Treatment Haemoglobin 
(mg.dl
-1
) 
RBC 
(10
6
 /mm
3
) 
WBC 
(10
6 
/mm
3
) 
Calcium 
(mg.dl
-1
) 
Control 13.35± 0.25 9.12± 0.02 12.4± 0.05  9.45 ±0.02 
Thiripalai Mathirai 
@ 50 mg.kg
-1
 
14.55± 0.26
*
 9.47± 0.04
*
   10.5± 0.01
*
  9.21 ±0.02 
Thiripalai Mathirai 
@ 100 mg.kg
-1
 
14.35± 0.15
*
 9.52± 0.02
*
   9.3± 0.32
*
  9.27 ±0.20 
Thiripalai Mathirai 
@ 200 mg.kg
-1
 
12.75± 0.20
*
 8.30± 0.12
*
 11.4± 0.03
*
  9.61 ±0.13 
Thiripalai Mathirai 
@ 400 mg.kg
-1
 
13.55± 0.35
*
 8.48± 0.45
*
   11.5± 0.13
*
  9.75 ±0.02 
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A study on the effect of Thiripalai Mathirai on haematological parameters 
such as Hb, RBC, WBC, and Calcium in rats was tested. where, group I animals (GPI) 
treated with normal saline (5 ml.kg
1
), group II animals (GPII)  with 50 mg.kg
-1
 of 
Thiripalai Mathirai,  group III animals (GPIII)   with 100 mg.kg
-1
 of Thiripalai 
Mathirai,   group IV animals (GPIV)   with 200 mg.kg
-1 
of Thiripalai Mathirai, and  
group V animals (GPV)  with 400 mg.kg
-1
 Thiripalai Mathirai. The values are 
expressed as mean ± S.E.M. n=6. The results of group I were compared with other 
groups such as II, III, IV and V.   The statistical analysis was carried out using one 
way ANOVA method, where *P<0.05. 
 
5.1.5.2 Acute toxicity study with Karisalai Kudineer 
  The acute toxicity of Karisalai Kudineer was evaluated using OECD- 423 
guidelines. There was no mortality or morbidity observed in animals through the 15-
days period following single oral administration at all selected dose levels of the 
Karisalai Kudineer (Table 5.1.5.2a).   The animals did not show any changes in the 
general appearance during the observation period. Morphological characteristics such 
as fur, skin, eyes and nose appeared normal. No tremors, convulsion, salivation, 
diarrhea, lethargy or unusual behaviors such as self mutilation, walking backward and 
so forth were observed.   Gait and posture, reactivity to handling or sensory stimuli, 
grip strength was also normal.  
 
Table 5.1.5.2a) Acute toxicity study of KK on experimental mice 
 Dose (mg.kg
-1
) Sign of Toxicity (ST.NB
-1
) Mortality (D.S
-1
) 
Group I              0                      0/3            0/3 
Group II            300                      0/3            0/3 
Group III           2000                      0/3            3/3 
The acute toxicity of Karisalai Kudineer on experimental mice was tested 
using OECD-423 guidelines, where ST- sign of toxicity; NB- normal behaviour; D- 
died; S- survive.  Values are expressed as number of animals (n=3). 
Effect of Karisalai Kudineer in Subacute Toxicity  
Karisalai Kudineer was evaluated for subacute toxicity. 
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Effect of Karisalai Kudineer on body weight changes in rats 
The effect of Karisalai Kudineer was observed for their effect on the body 
weight changes from the study it was observed that, there was significant increase 
(p<0.05) in body weight in all the animals observed. The results are shown in Table 
5.1.5.2b.  
Table 5.1.5.2b) Effect of KK on body weight changes in rats.    
Treatment Day 1 Day 5 Day 10 Day 20 
Control 189.00±6.4 185.40  ±6.30 195.00 ±6.30 195.00±6.50 
Karisalai Kudineer 
 50 mg.kg
-1
 
195.00 ±6.9 194.00  ±6.42 199.00 ±6.70 196.00±6.54
*
 
Karisalai Kudineer 
100 mg.kg
-1
 
188.00 ±5.6 188.00  ±6.32 195.00  ±6.25 198.00±6.58
*
 
Karisalai Kudineer 
200 mg.kg
-1
 
192.00  ±7.4 197.00±6.50 197.00  ±6.45
**
 204.00±7.35
**
 
Karisalai Kudineer 
400 mg.kg
-1
 
185.00  ±5.4 194.00 ±5.60 194.00  ±6.35
**
 206.00±7.40
**
 
A study on the effects of Karisalai Kudineer on body weight changes in rats 
was carried out, where group I animals (GPI) were treated with normal saline (5 
ml.kg
-1
), group II animals (GPII) with 50 mg.kg
-1
 of Karisalai Kudineer, group III 
animals (GPIII) with 100 mg.kg
-1
 of Karisalai Kudineer, group IV animals (GPIV)  
with 200 mg.kg
-1 
of Karisalai Kudineer, group V animals (GPV)  with 400 mg.kg
-1
 
Karisalai Kudineer. The values are expressed as mean ± S.E.M. n=6. The results of 
group I were compared with other groups such as II, III, IV, and V.   The statistical 
analysis was carried out using one way ANOVA method, where **P<0.01 *P<0.05. 
Effect of Karisalai Kudineer on kidney, heart, liver and brain in rats  
The effects of Karisalai Kudineer on kidney, heart, liver and brain of the rats 
were observed. From the study it was clear that, significant (p<0.01) changes in the 
weights of various organs of the animals occurred with higher doses of the extract 
(400 mg.kg
-1
 bwt), but macroscopic examinations did not show any changes in colour 
of the organs of the treated animals compared with the control.   The results are 
shown in Table 5.1.5.2c. 
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Table 5.1.5.2c) Effect of KK on kidney, heart, liver and brain of the rats. 
Treatment Heart (gms) Kidney (gms) Liver (gms) Brain (gms)   
Control 0.35 ± 0.06 0.67± 0.05 3.30± 0.07 0.68± 0.09 
Karisalai Kudineer 
@ 50 mg.kg
-1
 
0.36± 0.05 0.80± 0.05 3.42± 0.05 0.71± 0.10 
Karisalai Kudineer 
@ 100 mg.kg
-1
 
0.37± 0.06 0.81± 0.06 3.38±0.04 0.69± 0.8 
Karisalai Kudineer 
@ 200 mg.kg
-1
 
0.38± 0.07 0.76± 0.04 3.35± 0.04 0.76± 0.11 
Karisalai Kudineer 
@ 400 mg.kg
-1
 
0.34± 0.04 0.77± 0.05 3.36± 0.05 0.78± 0.12 
A study on the effects of Karisalai Kudineer on kidney, heart, liver and brain 
of the rats was tested. where, group I animals (GPI) treated with normal saline (5 
ml.kg
-1
), group II animals (GPII)  with 50 mg.kg
-1
 of Karisalai Kudineer,  group III 
animals (GPIII)   with 100 mg.kg
-1
 of Karisalai Kudineer, group IV animals (GPIV)   
with 200 mg.kg
-1 
of Karisalai Kudineer, group V animals (GPV)  with 400 mg.kg
-1
 
Karisalai Kudineer.  The values are expressed as mean ± S.E.M. n=6.   The results of 
group I were compared with other groups such as II, III, IV, and V.  The statistical 
analysis was carried out using one way ANOVA method, where **P<0.01. 
Effect of Karisalai Kudineer on biochemical profiles of rats   
The effect of Karisalai Kudineer on various biochemical parameters of the 
experimental animal ‘rats’ were tested.  From the study it was evident that, there was 
significant decrease (p<0.05) in the plasma glucose level in treated rats especially at 
higher dose (400 mg.kg
-1
) compared with control rats. The control rats were 
administered only with 5 ml of normal saline. Significant decrease (p<0.05) in the 
plasma total cholesterol (TC), triglyceride (TG) and LDL-cholesterol levels were 
observed. But a significant increase (p<0.05) in HDL-cholesterol levels were 
observed in all the treated animals compared with the control animals. AST, ALT and 
ALP levels were also normal in the Karisalai Kudineer treated animals. From the 
results of biochemical study there was no evidence of severe toxicity associated with 
the administration of higher concentration of Karisalai Kudineer. The results are 
shown in Table 5.1.5.2d and Table 5.1.5.2e. 
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Table 5.1.5.2d) Effect of KK on biochemical parameters such as glucose, 
cholesterol, triglyceride, HDL and LDL 
Treatment Glucose 
(mg.dl
-1
) 
Cholesterol 
(mg.dl
-1
) 
Triglyceride 
(mg.dl
-1
) 
HDL 
(mg.dl
-1
) 
LDL 
(mg.dl
-1
) 
Control 95.65±0.68 40.65±0.55 29.28± 0.48 134.30± 0.58 83.20±1.70 
Karisalai 
Kudineer@ 
50 mg.kg
-1
 
94.50±0.64 26.80±0.28
*
 13.28±0.24
*
 176.30±0.68
*
 71.62±1.34 
Karisalai 
Kudineer@ 
100 mg.kg
-1
 
96.28±0.50 26.70±0.24
*
 15.40±0.30
*
 165.20±0.80
*
  68.86±1.25 
Karisalai 
Kudineer@ 
200 mg.kg
-1
 
97.22±0.62
**
 33.20± 0.34 16.86±0.40
*
 184.25±0.86
*
 48.55±1.32 
Karisalai 
Kudineer@ 
400 mg.kg
-1
 
90.35±0.35
**
 32.80± 0.32 17.30±0.36
*
 182.0± 0.86
*
 46.45±0.82 
 
 
A study on the effect of Karisalai Kudineer on biochemical parameters such as 
glucose, cholesterol, triglyceride, HDL and LDL in rats was tested. where, group I 
animals (GPI) treated with normal saline (5 ml.kg
-1
), group II animals (GPII)  with 50 
mg.kg
-1
 of Karisalai Kudineer,  group III animals (GPIII)  with 100 mg.kg
-1
 of 
Karisalai Kudineer, group IV animals (GPIV)  with 200 mg.kg
-1 
of, group V animals 
(GPV) with 400 mg.kg
-1
 Karisalai Kudineer. The values are expressed as mean ± 
S.E.M. n=6.   The results of group I were compared with other groups such as II, III, 
IV, and V.  The statistical analysis was carried out using one way ANOVA method, 
where **P<0.01 *P<0.05 
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Table 5.1.5.2e) Effects of KK on biochemical parameters such as AST, ALT, 
ALP, TP and Albumin in rats 
Treatment AST 
(IU.l
-1
) 
ALT 
(IU.l
-1
) 
ALP 
(IU.l
-1
) 
TP 
(g.l
-1
) 
ALBUMIN 
(g.l
-1
) 
Control 330.4±11.25 72.4±3.20 252.60±8.75 68.80±3.25 38.20±2.30 
Karisalai 
Kudineer@ 
50 mg.kg
-1
 
318.2±9.45
**
 69.4±2.22
**
 265.14±2.80
**
 69.18±2.28 36.23±2.60 
Karisalai 
Kudineer@ 
100 mg.kg
-1
 
319.5±7.15
**
 68.2±3.18
**
 261.20±6.68
**
 80.24±2.65 37.25±2.18 
Karisalai 
Kudineer@ 
200 mg.kg
-1
 
313.5±7.90 62.5±2.88 264.15±5.24 69.34±2.34 40.05±2.45 
Karisalai 
Kudineer@  
400 mg.kg
-1
 
322.4± 8.22 64.2±3.50 270.38±4.45 73.18±2.56  39.15±2.38 
 
A study on the effects of Karisalai Kudineer on biochemical parameters such 
as AST, ALT, ALP, TP and Albumin rats was tested. where, group I animals (GPI)  
were treated with normal saline (5ml.kg
-1
),  group II animals (GPII) with 50 mg.kg
-1
 
of HAEBD group III animals (GPIII)  with 100 mg.kg
-1
 of Karisalai Kudineer, group 
IV animals (GPIV)  with 200 mg.kg
-1 
of Karisalai Kudineer,  and group V animals 
(GPV)  with 400 mg.kg
-1
 Karisalai Kudineer. The values are expressed as mean ± 
S.E.M. n=6.   The results of group I were compared with other groups such as II, III, 
IV, and V.   The statistical analysis was carried out using one way ANOVA method, 
where **P<0.01 *P<0.05. 
Effect of Karisalai Kudineer on haematological parameters in rats   
The effects of Karisalai Kudineer were observed for its effect on 
haematological parameters on the experimental rats. From the study it was evident 
that, a significant increase (p<0.01) were observed in the haemoglobin contents and  
RBC count  in the group treated with 200 mg.kg
-1
 body weight of Karisalai Kudineer 
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and a significant decrease of the parameters occurred in the group treated with 400 
mg.kg
-1
 b.w.t compared with the control. There was no significant change in the 
calcium level in all the treated animals compared to the control. 
Table 5.1.5.2f) Effect of KK on haematological parameters such as HB, Calcium, 
RBC and WBC in rats 
Treatment Haemoglobin 
(mg.dl
-1
) 
RBC 
(10
6
 /mm
3
) 
WBC 
(10
6 
/mm
3
) 
Calcium 
(mg.dl
-1
) 
Control 13.75± 0.28 9.18± 0.03 12.6± 0.04  9.48 ±0.03 
Karisalai Kudineer 
@ 50 mg.kg
-1
 
14.68± 0.38
*
 9.49± 0.04
*
   10.2± 0.02
*
  9.20 ±0.02 
Karisalai Kudineer 
@ 100 mg.kg
-1
 
14.22± 0.34
*
 9.55± 0.03
*
   9.1± 0.01
*
  9.29 ±0.04 
Karisalai Kudineer 
@ 200 mg.kg
-1
 
13.70± 0.30
*
 8.34± 0.02
*
 11.6± 0.03
*
  9.60 ±0.06 
Karisalai Kudineer 
@ 400 mg.kg
-1
 
13.58± 0.29
*
 8.40± 0.02
*
   11.4± 0.04
*
  9.70 ±0.08 
 
A study on the effect of Karisalai Kudineer on haematological parameters 
such as Hb, RBC, WBC, and Calcium in rats was tested. where, group I animals (GPI) 
treated with normal saline (5 ml.kg
1
), group II animals (GPII)  with 50 mg.kg
-1
 of 
Karisalai Kudineer,  group III animals (GPIII)   with 100 mg.kg
-1
 of Karisalai 
Kudineer,   group IV animals (GPIV)   with 200 mg.kg
-1 
of Karisalai Kudineer, and  
group V animals (GPV)  with 400 mg.kg
-1
 Karisalai Kudineer. The values are 
expressed as mean ± S.E.M. n=6. The results of group I were compared with other 
groups such as II, III, IV and V.   The statistical analysis was carried out using one 
way ANOVA method, where *P<0.05. 
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5.2. CLINICAL STUDY 
The results were observed on the basis of the following criteria by conducting 
clinical study on 20 inpatients and 20 outpatients, totally 40 patients. 
 Distribution of Gender 
 Distribution of Age 
 Distribution of Occupational status 
 Distribution of Socio economic status  
 Distribution of Dietary habits 
 Distribution of Marital Status 
 Distribution of Thegi 
 Distribution of Nilam 
 Distribution of Kaalam 
 Distribution of Paruvakaalam 
 Distribution of Imporigal 
 Distribution of Kanmendriyam 
 Distribution of Kosangal 
 Distribution of Mukkutram- Vatham, Pitham, Kabam 
 Distribution of Ezhu Udal Thathukkal 
 Distribution of Ennvagai Thervu 
 Distribution of Naadi 
 Distribution of Neikuri 
 Distribution of Aetiological  factors 
 Distribution of Clinical Features and prognosis 
 Distribution of Haemoglobin  level 
 Gradation of Results 
 Assessment of results by Laboratory investigation. 
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5.2.1 Distribution of Gender  
Table-5.2.1 
S.No Sex 
No. of Cases Percentage 
OP IP OP IP 
1. Male 3 1 15 5 
2. Female 17 19 85 95 
 Total 20 20 100 100 
 
Figure – 5.2.1
 
 
Inference:  
  Among the 40 cases of Pitha paandu, 36 patients were females and 4 patients 
were male.  
 
 
 
15%
5%
85%
95%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
OP IP
Male
Female
Gender
82 
 
5.2.2. Distribution of Age  
Table – 5.2.2 
S.No 
Age group 
in year  
No. of Cases Percentage 
OP IP OP 
 
IP 
1. 20-30 5 1 25 5 
2. 31-40 5 2 25 10 
3. 41-50 4 6 20 30 
4. 51-60 6 11 30 55 
 Total 20 20 100 100 
 
Figure-5.2.2 
 
Inference :  
 Out of  40 cases, 17 patients were in the age group 51-60, 10 patients in the 
age group 41-50 years, 7 patients belongs to 31-40 years of age group and 6 patients 
belongs to 20-30 years of age group.  
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5.2.3 Distribution of Occupational Status  
Table -5.2.3 
S.No 
Occupational status 
 
No. of Cases Percentage 
OP IP OP 
 
IP 
1. Students  3 0 15 0 
2. Labours 4 7 20 35 
3. House wife 8 13 40 65 
4. Office going 5 0 25 0 
 Total 20 20 100 100 
 
Figure – 5.2.3 
 
Inference:  
 Out of 40 cases, 3 patients were students, 11 patients were labours, 21 patients 
were House wife and 5 patients were office going.  
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5.2.4 Distribution of Socio- Economic status  
Table -5.2.4 
S.No Socio- Economic Status  
No. of Cases Percentage 
OP IP OP 
 
IP 
1. Low Income group  
(Below 20,000) 
15 20 75 100 
2. Middle Income group 
(20,000-50,000) 
5 0 25 0 
3. High income group 
(above 50,000)  
0 0 0 0 
 Total 20 20 100 100 
 
      Figure- 5.2.4 
 
 
 
Inference:  
 Out of 40 cases, 35 patients belong to low income group and 5 patients belong 
to middle income group.  
 
 
 
0%
20%
40%
60%
80%
100%
OP IP
75%
100%
25%
0%0% 0%
Low Income group (Below 
20,000)
Middle Income 
group(20,000-50,000)
High income group(above 
50,000) 
Socio-Economic status
85 
 
5.2.5 Distribution of Dietary Habits 
Table -5.2.5 
S.No Dietary Habits 
No. of Cases Percentage 
OP IP OP 
 
IP 
1. Vegetarian 4 0 20 0 
2. Mixed Diet 16 20 80 100 
 Total 20 20 100 100 
 
 
Figure-5.2.5 
 
 
Inference:  
 Out of 40 cases, 36 patients were mixed diet and 4 patients were vegetarian. 
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5.2.6  Distribution of Marital status 
Table -5.2.6 
S.No Marital status 
No. of Cases Percentage 
OP IP OP 
 
IP 
1. Married 17 20 85 100 
2. Unmarried 3 0 15 0 
 Total 20 20 100 100 
 
Figure-5.2.6 
 
 
Inference:  
 Out of 40 cases, 37 patients were married and 3 patients were unmarried. 
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5.2.7 Distribution of Thegi  
Table -5.2.7 
S.No Thegi 
No. of Cases 
 
Percentage 
OP IP OP IP 
1. Vatham 3 4 15 20 
2. Pitham 10 10 50 50 
3. Kabam  0 0 0 0 
4. Thondham 7 4 35 20 
 
 
Figure-5.2.7 
 
Inference:  
 Among 40 cases, 7 patients were vatha thegi, 20 patients were pitha thegi and 
11 patients were thontha thegi. 
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5.2.8 Distribution of Nilam  
Table – 8 
S.No Thinai 
No. of Cases Percentage 
OP IP OP 
 
IP 
1. Kurinji 0 0 0 0 
2. Mullai  0 0 0 0 
3. Marutham 16 15 80 75 
4. Neithal 4 5 20 25 
5. Palai 0 0 0 0 
 Total 20 20 100 100 
 
Figure -5.2.8 
 
 
Inference:  
 Out of 40 cases, 31 patients come under Marutha nilam and 9 patients come 
under Neithal nilam. 
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5.2.9 Distribution of Kaalam  
Table – 9 
S.No Kaalam 
No. of Cases Percentage 
OP IP OP 
 
IP 
1. Vadha Kaalam 
(First 33 yrs and 4 months) 
8 3 40 15 
2. Pitha Kaalam 
 (Second 33 yrs and 4 
months) 
12 17 60 85 
3. Kabha Kaalam 
(Third 33 yrs and 4 months) 
0 0 0 0 
 Total 20 20 100 100 
 
Figure –5.2.9 
 
Inference:  
    Out of 40 cases, 11 patients were under vathakaalam of their life span, and 29 
patients were under pitha kaalam of their life span.  
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5.2.10 Distribution of Paruvakalam 
Table-10 
S.No Paruvakalam Months 
No. of Cases Percentage  
OP IP OP 
 
IP 
1. Kar Kalam Aavani- Puratasi 1 0 5 0 
2. Koothir Kalam Iyppasi - 
Karthigai  
1 4 5 20 
3. Munpani kalam Markazhi – Thai 5 5 25 25 
4. Pinpani kaalam Masi- Panguni 5 10 25 50 
5. Elavenil 
Kaalam 
Chithirai - 
Vaikasi  
3 1 15 5 
6. Muthuvenil 
kaalam 
Aani- Aadi 5 0 25 0 
 Total  20 20 100 100 
 
  Figure -5.2.10   
 
 
Inference:  
  Out of 40 cases, 1 patient comes under Kar kaalam, 5 patients comes under 
Koothir  kaalam, 10 patients comes under Munpani  kaalam, 15 patients comes under 
Pinpani  kaalam, 4 patients comes under Elavenil kaalam and 5 patients comes under 
Muthuvenil kaalam. 
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5.2.11 Distribution of Imporigal  
Table – 5.2.11 
S.No Imporigal 
No. of Cases Percentage 
OP IP OP 
 
IP 
1. Mei 7 5 35 25 
2. Vai  15 18 75 90 
3. Kan 20 20 100 100 
4. Mooku 0 0 0 0 
5. Sevi 0 0 0 0 
 
Figure-5.2.11 
 
Inference:  
 Among 40 cases, Mei was affected in 12 patients, Vai was affected in 33 
patients and Kan was affected in all patients. 
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5.2.12. Distribution of Kanmendriyam  
Table – 5.2.12 
S.No Kanmendriyam 
No. of Cases Percentage 
OP IP OP 
 
IP 
1. Kai 8 10 40 50 
2. Kaal  8 16 40 80 
3. Vai 15 18 75 90 
4. Eruvai 6 4 30 20 
5. Karuvai 4 4 20 20 
 
Figure-5.2.12 
 
 
Inference :  
 Among 40 cases, Kai was affected in 18 patients, Kaal was affected in 24 
patients, Vai was affected in 33 patients, Eruvai was affected in 10 patients and 
Karuvai was affected in 8 patients. 
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5.2.13. Distribution of Kosangal  
Table – 5.2.13 
S.No Kosam 
No. of Cases Percentage 
OP IP OP 
 
IP 
1. Annamayakosam 4 7 20 35 
2. Pranamayakosam  11 16 55 80 
3. Manomayakosam 6 3 30 15 
4. Vinganamayakosam 8 16 40 80 
5. Anandamayakosam 6 4 30 20 
 
Figure-5.2.13 
 
Inference:  
 Among 40 cases, Annamayakosam was affected in 11 patients, 
Pranamayakosam was affected in 27 patients, Manomayakosam was affected in 9 
patients, Vinganamayakosam was affected in 24 patients and Anandamayakosam was 
affected in 10 patients. 
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5.2.14. Distribution of Vatham: 
Table -5.2.14 
S.No Vaatham 
No. of Cases Percentage 
OP IP OP IP 
1. Piranan 11 16 55 80 
2. Abanan  6 4 30 20 
3. Viyanan 8 16 40 80 
4. Udhanan 11 16 55 80 
5. Samanan 20 20 100 100 
6. Naagan  0 0 0 0 
7. Koorman  0 0 0 0 
8. Kirukaran 4 7 20 35 
9. Dhevathathan 20 20 100 100 
10. Dhananjeyan 0 0 0 0 
 
Figure – 5.2.14 
 
Inference:  
 Among  the 40 cases of pitha paandu, Samanan, Devathathan were affected in 
all patients, Piranan was affected in 27 patients, Abanan was affected in 10 patiens 
and Viyanan was affected in 24 patients, Udhanan was affected in 27 patients and 
Kirukaran was affected in 11 patients.  
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5.2.15. Distribution of  Pitham   
Table -5.2.15 
S.No Pitham 
No. of Cases Percentage 
OP IP OP 
 
IP 
1. Analagam 4 7 20 35 
2. Ranjagam 20 20 100 100 
3. Sathagam 20 20 100 100 
4. Alosagam 0 0 0 0 
5. Prasagam 7 5 35 25 
 
Figure - 5.2.15 
 
Inference  :  
 Among 40 cases of pitha paandu, Analagam were affected in 11 patients, 
Ranjagam, Sathagam were affected in all patients and Prasagam was affected in 12 
patients.  
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5.2.16. Distribution of Kabam 
Table -5.2.16 
S.No Kabam 
No. of Cases Percentage 
OP IP OP IP 
1. Avalambagam 20 20 100 100 
2. Kilethagam 0 0 0 0 
3. Pothagam 0 0 0 0 
4. Tharpagam 0 0 0 0 
5. Santhigam 8 16 40 80 
 
Figure-5.2. 16 
 
 
Inference:  
 Among 40 cases in pitha paandu, Avalambagam was affected in all patients 
and Sathigam were affected in 24 patients.  
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5.2.17. Distribution of Ezhu Udalthathukal  
Table -5.2.17 
S.No Ezhu Udalthathukal  
No. of Cases Percentage  
OP IP OP 
 
IP 
1. Saaram 20 20 100 100 
2. Senneer 20 20 100 100 
3. Oon 0 0 0 0 
4. Kozhuppu  0 0 0 0 
5. Enbu  8 16 40 80 
6. Moolai  0 0 0 0 
7. Suronitham 0 0 0 0 
 
 
Figure-5.2.17 
 
 
 
Inference:  
 Out of 40 cases in pitha paandu, saaram, senneer were affected in all patients 
and Enbu affected in 24 patients.  
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5.2.18. Distribution of Envagai Thervugal  
Table -5.2.18 
S.No Envagai Thervugal 
No. of Cases Percentage 
OP IP OP IP 
1. Naadi  20 20 100 100 
2. Sparisam 0 0 0 0 
3. Naa 15 18 75 90 
4. Niram  20 20 100 100 
5. Mozhi  0 0 0 0 
6. Vizhi  20 20 100 100 
7. Malam  6 4 30 20 
8. Moothiram  0 0 0 0 
 
 
Figure-5.2.18 
 
 
 
Inference:  
  Among the 40 cases, Niram, vizhi, Naadi were affected in all patients, Naa 
was affected in 33 patients and Malam was affected in 10 patients.  
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5.2.19. Distribution of Naadi  
Table -5.2.19 
S.No Naadi 
No. of Cases Percentage 
OP IP OP 
 
IP 
1. Pitha vatham   10 10 50 100 
2. Vatha kabham  7 8 35 40 
3. Kabha Vatham 3 2 15 10 
 Total 20 20 100 100 
 
 
Figure-5.2.19 
 
 
 
Inference:  
 Out of 40 cases in pitha paandu, Naadi was observed in which 20 patients had 
pitha vatha naadi, 15 patients had vatha kabham naadi and 5 patients had Kabha vatha 
naadi.  
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5.2.20. Distribution of Neikuri  
Table -5.2.20 
S.No Neikuri  
No. of Cases Percentage 
OP IP OP IP 
1. Vatham (Snake like) 8 10 40 50 
2. Pitham (Ring like) 10 6 50 30 
3. Kabham (Pearl like) 2 4 10 20 
 Total 20 20 100 100 
 
 
Figure-5.2.20 
   
 
Inference:  
Neikuri were observed in 40 pitha paandu patients. Out of which 18 patients 
had vatha neer, 16 patients had pitha neer, and 6 patients had kabha neer. 
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5.2.21. Distribution of Aetiological factors  
Table -5.2.21 
S.No Aetiological factors 
No. of Cases Percentage 
OP IP OP 
 
IP 
1. Nutritional deficiency  11 12 55 60 
2. Blood loss menorrhagia 4 4 20 20 
3. Piles 6 4 30 20 
 Total 20 20 100 100 
 
 
Figure-5.2.21 
 
 
Inference:  
  Out of 40 cases with pitha paandu, 23 patients were due to nutritional 
deficiency, 8 patients were due to blood loss menorrhagia and 10 patients were due to 
piles.  
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5.2.22. Distribution of Clinical features  
Table -5.2.22 
Sl.No Clinical Features 
No. of Cases Percentage 
OP IP OP IP 
1. Pallor  of  conjunctiva  and  nail bed 20 20 100 100 
2. Fatigue 20 20 100 100 
3. Loss  of  appetite 4 7 20 35 
4. Dyspnoea  on  exertion 11 16 55 80 
5. Headache 4 5 20 25 
6. Glossitis 0 0 0 0 
7. Constipation 6 4 30 20 
8. Giddiness 13 11 65 55 
9. Palpitation 6 3 30 15 
 
Figure-5.2.22 
 
 
Inference:  
  For 40 cases, clinical features of pitha paandu were reported. All the 40 
patients had the symptoms of pallor of conjunctiva and nail bed, fatigue, 11 patients 
had loss of appetite, 27 patients had dyspnoea on exertion, 9 patients had head ache, 
10 patients had constipation, 24 patients had giddiness and 9 patients had palpitation.  
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RESULTS AFTER TREATMENT 
 Results were observed on the basis of two main criteria.  
 
Primary Outcome:  
 Primary Outcome is mainly assessed by comparing the pre and post 
treatmental Hemoglobin level, of the trial patient.  
 
Secondary Outcome:  
 Secondary outcome is assessed by comparing the following parameters, before 
and after the treatment.  
1) Reduction of Clinical symptoms 
2) Changes in Complete Blood Count  
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5.2.23. Distribution of Clinical prognosis  
Table -5.2.23 
Sl.No Signs & Symptoms 
Before Treatment After Treatment 
No. of 
Cases 
Percentag
e (%) 
No. of 
Cases 
Percentage 
(%) 
OP IP OP IP OP IP OP IP 
1. Pallor of  conjunctiva  
and nail  bed 
20 20 100 100 8 9 40 45 
2. Fatigue 20 20 100 100 6 7 30 35 
3. Loss  of  appetite 4 7 20 35 2 2 10 10 
4. Dyspnoea on exertion 11 16 55 80 6 7 30 35 
5. Headache 4 5 20 25 1 2 5 10 
6. Glossitis 0 0 0 0 0 0 0 0 
7. Constipation 6 4 30 20 2 1 10 5 
8. Giddiness 13 11 65 55 6 4 30 20 
9. Palpitation 6 3 30 15 3 1 15 5 
 
 After treatment, in case of pitha paandu - pallor of conjunctiva present in 17 
patients, fatigue and dyspnoea on exertion present in 13 patients, loss of appetite 
present in 4 patients, headache and constipation in 3 patients, Palpitation present in 4 
patients and Giddiness in 5 patients.  
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5.2.24.a) Haemoglobin level of outpatients 
Table -5.2.24.a 
S. 
No 
O.P. No NAME 
BeforeTreatment 
(gms/dl) 
AfterTreatment 
(gms/dl) 
1. 34708 Subashini 7.0 8.4 
2. 40532 Subbulakshmi 7.0 9.0 
3. 44599 Najima 10.0 10.1 
4. 51619 Ponnu 8.4 9.5 
5. 59578 Ponselvi 9.8 11.8 
6. 63211 Fouzia 9.6 11.1 
7. 65610 Shanmugam 9.7 11.8 
8. 67147 Jansi Rani 9.0 10.2 
9. 70157 Chellakutty 8.7 10.4 
10. 98638 Esakkiammal 7.6 11.0 
11. 105310 Sivagami 9.8 11.8 
12. 108697 Usha 10 11.6 
13. 10281 Kanniga 9.5 10.8 
14. 10248 Kavitha 9.7 11.1 
15. 13993 Nandhana 9.6 11.6 
16. 17049 Murugan 9.2 11.4 
17. 22601 Kajara 8.4 10.5 
18. 22602 Kannan 7.2 9.4 
19. 25079 Subhashini 7.8 9.2 
20. 25868 Pitchumani 8.4 8.5 
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5.2.24.b) Haemoglobin level of In patients 
 
Table -5.2.24.b 
S. 
No 
I.P. 
No 
NAME BeforeTreatment(gms/dl) AfterTreatment(gms/dl) 
1. 1266 Parvathi 7.6 8.7 
2. 2900 Arumugam 7.5 7.8 
3. 2901 Sabeena 7.1 9.8 
4. 2986 Thangam 9.6 10.5 
5. 2990 Naagammal 9.6 11.7 
6. 3117 Chandiran 8.2 9.7 
7. 139 Bagavathi 7.0 9.2 
8. 144 Rajakumari 8.2 10.4 
9. 207 Maharasi 9 11.2 
10. 211 Thangam 9.1 11.4 
11. 441 Vijayalakshmi 9 9.7 
12. 558 Arumugam 9.6 11.2 
13. 641 Muthulakshmi 9.2 10.3 
14. 653 Samuthrakani 10 11.5 
15. 660 Subbulakshmi 9.9 11.5 
16. 687 Sudamani 10 12.4 
17. 707 Vadivu 7.8 9.9 
18. 806 Sornam 9.2 11.2 
19. 807 Malaiammal 9.9 10.8 
20. 908 Velammal 9.1 11.8 
 
 
  
107 
 
5.2.25 Gradation of Results  
 
Table -5.2.25 
S.No 
Gradation of Result 
 
No. of Cases Percentage 
OP IP OP 
 
IP 
1. Good response 11 12 55 60 
2. Moderate response 7 4 35 20 
3. Poor response 2 4 10 20 
 
Figure- 5.2.25  
 
 
 
 Good Response: Increased in Hb 2gm% and above after treatment   
  Moderate Response: Increased in Hb 1.5gm% after treatment       
   Poor Response: Increase in Hb 1gm% after treatment  
    
Inference: 
Out of 40 cases, 23 patients showed good result, 11 patients showed moderate 
result and 6 patients showed poor result. 
58%28%
15%
Good response
Moderate response
Poor response
Gradation of Results
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5.2.26 a) CASE SUMMARY OF OUT-PATIENTS 
 
 
S.No. 
OP. 
No 
Name 
Age/ 
Sex 
Occupation 
Duration of 
the illness 
Starting of 
Treatment 
End of 
Treatment 
No. of days 
Treated 
Results 
1. 34708 Subashini 26/F Student 1Year 16.04.18 15.05.18 30days Moderate 
2. 40532 Subbulakshmi 43/F Office going 2Years 07.05.18 05.06.18 30days Good 
3. 44599 Najima 40/F Housewife 1Month 21.05.18 20.06.18 30days Poor 
4. 51619 Ponnu 60/F Housewife 4Years 18.06.18 18.07.18 30days Moderate 
5. 59578 Ponselvi 58/F Housewife 6Months 17.07.18 16.08.18 30days Good 
6. 63211 Fouzia 29/F Office going 1Month 30.07.18 29.08.18 30days Moderate 
7. 65610 Shanmugam 34/F Office going 6Months 07.08.18 06.09.18 30days Good 
8. 67147 Jansi Rani 20/F Student 6Months 13.08.18 12.09.18 30days Moderate 
9. 70157 Chellakutty 60/F Housewife 1Month 23.08.18 22.09.18 30days Good 
10. 98638 Esakkiammal 38/F Coolie 2Years 28.11.18 27.12.18 30days Good 
11. 105310 Sivagami 43/F Office going 6Months 20.12.18 19.01.19 30days Good 
12. 108697 Usha 35/F Housewife 4Months 31.12.18 29.01.19 30days Good 
13. 10281 Kanniga 51/F Housewife 2Years 28.01.19 27.02.19 30days Moderate 
14. 10248 Kavitha 43/F Officegoing 1Month 28.01.19 27.02.19 30days Moderate 
15. 13993 Nandhana 23/F Student 1Week 07.02.19 08.03.19 30days Good 
16. 17049 Murugan 60/M Coolie 1Year 15.02.19 16.03.19 30days Good 
17. 22601 Kajara 35/F Housewife 1Year 04.03.19 03.04.19 30days Good 
18. 22602 Kannan 58/M Coolie 6Months 04.03.19 03.04.19 30days Good 
19. 25079 Subhashini 28/F Housewife 6Months 12.03.19 11.04.19 30days Moderate 
20. 25868 Pitchumani 46/M Coolie 1Year 14.03.19 13.04.19 30days Poor 
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5.2.26 b) CASE SUMMARY OF IN-PATIENTS 
 
S.No IP. No Name 
Age 
/ Sex 
Occupation 
Duration 
of the 
illness 
Starting of 
Treatment 
End of 
Treatment 
No. of days 
Treated Results 
IP OP Total 
1. 1266 Parvathi 40/F Coolie 1Year 10.05.18 11.06.18 30 - 30 Moderate 
2. 2900 Arumugam 55/F Housewife 5Years 27.11.18 27.12.18 30 - 30 Poor 
3. 2901 Sabeena 26/F Housewife 1Year 27.11.18 27.12.18 30 - 30 Good 
4. 2986 Thangam 43/F Housewife 2Weeks 07.12.18 29.12.18 22 08 30 Poor 
5. 2990 Naagammal 55/F Coolie 5Years 07.12.18 02.01.19 26 04 30 Good 
6. 3117 Chandiran 55/M Coolie 2Years 21.12.18 20.01.19 30 - 30 Moderate 
7. 139 Bagavathi 42/F Housewife 1Month 23.01.19 22.02.19 30 - 30 Good 
8. 144 Rajakumari 40/F Housewife 1Year 23.01.19 22.02.19 30 - 30 Good 
9. 207 Maharasi 48/F Coolie 1Year 31.01.19 30.02.19 30 - 30 Good 
10. 211 Thangam 43/F Coolie 2Years 31.01.19 30.02.19 30 - 30 Good 
11. 441 Vijayalakshmi 55/F Housewife 5Years 21.02.19 20.03.19 30 - 30 Poor 
12. 558 Arumugam 60/F Housewife 1Month 05.03.19 04.04.19 30 - 30 Good 
13. 641 Muthulakshmi 46/F Housewife 1Year 12.03.19 11.04.19 30 - 30 Moderate 
14. 653 Samuthrakani 60/F Housewife 1Year 13.03.19 12.04.19 30 - 30 Moderate 
15. 660 Subbulakshmi 53/F Coolie 6Months 14.03.19 13.04.19 30 - 30 Good 
16. 687 Sudamani 53/F Coolie 1Year 18.03.19 17.04.19 30 - 30 Good 
17. 707 Vadivu 60/F Housewife 1Year 20.03.19 19.04.19 30 - 30 Good 
18. 806 Sornam 59/F Housewife 1Year 28.03.19 27.04.19 30 - 30 Good 
19. 807 Malaiammal 45/F Housewife 6Months 28.03.19 18.04.19 22 08 30 Poor 
20. 908 Velammal 55/F Housewife 3Months 09.04.19 09.05.19 30 - 30 Good 
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5.2.27 a) LABORATORY INVESTIGATION REPORT OF THE OUT PATIENTS 
S. 
no 
OP  
No 
Name 
Age / 
Sex 
Before treatment After Treatment ESR (mm) Blood Sugar  
®(gms/dl) 
Urine analysis 
TC 
(cu/mm 
DC 
TC 
(cu/mm 
DC BT AT BT AT 
P% L% E% P% L% E% 
½ 
hr 
1 
hr 
½ 
hr 
1 
hr 
BT AT Alb Sug Dep Alb Sug Dep 
1 34708 Subashini 26/F 7610 54 38 1 7800 56 48 1 10 20 9 18 82 78 N N FEC N N FEC 
2 40532 Subbulakshmi 43/F 7600 63 33 4 8100 62 38 2 18 35 12 22 86 110 N N FEC N N FEC 
3 44599 Najima 40/F 7500 62 36 2 9300 60 33 7 15 30 23 45 98 82 N N NAD N N FP 
4 51619 Ponnu 60/F 8500 58 42 0 8300 54 46 2 14 24 11 22 104 98 N N FEC N N FEC 
5 59578 Ponselvi 58/F 7800 60 38 1 8100 55 42 0 8 16 7 12 96 94 N N FEC N N NAD 
6 63211 Fouzia 29/F 8000 58 35 7 8200 56 40 2 9 20 8 16 87 91 N N NAD N N NAD 
7 65610 Shanmugam 34/F 7000 55 32 1 7100 60 35 5 19 38 23 45 90.8 77 N N FP N N FP 
8 67147 Jansi Rani 20/F 9200 48 47 3 9300 50 44 1 16 30 9 20 82 80 N N FEC N N FEC 
9 70157 Chellakutty 60/F 7400 62 37 0 7600 60 40 0 10 25 15 30 90 94 N N NAD N N NAD 
10 98638 Esakkiammal 38/F 7600 50 45 5 7300 64 34 2 7 12 7 14 82 98 N N FP N N FP 
11 105310 Sivagami 43/F 7600 54 41 4 9000 56 32 6 25 50 10 20 108 90 N N NAD N N NAD 
12 108697 Usha 35/F 8300 60 35 5 7400 57 33 1 16 30 21 40 140 133 N N NAD N N NAD 
13 10281 Kanniga 51/F 6300 64 29 7 7100 68 32 2 20 40 12 24 156 120 N N NAD N N NAD 
14 10248 Kavitha 43/F 7100 66 30 2 7640 65 29 3 15 30 13 25 131 110 N N FEC N N NAD 
15 13993 Nandhana 23/F 7000 60 37 3 7400 72 40 1 6 13 11 20 94 82 N N NAD N N NAD 
16 17049 Murugan 60/M 5900 50 49 1 6400 60 54 1 7 14 10 20 99 98 N N NAD N N NAD 
17 22601 Kajara 35/F 6500 66 30 4 6800 60 36 2 9 16 7 14 96 94 N N FP N N NAD 
18 22602 Kannan 58/M 6500 60 36 4 7200 65 42 2 20 40 16 30 105 92 N N NAD N N NAD 
19 25079 Subhashini 28/F 9100 54 42 1 9400 42 47 1 10 18 8 16 88 78 N N FEC N N FEC 
20 25868 Pitchumani 46/M 8100 73 20 7 7700 67 22 5 38 70 10 22 111 103 N N NAD N N NAD 
BT – Before Treatment, AT – After Treatment, N – Nil  TC – Total Blood Count, DC – Differential Blood Count, P – Polymorphs, L – Leucocytes ,E-Eosinophils 
ESR – Erythrocytes Sedimentation Rate, mm   , Alb – Albumin, Sug – Sugar, Dep– Deposits, FE – Few Epithelial cells, FP – Few Pus cells 
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5.2.27 b) LABORATORY INVESTIGATION REPORT OF THE IN PATIENTS 
S. 
no 
IP  
No 
Name 
Age / 
Sex 
Before treatment After Treatment ESR (mm) Blood 
Sugar  
®(gms/dl) 
Urine analysis 
TC 
(cu/m 
DC 
TC 
(cu/mm 
DC BT AT BT AT 
P% L% E% P% L% E% 
½ 
hr 
1 
hr 
½ 
hr 
1 
hr 
BT AT Alb Sug Dep Alb Sug Dep 
1 1266 Parvathi 40/F 6100 65 31 4 7300 58 40 2 20 40 30 62 84 83 N N NAD N N NAD 
2 2900 Arumugam 55/F 7300 58 38 4 6500 68 26 6 15 30 12 26 113 84 N N FEC N N FEC 
3 2901 Sabeena 26/F 8500 60 36 4 8100 60 38 2 16 32 18 40 74 78 N N FEC N N FEC 
4 2986 Thangam 43/F 9500 51 45 4 9200 54 46 2 10 20 10 18 88 86 N N FP N N FEC 
5 2990 Naagammal 55/F 8600 54 38 2 8200 56 41 1 10 18 9 16 88 92 N N NAD N N NAD 
6 3117 Chandiran 55/M 7500 78 16 3 7600 72 18 2 48 96 42 88 110 104 N N FP N N FP 
7 139 Bagavathi 42/F 7900 69 27 4 8100 72 24 1 37 70 32 64 111 98 N N FP N N FEC 
8 144 Rajakumari 40/F 9200 66 30 4 9000 60 38 2 6 12 10 20 92 88 N N NAD N N NAD 
9 207 Maharasi 48/F 8300 70 23 7 8600 66 23 1 5 11 8 12 90 86 N N NAD N N FP 
10 211 Thangam 43/F 6500 66 31 3 7100 64 30 2 13 25 15 30 80 78 N N NAD N N NAD 
11 441 Vijayalakshmi 55/F 6600 57 40 3 8100 64 24 2 22 45 26 50 120 105 N N FP N N FP 
12 558 Arumugam 60/F 6400 62 30 8 7000 68 29 3 12 25 16 28 116 98 N N FP N N NAD 
13 641 Muthulakshmi 46/F 8700 73 24 3 8500 57 37 6 16 30 9 16 112 105 N N NAD N N NAD 
14 653 Samuthrakani 60/F 6500 58 40 2 7000 60 35 1 27 58 19 38 108 86 N N NAD N N NAD 
15 660 Subbulakshmi 53/F 7600 67 30 1 7400 68 30 2 14 26 10 20 120 122 N N FEC N N FEC 
16 687 Sudamani 53/F 6900 71 22 7 7200 68 24 4 20 40 15 32 84 92 N N NAD N N NAD 
17 707 Vadivu 60/F 7400 60 35 5 7200 62 34 2 48 95 42 84 116 108 N N FP N N FP 
18 806 Sornam 59/F 8700 63 32 5 8200 68 30 3 14 28 15 30 98 90 N N NAD N N NAD 
19 807 Malaiammal 45/F 8500 57 30 3 8200 62 29 9 25 55 32 66 116 99 N N FP N N NAD 
20 908 Velammal 55/F 9000 54 34 2 9200 67 27 6 13 25 11 20 98 85 N N FEC N N FP 
BT – Before Treatment, AT – After Treatment, N – Nil TC – Total Blood Count, DC – Differential Blood Count, P – Polymorphs, L – Leucocytes, E – Eosinophils 
ESR – Erythrocytes Sedimentation Rate, mm – Milli meter, Sug-Sugar,Dep- Deposits, FEC – Few Epithelial cells, FPC – Few Pus cells 
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5.2.28 a) BIOCHEMICAL   AND   HAEMATOLOGICAL   REPORTS OF THE OUTPATIENT 
S .  
No 
OP 
No 
Name 
Age / 
Sex 
Blood urea 
Serum 
Creatinine 
Hb(gms/dl) 
RBC 
(millions/cu.mm) 
PCV 
(%) 
MCV 
(fl) 
MCH 
(pg) 
MCHC 
(%) 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1 34708 Subashini 26/F 20 21 0.4 0.4 7.0 8.4 4.21 4.5 24.4 28 61 70.1 16.6 22 28.7 31 
2 40532 Subbulakshmi 43/F 16 20 0.7 0.8 7.0 9.0 4.1 4.35 26 32 64 75 18 24 26 32 
3 44599 Najima 40/F 22 19 0.7 0.8 10.0 10.1 4.2 4.3 30 32 85 88 24 26 26 28 
4 51619 Ponnu 60/F 28 30 0.4 0.6 8.4 9.5 3.8 4.2 28 36 76 80 26 28 28 34 
5 59578 Ponselvi 58/F 32 34 0.6 0.4 9.8 11.8 4.14 4.26 34 33 80 82 20 24 25 28 
6 63211 Fouzia 29/F 16 17 0.7 0.6 9.6 11.1 3.8 4.25 32 33 78 82 24 26 26 27 
7 65610 Shanmugam 34/F 16 20 0.6 0.6 9.7 11.8 3.9 4.5 30 33 80 84 21 22.3 21 26 
8 67147 Jansi Rani 20/F 26 28 0.4 0.6 9.0 10.2 3.1 4.1 27 30 88 90 29 30 32 34 
9 70157 Chellakutty 60/F 20 22 0.7 0.6 8.7 10.4 2.8 3.8 30 32 92 94 30 31 33 34 
10 98638 Esakkiammal 38/F 26 24 0.8 0.8 7.6 11.0 3.6 4.12 28 30 66 68 22 23 24 28 
11 105310 Sivagami 43/F 30 32 0.6 0.4 9.8 11.8 3.74 4.42 32.2 35.4 86.1 80 23.5 26.6 27.3 33.2 
12 108697 Usha 35/F 18 17 0.8 0.9 10 11.6 3.90 3.88 36.1 32.4 92.8 88 25.1 25 27.1 29 
13 10281 Kanniga 51/F 32 30 0.6 0.5 9.5 10.8 3.91 4.03 28 33 72 82 26 28 30 31 
14 10248 Kavitha 43/F 25 24 0.4 0.6 9.7 11.1 4.45 4.17 36.4 35.8 78 85.9 23 26.6 24 31 
15 13993 Nandhana 23/F 26 31 0.6 0.4 9.6 11.6 4.34 4.5 33 30 80 82 24 26 30 33 
16 17049 Murugan 60/M 34 32 0.8 0.6 9.2 11.4 3.64 3.8 28 34 80 88 26 29 28 34 
17 22601 Kajara 35/F 22 20 0.4 0.6 8.4 10.5 3.7 4.2 30 28 74 76 25 28 26 29 
18 22602 Kannan 58/M 23 22 0.4 0.8 7.2 9.4 3.4 4.6 31 36 81 90 22 28 28 32 
19 25079 Subhashini 28/F 28 26 0.6 0.8 7.8 9.2 3.61 4.58 26 30.4 62 66.4 19 20.1 25 30.3 
20 25868 Pitchumani 46/M 34 31 0.8 0.4 8.4 8.5 3.8 3.9 34 38 76 81 21 23 26 28 
BT-BeforeTreatment, RBC-Red  Blood  Cells, PCV-Packed Cell Volume, MCV-Mean  Corpuscular  Volume, MCH-Mean  Corpuscular Haemoglobin,  
MCHC-Mean  Corpuscular  Haemoglobin  Concentration 
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5.2.28 b) BIO CHEMICAL AND HAEMATOLOGICAL REPORTS OF THE IN PATIENT 
S.No 
IP 
No 
Name Age / Sex 
Blood urea 
Serum 
Creatinine 
Hb(gms/dl) 
RBC 
(millions/cu.mm) 
PCV 
(%) 
MCV 
(fl) 
MCH 
(pg) 
MCHC 
(%) 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1 1266 Parvathi 40/F 24 22 0.7 0.7 7.6 8.7 3.45 4.7 26 32 64 73 21 25 24 30 
2 2900 Arumugam 55/F 15 16 0.4 0.7 7.5 7.8 3.3 3.9 30 33 76 78 25 27 25 27 
3 2901 Sabeena 26/F 24 20 0.8 0.7 7.1 9.8 3.9 4.2 28 32 68 72 22 24 23 29 
4 2986 Thangam 43/F 20 22 0.8 0.6 9.6 10.5 3.84 4.3 35.9 37 93.7 92 25 28 26.7 33 
5 2990 Naagammal 55/F 31 28 0.4 0.6 9.6 11.7 3.89 4.5 30 32 78 85 25 29 26 32 
6 3117 Chandiran 55/M 25 24 0.9 0.6 8.2 9.7 3.6 4.82 32.5 31 62 68 25.3 26 30 32 
7 139 Bagavathi 42/F 27 29 0.8 0.6 7.0 9.2 3.5 4.53 24 28 64 72 18 22 24 29 
8 144 Rajakumari 40/F 30 28 0.4 0.8 8.2 10.4 3.8 4.4 29 32 68 75 23 25 23 28 
9 207 Maharasi 48/F 34 30 0.3 0.4 9 11.2 4.1 4.6 26 34 72 84 21 27 26 31 
10 211 Thangam 43/F 28 29 0.6 0.5 9.1 11.4 4 4.8 30 33 70 72 20 24 25 29 
11 441 Vijayalakshmi 55/F 22 24 0.6 0.8 9 9.7 3.9 4.2 28 32 69 71 24 26 27 33 
12 558 Arumugam 60/F 18 20 0.6 0.5 9.6 11.2 3.94 4.3 30 33 72 76 28 24 26 30 
13 641 Muthulakshmi 46/F 16 20 0.8 0.7 9.2 10.3 3.8 4.1 29 34 68 74 23 26 25 31 
14 653 Samuthrakani 60/F 27 25 0.8 0.9 10 11.5 4.2 4.4 30 32 70 78 26 28 27 32 
15 660 Subbulakshmi 53/F 16 19 0.6 0.6 9.9 11.5 3.85 4.5 29 32 78 82 24 26 25.1 29 
16 687 Sudamani 53/F 16 18 0.7 0.4 10 12.4 4.08 4.45 28 31 68 70 19 24 28 34 
17 707 Vadivu 60/F 30 31 0.9 1.0 7.8 9.9 3.4 3.9 25 30 66 72 21 23 24 29 
18 806 Sornam 59/F 24 20 0.9 0.6 9.2 11.2 3.8 4.2 28 32 64 78 22 24 30 34 
19 807 Malaiammal 45/F 26 29 0.7 0.8 9.9 10.8 3.9 4.6 27 32 68 79 26 29 27 32 
20 908 Velammal 55/F 18 20 0.6 0.7 9.1 11.8 3.75 4.7 26 30 64 69 24 26 28 35 
BT-BeforeTreatment, AT-After Treatment, RBC-Red  Blood  Cells, PCV-Packed Cell Volume, MCV-Mean  Corpuscular  Volume, MCH-Mean   
Corpuscular Haemoglobin,  MCHC-Mean Corpuscular Haemoglobin Concentration 
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5.3 STATISTICAL ANALYSIS 
 
Table 5.3 Haematogical variables in study patients 
 Group 
Hb (gm/dl) RBC (cu mm) PCV (%) 
Before 
treatment 
After     
treatment 
Before 
treatment 
After   
treatment 
Before    
treatment 
After      
treatment 
Mean  8.826 10.498 3.804 4.314 29.388 32.350 
SD 1.003 1.129 0.326 0.273 3.123 2.297 
SEM  0.159 0.179 0.052 0.432 0.494 0.363 
t value -15.029 -8.933 -7.082 
p value <0.01 <0.01 <0.01 
 
By Paired‘t’ test, p value followed to be less than 0.01 is considered to be statistically 
significant. 
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CHAPTER - 6 
DISCUSSION 
          The Pitha paandu noi (Iron deficiency anaemia) is caused due to the 
derangement of Pitha thathu. The signs and symptoms of Pitha paandu such as pallor, 
fatigue, dyspnoea, palpitation, giddiness, pungent taste of tongue etc., are correlated 
with Iron Deficiency Anaemia (IDA) in Modern Science. The aim of the study was to 
find the therapeutic efficacy of the herbo mineral Siddha formulation “Thiripalai 
mathirai” on Pitha paandu noi.  
 
SELECTION OF TRIAL DRUG  
The clinical drug „„THIRIPALAI MATHIRAI” with its reference in 
“KADUKKAI VALLARAIYIN THANI MAANBU”, a Siddha  formulary text by 
the author Hakkim. P. Mohammed Abdullah Sahib, which is indicated for 
„„Paandu Noi” (page no: 81).  
 
PRECLINICAL STUDIES 
Preclinical studies were carried out and results are discussed below. 
Biochemical analysis:  
 The result of Biochemical analysis of “Thiripalai mathirai” shows the 
presence of sulphate, chloride, starch, ferrous iron, ferric iron, tannic acid 
and reducing sugar. The presence of ferrous iron and ferric iron in 
Thiripalai mathirai may help hemoglobin synthesis in anaemic patients due 
to nutritional deficiency.  
 The result of Biochemical analysis of “Karisalai kudineer” shows the 
presence of sulphate, chloride, starch, ferrous iron, unsaturated compound, 
reducing sugar and amino acid. The presence of ferrous iron in the 
adjuvant also adds additional nutrition in anaemic patients due to 
nutritional deficiency.  
Pharmacological Studies 
Pharmacological studies of Thiripalai mathirai and karisalai kudineer showed 
significant haematinic activity (P<0.01). 
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Toxicity Studies 
The administration of trial drug Thiripalai mathirai with the adjuvant karisalai 
kudineer in selected patients is considered to be safe since acute and subacute toxicity 
study in animals showed no morbidity and mortality. And also the effect on 
haematological parameters showed significant increase in Hb level (P<0.01) which is 
the main objective of this study. 
 
CLINICAL TRIAL  
 Totally 40 patients were selected 20 patients were treated in OPD and 20 
patients were treated in IPD of PG Pothu maruthuvam Department, 
Government Siddha medical College and Hospital, Palayamkottai.  
 The patients with the complaints of pallor, fatigue, dyspnoea, palpitation, 
giddiness, loss of appetite, headache, constipation etc., were screened using 
screening proforma, for Pitha paandu.   
 All the patients were administered with the trial drug “Thiripalai mathirai” 
and the adjuvant “Karisalai kudineer”.  
 The duration of treatment was 30 days and all necessary investigations were 
carried out to all patients; they were followed up regularly in the OP & IP 
department.        
 The aim of the treatment was to regulate the deranged Pitha dosha, to relieve 
clinical symptoms and to improve the Hemoglobin level.  
 Labarotary investigations were done before and after treatment for the 
assessment of safety of the patients and efficacy of the drug.  
 After the completion of treatment with the trial drug in all 40 cases, highly 
encouraging results were observed in the following Clinical, Haematological, 
Stastical parameters as follows,  
Incidence according to Sex: 
 Among 40 cases, 36 Patients (90%) were females and 4 Patients (10%) were 
males. 
 Though Pitha paandu affects both sexes, Females are mostly affected than 
males. This may be due to excessive menstrual blood loss which aggregates the 
already existing malnutrition. 
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Incidence according to Age: 
 Out of 40 patients, 17 Patients (42.5%) were in the age group of 51-60, 10 
Patients (25%) were in the age group of 41-50, 7 Patients (17.5%) were in the age 
group of 31-40 and 6 Patients (15 %) were in the age group of 20-30. 
Incidence according to Occupation: 
 Out of 40 patients, 21 Patients (52.5%) were House wife, 11 Patients (27.5%) 
were Labours, 5 Patients (12.5%) were office going and remaining 3 Patients (7.5%) 
are students. Labours were more affected due to malnourished diet. 
Incidence according to Socio-economical status: 
           Out of 40 patients, 35 Patients (87.5%) belongs to low income group, 5 
Patients (12.5%) belong to middle income group. Economically low income group 
were  more  affected  than  middle or  high  income group. 
 Incidence according to Dietary habits: 
Out of 40 patients, 36 Patients (90%) were mixed diet and 4 Patients (10%) 
were Vegetarian. 
Incidence according to marital status: 
Out of 40 patients, 37 Patients (92.5%) were married and 3 Patients (7.5%) 
were Unmarried. 
Incidence according to Thegi: 
 Out of 40 patients, 7 Patients (17.5%) were Vaatha thegi, 20 Patients (50%) 
were Pitha thegi and 11 Patients (27.5%) were Thontha thegi. 
Incidence according to Nilam: 
 Out of 40 patients, 31 Patients (77.5%) come under Marutham and 9 patients 
(22.5%) come under Neithal. 
Incidence according to Kaalam: 
 Out of 40 patients, 11 Patients (27.5%) comes under Vatha Kaalam and 29 
Patients (72.5%) comes under Pitha Kaalam. 
Incidence according to Paruvakaalam: 
              Out of 40 patients, 1(2.5%) Patient comes under Kar, 5(12.5%) Patients 
come under Koothir, 10(25%) Patients come under Munpani, 15 Patients (37.5%) 
come under Pinpani, 4 Patients (10%) come under Elavenil, and 5 Patients (12.5%) 
come under Munpani kaalam. 
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Incidence according to Imporigal: 
 Among 40 cases, Mei was affected in 12 Patients (30%) denotes pallor and 
dryness, Vai was affected in 33 Patients (82.5%) denotes glossitis, bitter or pungent 
taste, dryness, pallor, fissured and coated tongue, Kan was affected in all patients 
(100%) denotes pallor. 
Incidence according to Kanmendriyam: 
Among 40 cases, Kai was affected in 18 Patients (45%) denotes pain, Kaal 
was affected in 24 Patients (60%) denotes pain and pedal edema, Vai was affected in 
33 Patients (82.5%) denotes glossitis, bitter or pungent taste, dryness, pallor, fissured 
and coated tongue, Eruvai was affected in 10 Patients (25%) denotes constipation and 
Karuvai was affected in 8 Patients (20%) denotes menorrhagia. 
Incidence according to Kosangal: 
 Among 40 cases, Annamayakosam was affected in 11 Patients (27.5%) noted as 
loss of appetite, Pranamayakosam was affected in 27 Patients (67.5%) noted as 
dyspnoea, Manomayakosam was affected in 9 Patients (22.5%) noted as palpitation, 
Vinganamayakosam was affected in 24 Patients (60%) noted as pain and 
Anandamayakosam was affected in 10 Patients (25%) noted as menorrhagia and 
constipation. 
Incidence according to Mukkutram: 
Vatham: 
 Pranan was affected in 27 patients (67.5%), noted as dyspnoea on exertion. 
 Abanan was affected in 10 patients (25%) noted as constipation and 
menorrhagia. 
 Viyanan was affected in 24 patients (60%), noted as headache and joint 
pain. 
 Udhanan was affected in 27 patients (67.5%), noted as breathlessness. 
 Kirukaran was affected in 11 patients (12.5%), noted as loss of appetite.  
 Samanan was affected in all patients 100%, noted as loss of appetite. 
 Devathathan was affected in all patients 100%, noted as fatigue. 
 
Pitham: 
 Analagam was affected in 11 patients (12.5%) producing loss of appetite. 
 Ranjagam was affected in all patients (100%) resulting in pallor of 
conjunctiva and nail bed. 
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 Sathagam was affected in all patients (100%) resulting in fatigue   
 Pirasagam was affected in 12 patients (30%) resulting in   pallor of skin (Hb 
below 8gms/dl). 
 
Kabham: 
 Avalambagam was affected in all patients (100%) resulting in dyspnoea on 
exertion. 
 Santhigam was affected in 24 cases (60%) resulting pain in knee joints. 
  
Incidence according to Ezhu udal thathukkal: 
 Saaram was affected in all patients (100%) causing tiredness.  
 Senneer was affected in all patients (100%) producing pallor of conjunctiva 
and nail bed. 
 Enbu was affected in 24 patients (60%) causing joint pain. 
 
Incidence according to Ennvagai thervugal: 
 In all patients (100%) Naadi, Niram and Vizhi were affected, noted as pallor 
of conjunctiva and nailbed. 
 Naa was affected in 33 patients (82.5%) due to pallor. 
 Malam was affected in 10 patients (25%) due to constipation. 
 
Naadi: 
 20 cases (50%) had Pitha Vatha Naadi, 15 cases (37.5%) had Vatha Kabha 
Naadi and 5 cases (12.5%) had Kabha Vatha Naadi. 
 
Neikuri:  
 Out of 40 patients, 18 patients (45%) had Vatha Neer, 16 patients (40%) had 
Pitha Neer and 6 patients (15%) had Kabha Neer Neikuri. 
 
Incidence according to Aetiological factors: 
 Out of 40 patients, 23 patients (57.5%) were due to nutritional deficiency, 8 
patients (20%) were due to blood loss - menorrhagia and 10 patients (25%) were due 
to piles. So it is evident  that  nutritional  deficiency  plays  a  major  role in  causing  
Iron deficiency Anaemia. 
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Investigations: 
            TC, DC, ESR, Hb, PCV, MCV, MCH, MCHC, Blood sugar, Blood urea, 
Serum creatinine and routine  urine test were  taken and recorded before and  after 
treatment. 
 
Incidence according to Prognosis Assessment and Efficacy of Trial drug 
Thiripalai mathirai with the adjuvant Karisalai kudineer 
  After confirming the diagnosis of Pitha Paandu, all the patients were treated 
with Thiripalai mathirai 1 tablet twice a day with Karisalai kudineer 100 ml of for an 
average of 30 days. The observation of the signs and symptoms were followed as long 
as in the hospital as outpatients and inpatients. The prognosis was clearly recorded. 
When symptoms disappeared the patients were discharged by examination of the 
systemic signs and symptoms, haematological parameters once again. As the trial 
drug has significant haematinic activity, the aim was attained. Vitamin C is essential 
for iron absorption and the presence of kadukkaithol, nellikkai, vallarai in the trial 
medicine enhances the absorption  
 
Clinical symptoms: 
           Out of 40 patients, 40 patients (100%) had Pallor of conjunctiva and nail bed, 
Fatigue, 11 patients (27.5%) had Loss of appetite, 27 patients (67.5%) Dyspnoea on 
exertion, 9 Patients (22.5%) had Headache, 10 patients (25%) had Constipation, 24 
patients (60%) had Giddiness and 9 patients (22.5%) had Palpitation. 
 
Clinical Prognosis: 
        After 30 days of treatment  Pallor of conjunctiva  and nail bed and  Fatigueness  
present in 17 patients(42.5), Dyspnoea on exertion  present in 13 
patients(32.5%),Loss of appetite and palpitation present in 4 patients(10%), Headache 
and constipation present in 3 patients (7.5%), Giddiness present in 5 patient(12.5%). 
 
Haemoglobin level: 
           After treatment 23 patients (57.5%) show increase in Hb 2gms/dl, 11 patients 
(27.5%) show increased in Hb 1.5 gms/dl and 6 patients (15%) show increase in less 
than 1gm/dl. 
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Grading of results: 
 Among 40 patients, 23 cases (57.5%) showed good result, 11 cases (27.5%) 
showed   moderate result, 6 cases (15%) showed poor result. 
 
STATISTICAL ANALYSIS 
 Paired„t‟ test was used to test the significance of treatment before and after 
using the data on haematological parameters. The level of significance probability 
0.05 was used to test the difference and the values are statistically significant. 
Statistical analysis of Haemoglobin level 
 The mean value of Hb before treatment is 8.826 and after treatment is 10.498 
and t value is -15.029 which is statistically significant (p<0.01). 
Statistical analysis of RBC 
 The mean value of RBC before treatment is 3.804 and after treatment is 4.314 
and t value is -8.933 which is statistically significant (p<0.01). 
Statistical analysis of PCV 
 The mean value of PCV before treatment is 29.388 and after treatment is 
32.350 and t value is -7.082 which is statistically significant (p<0.01) 
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CHAPTER - 7 
SUMMARY 
Pitha paandu Noi (Iron deficiency anaemia), a type of clinical condition is the 
most common and widespread nutritional disorder in the world affecting a large 
number of children and women in developing countries. It is the only nutrient 
deficiency which is significantly prevalent and hence taken for this study. 
The various Siddha literature collections has clearly mentioned the etiological 
factors, classifications of the disease and symptoms, complications, diet etc., 
according to their views. I have chosen my clinical drug as „„THIRIPALAI 
MATHIRAI” with its reference in “KADUKKAI VALLARAIYIN THANI 
MAANBU”, a Siddha formulary text by the author Hakkim. P. Mohammed Abdullah 
Sahib, which is indicated for „„Paandu Noi”. The efficacy of this medicine was 
studied and observed during this research work. 
 In every aspect, Anemia with symptoms of pallor, anorexia, loss of appetite, 
lassitude, giddiness, constipation, palpitation discussed in the modern medicine text 
books is similar to the clinical features of paandu noi in Siddha medicine. The 
feasibility of considering Pitha paandu noi as Iron Deficiency Anaemia is observed 
after considering the Siddha etiological factors which coincides with the modern 
aspects. 
 In this study 20 patients of both sexes of different age groups with classical 
clinical symptoms were selected as inpatients and another 20 patients were taken as 
out patients in post graduate department of Maruthuvam, Government Siddha Medical 
College and Hospital, Palayamkottai.  
            A total of 40 patients were treated in the OPD & IPD. The clinical and 
pathological  assessment  was  carried  out  on  the  basis of both Siddha  and  modern 
aspects. 
            All the 40 patients were administered with THIRIPALAI MATHIRAI - 1 
Tablet (130mg) with the adjuvant KARISALAI KUDINEER – 100ml twice a day 
after food. The duration of the treatment was 30 days. The responses were assessed 
and recorded. 
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 Socio-economical status plays an important role in this ailment. Well balanced 
diet is essential for overcoming this disease. The poor unhygienic people with the 
usage of contaminated food and water were more prone to worm infestation causing 
the disease. 
 The trial medicine is less cost effective and is easily acceptable by patients 
without any side effects. Bio-chemical and pharmacological studies reveal that the 
trial medicine has significant haematinic effect which promotes cure of the disease. 
Both Hematological and Clinical improvement of the patient was noted. In this 
Clinical study, the efficacy of the drug in increasing the Hb level was noted in all 
patients.  No adverse effects were reported during or after the course of treatment.  
The Statistical analysis showed the data obtained from the Hematological 
parameters were statistically significant (p<0.01).    
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CHAPTER - 8 
CONCLUSION 
My study on open labeled non randomized phase-II clinical trial of 
“THIRIPALAI MATHIRAI” (INTERNAL) in the treatment of “PITHA PAANDU 
(IRON DEFICIENCY ANAEMIA)” concluded the clinical and therapeutic efficacy 
of Thiripalai mathirai for Pitha paandu by showing improvement in clinical and 
haematological parameters. No adverse effects were reported during the clinical 
study, so the trial drug appears to be safe. The dissertation medicine “Thiripalai 
Mathirai” is proved to be a potent drug in treating Pitha paandu noi (Iron Deficiency 
Anemia). 
The trial medicine (TPM) was found to neutralize the deranged humors there 
by regulizing the udal thathus and proved the effective management of Pitha paandu.   
Bio statistical analysis of pharmacological study showed the significant haematinic 
action (p value<0.01). The acute and subacute toxicity study showed the good safety 
profile of the trial drug. 
  The clinical studies in both OP & IP gave hope in the management of Pitha 
paandu. The gradation of result revealed that among 40 patients, 20 cases (50%) 
showed good improvement, 11 cases (27.5%) showed   moderate improvement and 9 
cases (22.5%) showed poor improvement. Both objective and subjective 
improvements were observed in the sample of 40 patients.   
The trial medicine is less cost effective and free from side effects, so they are 
suitable for long term use. It was therapeutically effective to the patients and there 
was no recurrence of symptoms. This is only a preliminary study and further more 
studies will be undertaken to assess the effect of Thiripalai mathirai. The significant 
results were obtained pre clinically and clinically, it is concluded that Thiripalai 
mathirai is therapeutically effective in the management of Pitha paandu.    
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ANNEXURE - I  
PREPARATION OF THE TRIAL MEDICINE 
 
Drug   : THIRIPALAI MATHIRAI (Internal) 
Reference  : KADUKKAI VALLARAIYIN THANI MAANBU 
Third Edition:1992, Page No:81. 
Author: Hakkim. P. Mohammed Abdullah Sahib 
Dosage          : 1 Tablet (130mg) twice a day after food 
Adjuvant      : Prepared drug is administered with KARISALAI  
  KUDINEER (decotion of Karisalai ver, Keezhanelli ver,     
   Neermulli ver) 
Duration       :30 days 
 
INGREDIENTS OF THIRIPALAI MATHIRAI 
 
 
 
SL. 
NO 
DRUGS BOTANICAL 
NAME(FAMILY)/ CHEMICAL 
NAME 
PART USED 
1. MANJAL 
KADUKKAITHOL 
Terminalia chebula 
(combretaceae) 
Outer covering 
of dried fruit 
2. NELLIMULLI Emblica officinalis 
(Euphorbiaceae) 
Dried fruit pulp 
3. THAANRIKKAI 
THOL 
Terminalia bellirica 
(Combretaceae) 
Outer covering 
of dried  fruit 
4. VALLARAI Centella asiatica 
(Apiaceae) 
Leaf juice 
5. NELLIKKAI 
 
Emblica officinalis 
(Euphorbiaceae) 
Fruit pulp 
6. ANNABEDHI 
CHENDURAM 
Ferri sulphas, Green vitriol, Iron 
Sulphate 
- 
INGREDIENTS OF KARISALAI KUDINEER 
 
Purification of raw drugs: 
Raw drugs are purified as mentioned as below, 
1. Manjal Kadukkai thol-cleaned and dried in sun light. 
2. Thanrikkai thol-cleaned and dried in sunlight. 
3. Nellimulli-cleaned and dried in sunlight. 
4. Vallarai-Fresh leaves of valarai is washed and cleaned thoroughly. 
5. Annabedhi-The required amount of Annabedhi is taken and dissolved in water, 
sulphuric acid is added and filtered and boiled until the salt crystals are 
formed. 
6. Karisalaiver, Keezhanelliver, Neermulliver-cleaned and dried in sunlight. 
 
Method of preparation: 
 1. Preparation of THIRIPALAI MATHIRAI: 
The above drugs 1,2,3 are taken in required quantity, powdered separately and 
sieved by sieving cloth. Then all powdered drugs are mixed and taken as a compound 
preparation.                                                                                                                                                                                                                                                                                                                                                                                                                                 
Preparation of Annabedhi chenduram:  
The purified Annabedhi is ground in mortar by adding lemon juice little by 
little and the paste is made into a cake and dried.Then the cake is kept in a mudpan, 
SL. 
NO 
DRUGS BOTANICAL NAME(FAMILY) PART USED 
1. KARISALAI  Eclipta prostrate 
(Asteraceae) 
Root 
2. KEEZHANELLI Phyllanthus amarus 
(Euphorbiaceae) 
Root 
3. NEERMULLI Hygrophila auriculata 
(Acanthaceae) 
Root 
covered with another mudpan, sealed with mudseal and put into puda process. After 
cooling there will be a fine chenduram. 
Preparation of mathirai: 
The prepared Annabedhi chenduram and the powdered drugs are mixed and ground in 
a mortar for one hour. Then vallarai juice is added in a required quantity, ground and 
then dried and again the dried paste is ground with required vallarai juice and dried. 
This process is done 7 times. Likewise, the drug is to be ground with Nellikkai juice 
for 7 times. Finally the paste is prepared into tablets of kundrimani size (130mg) and 
dried. 
 
 
2. Preparation of adjuvant – KARISALAI KUDINEER: 
 Karisalaiver, Keezhanelliver, and Neermulliver are taken in equal quantity, 
cleaned, dried and made into a coarse powder. For the preparation of decoction, 25 
grams of the powder is boiled with 500 ml. of water till reduced to 100 ml. of 
decoction. 
    
 
Drug storage and Dispensing: 
The prepared trial drug Thiripalai mathirai is stored in clean and dry air tight 
containers. 
The prepared adjuvant Karisalai kudineer chooranam is stored in clean and dry 
air tight containers. 
The trial drug is dispensed in tablet form–10 tablets in a packet. 1 tablet of 
Thiripalai mathirai twice a day for 5 days is given. For Outpatient 1packet is given for 
5 days. It has been advised for twice a day. 
The adjuvant Karisalai kudineer is dispensed in chooranam form - 25grams in 
a packet. 25gms of kudineer chooranam for 100 ml of kudineer twice a day for 5 days 
is given. For outpatient 10 packets are given for 5 days. The preparation of kudineer is 
well explained to the patients. 
 For Inpatient every day the mathirai and kudineer will be dispensed in person. 
 
KARISALAI KUDINEER 
  
 
 
 
  
 
 
 
  
 
 
  
 
 
 
 
  
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
 
